Duquesne University

Duquesne Scholarship Collection
Electronic Theses and Dissertations

Fall 12-21-2018

Synthesis of Novel 6-Substituted and 5-Substituted
Pyrrolo[2,3-D] Pyrimidine Antifolates as Targeted
Anticancer Therapies
Xinxin Li
Duquesne University

Follow this and additional works at: https://dsc.duq.edu/etd
Part of the Medicinal and Pharmaceutical Chemistry Commons
Recommended Citation
Li, X. (2018). Synthesis of Novel 6-Substituted and 5-Substituted Pyrrolo[2,3-D] Pyrimidine Antifolates as Targeted Anticancer
Therapies (Master's thesis, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1727

This One-year Embargo is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic
Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection.

SYNTHESIS OF NOVEL 6-SUBSTITUTED AND 5-SUBSTITUTED PYRROLO[2,3-d]
PYRIMIDINE ANTIFOLATES AS TARGETED ANTICANCER THERAPIES

A Dissertation
Submitted to the Graduate School of Pharmaceutical Sciences

Duquesne University

In partial fulfillment of the requirements for
the degree of Master of Science

By
Xinxin Li

December 2018

Copyright by
Xinxin Li

2018

SYNTHESIS OF NOVEL 6-SUBSTITUTED AND 5-SUBSTITUTED PYRROLO[2,3-d]
PYRIMIDINE ANTIFOLATES AS TARGETED ANTICANCER THERAPIES

By
Xinxin Li
Approved November 05, 2018

________________________________
Aleem Gangjee
Distinguished Professor, School of
Pharmacy
(Committee Chair)

________________________________
Marc W. Harrold
Professor, School of Pharmacy
(Committee Member)

________________________________
Kevin Tidgewell
Assistant Professor, School of Pharmacy
(Committee Member)

iii

ABSTRACT

SYNTHESIS OF NOVEL 6-SUBSTITUTED AND 5-SUBSTITUTED PYRROLO[2,3-d]
PYRIMIDINE ANTIFOLATES AS TARGETED ANTICANCER THERAPIES

By
Xinxin Li
December 2018

Dissertation supervised by Professor Aleem Gangjee, Ph. D.
The dissertation will give an introduction, background and current research progress in the
areas of antifolates and chemotherapy of anticancer. The design and synthesis of classical 6substituted pyrrolo[2,3-d]pyrimidines and 5-substituted pyrrolo[2,3-d]pyrimidines as potential
antifolates have been described. The design variations include: methylated thiophene regioisomers,
fluorinated phenyl regioisomers, thionyl regioisomers on the side chain of pyrrolo[2,3d]pyrimidines. As a part of this study, a series of new compounds have been synthesized and
characterized. Of these, ten final compounds were submitted for biological evaluation.
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BIOCHEMICAL REVIEW

Figure 1 Structure of folic acid illustrating the three principle moieties of the molecule.
Folic acid (FA) (Figure 1), a water-soluble vitamin of the B-complex group, was first
isolated by Mitchell and coworkers1 from spinach leaves in 1941. The structure of FA consists of
three principle moieties: a hetero-bicyclic pteridine (scaffold), a p-aminobenzoic acid (PABA) and
a glutamic acid (Figure 1). The FA structure probably does not occur in nature as such, but it can
be considered as the parent compound of a group of naturally occurring folates, which belong to
the B9 family. Folate refers to the various reduced derivatives of folic acid which is naturally found
in food. There are several differences between FA and folates: 1) The reduction states of the
pteridine ring (oxidized, 7,8-H2, and 5,6,7,8-H4) could occur in folates. 2) In folate, one carbon
unite can be attached to N5 or N10 or both. 3) Glutamate residues (poly-γ-glutamates) of folates may
be attached to the glutamate moiety by γ-peptide bonds to give folate polyglutamates.
Folates are anionic hydrophilic molecules at physiologic pH and because of that they can
not cross biological membranes by diffusion.2 As a result, mammalian cells have evolved several
sophisticated membrane transport systems for facilitating cellular uptake of folate cofactors. There
are three major uptake systems for the membrane transport of folates and antifolates across

-1-

biological membranes.These include the reduced folate carrier (RFC), 2 the folate receptors (FRs)
α and β,3and the proton-coupled folate transporter (PCFT).2-4 RFC is expressed ubiquitously and
is recognized to be the major transport system for folates in mammalian cells and tissues at
physiologic pH.2-4 FRs α and β are glycosylphosphatidylinositol-anchored proteins that transport
folates by receptor-mediated endocytosis.5-6 Finally, PCFT is a proton-folate symporter that
functions optimally at acidic pH by coupling the flow of protons down an electrochemical
concentration gradient to the uptake of folates into cells.7-9 The reduced form of folic acid including
5-methyltetrahydrofolate (N5-CH3-FH4) and10-formyl tetrahydrofolate (N10-CHO-FH4) are
actively taken up into the cell via the RFC system. However, folic acid has a higher affinity for
FRs, which has a higher affinity for the oxidized form of the folate cofactor than the reduced form.
Folic acid plays an important role in one-carbon transfers system, so it is essential for
deoxyribonucleic acid (DNA) synthesis, repair and cell replication.2,3,10 Folate antagonist or
antifolates with structures similar to folic acid are considered cytotoxic drugs. These drugs inhibit
one or more biosynthetic steps that required folate coenzymes. Antifolates represent an important
class of antimetabolites and are used as chemotherapeutic agents for cancer. 11-15
1. FOLATE METABOLISM
The mammalian folic acid cycle is a highly complex and crucial process for transferring
one-carbon unite to amino acids, nucleotides and other biomolecules. In mammals, folic acid
cannot be synthesized and must be obtained through the diet, primarily fruits and vegetables. 1 Folic
acid is the starting material for tetrahydrofolic acid (tetrahydrofolate, THF), which is the
fundamental molecule in folic acid cycle. Folic acid exists in several oxidative states, each of them
is critical for the entire biosynthesis of nucleic acid precursors and amino acids. Intracellular

-2-

reduction of the pteridine ring in folic acid is enzymatically reduced by nicotinamide adenine
dinucleotide phosphate (NADPH) - specific dihydrofolate reductase (DHFR) and leads to the
formation of 7,8-dihydrofolate (FH2) followed by 5,6,7,8-tetrahydrofolate (FH4) (Figure 2).7 FH4
functions as the coenzyme in the utilization of single-carbon units and is the central component of
folate metabolism. Tetrahydrofolate is subsequently processed through a variety of oxidative
enzymatic modifications that function as one-carbon donors. It is one of the critical components
in the synthesis of amino acids (glycine, serine, methionine, and histidine), nucleic acid (purine
nucleotide and the 5-methyl group of thymine) and the formation of formylmethionyl-tRNA.
(Figure 2). FH4 can carry various single carbon units, including methyl, methylene, and formyl
groups. These single carbon units can be oxidized to methanol, formaldehyde, and formic acid,
respectively. Subsequently these one-carbon units can be attached to the N5- and/or N10- positions
of FH4 to form 5-methyltetrahydrofolate (N5-CH3-FH4), 5,10-methylenetetrahydrofolate (N5,N10CH2-FH4), 5-formyltetrahydro-folate (N5-CHO-FH4),10-formyltetrahydrofolate (N10-CHO-FH4),
and 5-formiminotetra-hydrofolate (N5-CH=NH-FH4) respectively (Figure 2).
There are numbers of enzymes involve in folate-dependent reactions, using different
derivatives of FH4 in one-carbon transfer reactions. Such as: (i) 5,10-methylene tetrahydrofolate
(N5,N10-CH2-FH4) provides a carbon for the synthesis of thymidylate from deoxyuridylate
mediated by thymidylate synthase (TS), an initial step in the synthesis of precursors for DNA. (ii)
N10-CHO-FH4 could provide two carbons for the synthesis of the purine ring in reactions mediated
by

glycinamideribonucleotide

formyl

transferase

(GARFTase)

and

amino-imidazole-

carboxamideribonuleotide formyl transferase (AICARFTase). (iii) N5-CH3-FH4 provides the
methyl group for the vitamin B12 dependent synthesis of methionine from homocysteine mediated
by methionine synthetase, which is followed by the synthesis of S-adenosylmethionine (Figure 2).

-3-

Figure 2 Folates and their roles in the biosynthesis of nucleic acid precursors and amino acids.
Note: TS: Thymidylate Synthase; DHFR: Dihydrofolate Reductase; SHMT: Serine
Hydroxymethyltransferase; MTHFD: Methylenetetrahydrofolate Dehydrogenase; MTHFR:
Methylenetetrahydrofolate

Reductase;

GARFTase:

Glycinamide-ribonucleotide

Formyl

Transferase; AICARFTase: Amino-imidazole-carboxamide-ribonuleotide Formyl Transferase;

-4-

AICAR: Aminoimidazole-4-carboxamide ribosyl-5-phosphate; dTMP: 2’-Deoxythymidylate 5’monophosphate; dUMP: 2’-Deoxyuridylate-5’-monophosphate; dTMP: 2’-Deoxythymidylate 5’triphosphate; GAR: Glycinamide Ribosyl-5-phosphate; DNA: Deoxyribonucleotide; IMP: Inositol
monophosphate.

Figure 3 TS catalyzed biosynthesis of dTMP from dUMP.

TS can utilize the FH4 cofactor N5, N10-CH2- FH4, that acts as the source of the methyl group
as well as the reductant by concerted transfer of its methylene moiety and the 6-hydrogen atom in
the form of hydride to form the 5-methyl group of dTMP (Figure 3). This transformation represents

-5-

the only de novo source of dTMP in dividing cells; hence, inhibition of TS, in the absence of
salvage, could lead to “thymineless death”.16
“Thymineless death” is observed in mammalian cells when severe deoxythymidinetriphosphate (dTTP) depletion takes place due to methotrexate (MTX) or 5-fluorouracil (5-FU)
treatment.17 The dTTP depleted mammalian cells irreversible lose colony forming ability and
undergo cell death.16 The phenomenon of thymineless death is underlied in the mechanism of
several antibacterial, antimalarial and anticancer agents, such as sulfamethoxazole, trimethoprim,
methotrexate and fluorouracil16, 18-20. In 1954, Barner and Cohen21,22 discovered this phenomenon
that thymine requiring mutants of the E. coli bacterium lost viability when grown in a medium
lacking thymine but containing other essential nutrients. Subsequently, this discovery led to the
development of theories to explain the mechanism of action of several pyrimidine analogs that
targeted thymine metabolism in bacteria and tumor cells.23 The phenomenon was commonly
attributed to "unbalanced growth" wherein cells continued fundamental processes of RNA
transcription, protein synthesis and metabolism in the absence of DNA replication. 22 This effect is
unusual in that the deprivation of many other nutritional requirements such as amino acids or
vitamins has a biostatic, but not lethal effect.24-25 Studies on numerous tumor cells have indicated
that thymine starvation has both direct and indirect effects. The direct effects involve both singleand double-strand DNA breaks.17 Single-stand DNA breaks may be repaired effectively, but
double-strand DNA break will lead to cell death. Depletion of dTTP in mammalian cells induces
apoptosis, although the mechanism underlying this process remains to be elucidated. 26-28
Methotrexate and 5-FU cause a decrease in dTTP levels and a concomitant increase in dUTP,
which is incorporated into DNA. This leads to extensive DNA damage as a result of the active
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process of excision repair at the many uracil-containing sites in DNA, and thus triggers a DNAdamage-induced apoptosis.17
During the TS catalyzed reaction, N5,N10-CH2-FH4 is oxidized to FH2 and converted back
to FH4 by dihydrofolate reductase (DHFR) which maintains the intracellular reduced folate pool.
Thus, inhibition of DHFR leads to a partial depletion of the intracellular reduced folate pool which
consequently limits cell growth.29 Both human TS and human DHFR are essential enzymes for
cell growth and hence both continue to represent attractive targets for chemotherapeutic agents. 30,31
β-Glycinamide-ribonucleotide

transformylase(GARFTase)

and

aminoimidazole-

carboxamide ribosyl-5-phosphate formyl transferase (AICARFTase) are the other two enssential
folate related enzymes in the de novo biosynthesis of purine nucleotides (Figure 4). These two
enzymes utilize the cofactor, N10-CHO-FH4 to transfer one carbon units.32 The C-8 carbon and C2 carbon of purine nucleotides are comprised of these “one carbon units”. GARFTase catalyzes
the third in the series of ten reactions required for purine synthesis (Figure 4), the conversion of
glycinamide ribosyl-5-phosphate (GAR) to formyl-glycinamide ribosyl-5-phosphate (fGAR),
utilizing N10-formyl-FH4. In mammals, GARFTase occurs as one enzyme in a trifunctional protein,
which catalyzes the second and the fifth steps of this pathway in addition to the third step. Or
fGAR formed is converted further to aminoimidazolecarboxamide ribosyl-5-phosphate (AICAR).
AICARFTase is responsible for the catalysis of the last two steps in de novo biosynthesis of purine.
AICARFTase utilizes N10-CHO-FH4 and converts AICAR to formyl-aminoimidazolecarboxamide
ribosyl-5-phosphate (fAICAR). The fAICAR continues along the purine biosynthetic pathway and
leads to the formation of inosine-5’-monophosphate (IMP), the precursor of adenosine-5’triphosphate (ATP) and guanosine-5’-triphosphate (GTP) necessary for ribonucleic acid (RNA)
synthesis and of 2’-deoxyadenosine-5’-triphosphate (dATP) and 2’-deoxyguanosine-5’-7-

triphosphate (dGTP) necessary for DNA synthesis and 2’-deoxyguanosine-5’-triphosphate (dGTP)
necessary for DNA synthesis.30

Figure 4 De novo synthesis of Purines.
As mentioned above, mammalian cells have three main folate transport system. Once
transported inside the cell, the cofactors are converted to the poly-γ-glutamyl species by the
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enzyme folylpoly-γ-glutamate synthetase (FPGS), which adds glutamic acid residues to the
gamma carboxylic acid via amide bonds. Usually 4-8 glutamate residues are added to the γcarboxylic acid group of the cofactor or reduced folate. The polyglutamylated folates usually have
higher binding affinity to some folate dependent enzymes (e.g. TS) and have increased intracellular
retention time, because of their polyanionic nature. 33,34
Due to the crucial role in the biosynthesis of nucleic acid precursors, folates and their
metabolism have been recognized as attractive targets for cancer chemotherapy. 35-41 Based on the
transport mechanism and the ability to undergo polyglutamylation, antifolates are classified into
two types: classical antifolates and nonclassical antifolate.42 Classical antifolates contain an intact
L-glutamate side chain, while nonclassical antifolates contain a lipophilic side chain. 43,44As shown
in Figure 5, representatives of classical antifolates include methotrexate (MTX), aminopterin,
edatrexate, PDDF (N10-propargyl-5,8-dideazafolate), raltitrexed (RTX, ZD1694, Tomudex),
pemetrexed (PMX, LY231514, Alimta), GW1843U89 and plevitrexed (ZD9331). These analogs
closely resemble the structure of endogenous folates and its metabolites. They are actively taken
up into cells by RFC, FR and/or PCFT systems present on the cell surface.33,38 The nonclassical
antifolates

are

represented

by

structures

shown

in

Figure

6:

nolatrexed, (thymitaq), pyrimethamine, trimethoprim (TMP), piritrexim (PTX) and trimetrexate
(TMQ). Nonclassical antifolates are not taken up by the folate active transport systems (RFC, FR
and PCFT) and are presumably taken up by passive and/or facilitated diffusion. 33,38
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Figure 5 Representative examples of classical antifolates and their principal target enzyme.
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Figure 6 Representative examples of nonclassical antifolates and their principal target.
2. MEMBRANE TRANSPORT OF FOLATES
As mentioned above, due to the lack of de novo biosynthetic enzymes in mammals for
folates, folate cofactors must be obtained from dietary resources. Because folates are hydrophilic
anionic molecules and cannot passive diffuse across biological membranes, several sophisticated
membrane transport systems have evolved to facilitate membrane translocation of these essential
cofactors. The three main transport systems include RFC, FR, and PCFT. Each of these plays a
unique role in mediating folate transport across epithelia and into tissues.’
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2.1. The Reduced Folate Carrier (RFC)
RFC is the major transport system of folates in mammalian cells. It is ubiquitously
expressed in mammalian cells and tissues. In addition, RFC is the major transporter of antifolate
drugs used for cancer chemotherapy such as MTX, PMX, and RTX (Figure 5), and that the
effectiveness of these agents is closely linked to levels and activity of this transport system in both
tumors and normal tissues.45-47
2.1.1. Structure of RFC
In 1968, the functional properties of RFC were first report in murine leukemia cells by
Goldman and coworkers 48. RFC (SLC19A1) belongs to the major facilitator superfamily (MFS)
of transporters. It is characterized by its anion exchange property. Human RFC (hRFC) is
comprised of 591 amino acids and is 64-66% conserved with rodent RFCs. RFC is an integral
membrane protein characterized by 12 transmembrane domains (TMDs) and cytoplasmic-oriented
N- and C-termini.49-52 hRFC is N-glycosylated at an N-glycosylation consensus site (Asn58) in the
first extracellular loop (EL) connecting TMD1 and TMD2.53A large loop domain that connects
TMD6 and TMD7 is poorly conserved between species and can be replaced altogether by a
nonhomologous segment from the SLC19A2 carrier.54 When separate TMD1-TMD6 and TMD7TMD12 RFC half-molecules are co-expressed in human RFC-null cells, they are targeted to the
cell plasma membrane surface and restore RFC transport activity.
2.1.2. RFC distribution
RFC is the primary transport system for folates cofactors in mammalian cells and tissues.
It can transport folates into cells of peripheral tissues from blood.55 In human tissues, the highest
level of hRFC transcript were detected in liver and placenta.56 The appreciable levels of hRFC
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were recorded in kidney, leukocytes, lung, bone marrow, intestine, and portions of the central
nervous system (CNS) and brain.56 In other tissues such as the basolateral membrane of the renal
tubule epithelium, the apical brush border membrane of the small intestine and colon, hepatocyte
membranes, the apical surface of the choroid plexus, hRFC were also detected. RFC is essential
for tissue development since targeting both RFC alleles is embryonic lethal. 57 In addition, at least
in some tissues (e.g., small intestine), mouse RFC is responsive to dietary folates supply such that
increased RFC transcripts and proteins were detected under conditions of dietary folate
deficiency.58
2.1.3. Transport mechanism of RFC
RFC, a bidirectional anion transporter, can transport reduced folates via counter-transport
with organic anions.3 5-methyl THF is the physiologic substrate of RFC.As an integral
transmembrane protein, RFC has a high affinity (~50-100-fold) for reduced folates (Ki ~1-5 µM)
and a low affinity for FA (Ki ~200 µM). Transport by RFC is characterized by a neutral pH
optimum and significantly decreased transport activity in acidic environment when pH is below
7.3,4,8.
RFC can generate small transmembrane chemical gradient. However, due to two glutamate
carboxyl groups of folates that are fully ionized at physiological pH, folates are negatively charged.
If considered with the within the context of the membrane potential, RFC produces a substantial
electrochemical potential difference for folates across cell membranes. 49 The energy source for
this uphill process is unique. RFC function is not directly linked to ATP hydrolysis and it is neither
Na+ nor H+ dependent.59,60

Instead, RFC-mediated transport is highly sensitive to the

transmembrane anion gradient, especially, the organic phosphate gradient. 59,60 Organic phosphates
are highly concentrated in cells where they are synthesized by ATP-dependent reactions and are
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largely retained. Their resulting asymmetrical distribution across cell membranes provides the
driving force for RFC-mediated uphill transport of folates into cells. 60
2.1.4. RFC in antifolate chemotherapy
MTX, RTX, and PMX, classical antifolates (Figure 5), are all actively transported into
mammalian cells by RFC as the major transporter.47,61 Membrane transport of antifolates such as
MTX is critical to antitumor activity since this provides sufficient intracellular drug concentration
to sustain maximal inhibition of enzyme targets (e.g. DHFR and TS) and for synthesis of
polyglutamate derivatives required for high affinity binding to some intracellular
enzymes and for sustained drug effects as plasma antifolate level decline. However, the loss of
active transport of MTX in drug resistance has been documented as early as 1962 in MTX resistant
L5178 murine leukemia cells.62 Since that time, impaired transport has emerged as one of the
dominant modes of tumor resistance to classical antifolate inhibitors such as MTX. 63,64
Impaired transport that results in a loss of sensitivity to standard doses of antifolate should
be circumvented to some extent by increasing extracellular concentrations of drug. This increase
forces the drug into tumor cells expressing mutated or low levels of RFC, and involves alternate
uptake routes or passive diffusion, to a sufficient extent to inhibit intracellular enzymes and/or to
support polyglutamate synthesis. However, RFC is ubiquitously expressed in mammalian cells.
Therefore, the elevated extracellular antifolate concentration always results in dose-limiting
toxicity due to the lack of selectivity of uptake into the tumor cells compared to normal cells.
2.2 The folate receptors (FRs)
The FRs is a family of proteins with high affinity folate binding and represents another
mode of folate uptake into mammalian cells. They bind folic acid, reduced folates, many antifolates conjugates with high (low nanomolar) affinities.
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2.2.1. Structure of FRs
The FRs are encoded by three distinct genes, designated α, β and γ localized to
chromosome 11q13.3-q13.5.65 FRs α, β and γ are highly homologous proteins (68-79% identical
amino acid sequence) and contain from 229 to 236 amino acids with two (β, γ) or three (α) Nglycosylation sites.66 In contrast to RFC, FRα and FRβ are anchored in plasma membranes
via a glycosyl phosphatidylinositol (GPI) anchor, while FRγ is a secretory protein of unknown
function due to the lack of a signal sequence for GPI anchor attachment. 6
Recently, Melcher and co-workers66reported the first crystal structure of FRα with folic
acid at 2.8 Å resolution. FRα has a globular structure stabilized by eight disulpfide bonds and
contains a deep open folate-binding pocket comprised of residues that are conserved in all receptor
subtypes. The pteroate moiety of folate is buried inside the receptor, while its glutamate moiety is
solvent-exposed and sticks out of the pocket entrance, allowing it to be conjugated to drugs without
adversely affecting FRα binding.67 (Figure7, 8).

Figure 7. hFRα- folate scaffold buried inside and glutamic acid is solvent exposed. (MOE 2014, PDB ID
4LRH).67
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Figure 8. hFRα- interaction of folic acid with ligand-binding-pocket residues. (MOE 2014, PDB
ID 4LRH).67
2.2.2. FRs distribution
FRα is predominantly expressed on the apical (luminal) surface of polarized mammalian
epithelial cells, particularly in the proximal tubule cells of the kidney choroid plexus, retina, uterus
and placenta.68,69 Because FRα is predominantly expressed on the apical surface, it is not in contact
with the circulating folate. The unusual polarized expression of FRα appears to protect normal
tissues from FR-targeted cytotoxic agents in the circulation.70 FRβ is expressed in placenta, spleen,
thymus and in CD34+ monocytes and hematopoeitic cells.71-73 In normal bone marrow and
peripheral blood cells, expression of FRβ is restricted to myelomonocytic lineage (e.g. mature
neutrophils) and was reported to be nonfunctional. 74 hFRγ is secreted at low levels from lymphoid
cells in the spleen, thymus, and bone marrow.74
FRα has been reported to be overexpress in malignant tissues, such as non-mucinous
adenocarcinomas of the ovary, uterus and cervix, and ependymal brain tumors. 6 FRα levels
positively correlate with tumor stages and grades. 75 FRβ malignant expression has been reported
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to involve a substantial fraction of chronic myelogenous leukemia (CML) and acute myelogenous
leukemia (AML) cells, but not Acute Lymphoblastic Leukemia (ALL). 75-77 Both FRα and FRβ in
malignant tissues seem to be functional, prompting the use of folic acid and pteroyl moieties for
tumor targeting of toxins, liposomes, imaging and cytotoxic agents. 70,77,78
2.2.3. Transport mechanism of FRs

Figure 9. Endocytosis of FRs.
Folate internalization by membrane-associated FRs involves receptor-mediated
endocytosis.3,4,6,8 The process of internalization by FRs is initiated when a folate molecule binds
to a folate receptor on the cell surface. This is followed by invagination of the plasma membrane
at that site and the formation of vesicle (endosome) that migrates along microtubules in the
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cytoplasm to the perinuclear endosomal compartment where it is acidified to a pH of 6.0-6.5. The
decrease in pH results in a conformational change of the complex which leads to dissociation of
the folate from folate receptor complex.79 The folate ligand is then exported into the cytoplasm by
a process requiring a trans-endosomal pH gradient.80-83 The endosome then migrates to the cell
surface and is fused with the cell membrane, the same FRs recycle. (Figure 9)
2.2.4. FRs and antifolate chemotherapy
Many reports have shown that FRα is overexpressed in solid tumors such as ovarian, lung
and breast carcinomas, including up to 90% of ovarian cancers. 76 In addition, FRα expression has
been associated with higher stage, grade and differentiation status of ovarian tumors. However, in
normal tissues, FRα is reported to be inaccessible to the circulation.5 FRβ is expressed in a wide
range of myeloid leukemia cells, but FRβ is unable to bind folate, when it is in normal
hematopoetic cells.75 Thus, the high affinity FRs offer a potential means of selective tumor
targeting, given their restricted pattern of tissue expression and function. Folate-conjugated
cytotoxins, liposomes, radionuclides, or cytotoxic antifolates have all been used to target
FRs.5,33,84,85 However, for most folate-based therapeutics such as classical antifolates (including
MTX, RTX and PMX), tumor selectivity is lost, since substrates are shared between FRs and the
ubiquitously expressed RFC.
2.3. The proton-coupled folate transporter (PCFT)
In 2006, PCFT a new folate carrier (SLC46A1) and two other members of this family
(SLC46A2 and SLC46A3) were discovered.86,87 PCFT belongs to the superfamily of solute
transporter family. The gene that encodes human PCFT (SLC46A1) is located on chromosome
17q11.2. PCFT as a high-affinity folate transporter is a proton-folate symporter that functions
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optimally at acidic pH 5.5 by coupling the flow of protons down an electrochemical concentration
gradient to the uptake of folates into cells.49,87 PCFT is a high-affinity folate transporter with a low
acidic pH optimum. Its primary role appears to be intestinal absorption of dietary folates and plays
a major role in in vivo folate homeostasis.88-89
2.3.1. Structure of PCFT
Hydropathy analyses predict PCFT is comprised of 459 amino acids with a molecular mass
of 49.8 kDa. It is predicted to include 12 TMDs with N- and C-termini oriented to the cytoplasm
(Figure 10). This structure has been validated by immunofluorescence analysis of hemagglutin
(HA)-tagged hPCFT molecules.90,91 The loop domain between the first and second TMDs must be
extracellular because the two putative N-glycosylation consensus sites in this region are
glycosylated. N-glycosylation does not appear to be required for either PCFT trafficking or
function.92

Figure 10 Human PCFT structure.48
2.3.2. PCFT expression patterns in human tissue
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PCFT is expressed in many normal tissues including small intestine, colon, liver, kidney,
placenta, retina and brain. Within the intestine, high PCFT levels are found in the in apical brushborder membranes in the proximal jejunum and duodenum. In addition, PCFT is also found in the
choroid plexus.92
2.3.3. Transport mechanism of PCFT
Folate transport mediated by human, mouse and rat PCFTs is electrogenic,
indicating that there is a net translocation of positive charges as each folate molecule is
transported.7,93-95 PCFT functions as a folate-proton symporter: the downhill flow of
protons via PCFT is coupled with the uphill flow of folates into cells. A trans vesicular pH
gradient results in increased unidirectional folate transport and substantial transmembrane
folate concentration gradients from the low-pH to the high-pH compartment, which is
consistent with a proton-coupled process.96 Acidic pH optimum is a distinguishing characteristic
of PCFT. For PCFT, transport is maximal at pH 5-5.5. As the pH increases above pH 5.5, transport
decreases dramatically; above pH 7, activity is not detectable.4,8 This leads to an important cancer
chemotherapy hypothesis that selective transport via PCFT could afford targeted therapy access of
solid tumors expressing PCFT. The pH of solid tumors is often acidic, 94,97 which favors PCFT
transport. However, the role of hPCFT in antifolate activity and tumor selectivity is still under
investigation, transport of classical antifolates by PCFT has been described previously. 95
2.3.4. PCFT and antifolate chemotherapy
The expression of RFC in both normal and tumor cells presents a potential obstacle to
antitumor selectivity. Further, loss of RFC results in resistance to MTX and RTX, yet PTX
cytotoxic activity can be preserved or even increased if PCFT is present. 98 For agents such as PMX
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that are transported by both RFC and PCFT, loss of tumor selectivity could be due to RFC transport
in normal tissues. Thus, there is a compelling rationale for developing cytotoxic antifolates that
are substrates for transporters other than RFC with limited expression and/or transport in normal
tissues compared with tumors. This rationale provided the impetus to develop targeted agents that
are selectively transported into tumors by FRs and PCFT over RFC, with potent intracellular
targets inhibition.48 Recently, Gangjee and coworkers99-101reported novel 6-substituted classical
pyrrolo[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine as cytotoxic antifolates with varying
lengths of the carbon bridge region that are characterized by selective FR and/or PCFT transport
over RFC transport.
3. Glycinamide-ribonucleotide transformylase (GARTFase)
Glycinamide ribonucleotide transformylase (GARTFase) is one of the most important
trifunctional enzymes involved in purine synthesis. GARFTase (EC 2.1.2.2) was first discovered
and partially characterized from pigeon liver in pioneering investigations by Warren and
Buchanan.102 GARFTase catalyzes the transfer of the formyl group from N10-CHO-FH4 to the
primary,

side-chain

amino

group

of

glycinamide

ribonucleotide

(GAR)

to

yield

formylglycinamide ribonucleotide (FGAR) and tetrahydrofolate (Figure 4), ultimately resulting in
the incorporation of C-8 into inosinic acid (IMP). This reaction is the third step and the first of two
folate-dependent formyl transfers in the de novo purine biosynthetic pathway. Purine nucleotides
play a critical role as precursors to RNA and DNA. Therefore, inhibition of de novo purine
biosynthesis might be a viable approach for cancer chemotherapy.103,104 This suggestion was
confirmed when it was demonstrated that 5,10-dideazatetrahydrofolate, a potent experimental
antitumor agent, has, as its mechanism of action, the inhibition of GARFTase and, consequently,
of de novo purine biosynthesis.105 GARFTase is of mechanistic interest for the ease with which it
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catalyzes the formyl transfer,106,107of biological interest for its role in the synthesis of DNA
precursor purines.108 it is also structural interest for the delineation of key mechanistic features of
its catalytic reaction,109-112 and of medicinal interest as an important target for chemotherapeutic
drug design.113-123
3.1. Structure of GARFTase
Recently, The structure of the Escherichia coli (E. coli) GARFTase has been solved at pH
3.5 (1.8 Å),124 pH 6.75 (2.8 and 3.0 Å),125and pH 7.5 (1.9 Å)124 and at neutral pH in complexes
with GAR and 5-deazatetrahydrofolate (2.5 Å),110 GAR and 10-formyl-5,8,10- trideazafolic acid
(2.1 Å),111 and two multi-substrate adduct inhibitors (1.96 and 1.6 Å). 109 The hGARFTase domain
is now readily available through cloning and overexpression.126,127 The hGARFTase is located at
the C-terminus of a trifunctional enzyme with a molecular mass of more than 110 kDa, which is
also responsible for catalyzing the second (glycinamide ribonucleotide synthetase) and fifth
(aminoimidazole ribonucleotide synthetase) reactions of de novo purine biosynthesis.128 The
crystal structure of hGARFTase has been reported at pH 4.2 (1.7 Å), at pH 8.5 (2 Å), at pH 8.5 in
the binary complex with the substrate β-GAR (2.2 Å)112 and at pH 7 in a binary complex with the
co-substrate analog inhibitor 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8- tetrahydrofolic acid
(10-CF3CO-DDACTHF) (2 Å)129 and a series of other folate inhibitors.119
3.2. Catalytic Mechanism of GARFTase
Kinetic studies of the E. coli enzyme106, the human enzyme126 and the murine
enzyme130 suggest a sequential mechanism in which the formyl group is transferred by a direct
nucleophilic attack of the GAR amino group on the formyl carbon of the co-substrate, leading to
the formation of a tetrahedral intermediate. Formation of this intermediate and its collapse to
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product require proton transfers. It has been proposed that a “fixed” water molecule, rather than
the invariant amino acids in the active site,131 mediates the required proton transfer between the
substrate and cofactor, but this has not been verified experimentally.

Figure 11 Proposed mechanism for GARFTase.132
A proposed mechanism for GARFTase is shown in Figure 11. 132 As the cofactor
binds to the active site, Asp144 forms a salt bridge to the imidazolium of His108 and the
formyl group is positioned to form hydrogen bonds to Asn106 and the protonated
imidazolium group of His108. The free base form of the amino group of GAR then attacks the

- 23 -

activated formyl group to form a tetrahedral intermediate. A proton transfer from GAR to the N 10
of folate is mediated by a catalytic water molecule, followed by breakdown of the tetrahedral
intermediate to form products. The positioning of this water molecule may be assisted by a
hydrogen bond to the carboxylate of Asp144. (For clarity, Asp144 is shown twice in Figure 11; it
spans the N1 of His108 to the bound H2O molecule.)
3.3. Binding of Inhibitors
Zhang et al.129 reported a 1.98 Å X-ray crystal structure (Figure 12) of hGARTFase in a
binary complex with the co-substrate analog inhibitor 10-CF3CO-DDACTHF (Table 2) at pH 7
(PDB entry 1NJS). The cofactor binding pocket of GARTFase is located at the interface between
the N-terminal mononucleotide binding domain and the C-terminal half of the structure. The
binding site for the folate cofactor moiety consists of three parts: the pteridine binding cleft, the
benzoylglutamate region, and the formyl transfer region.

Figure 12 Crystal structure (MOE 2014) of hGARTase in a binary complex with inhibitor 10CF3CO-DDACTHF at pH 7 (PDB ID 1NJS).
Pteridine Binding Cleft. The diaminopyrimidinone ring is deeply buried in the active site
cleft and occupies the same location as the quinazoline ring of 10-formyl-5,8,10-trideazafolic acid
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(10-formyl-TDAF) in the E. coli GARFTase complex (PDB entry 1C2T). The connecting stem
from the diaminopyrimidinone ring, composed of single carbon bonds, is longer than its
counterpart in 10-formyl-TDAF, due to the removal of the fused benzene ring, which makes it
more flexible when adapting to the binding site to optimize the gem-diol interactions with the
protein. The diaminopyrimidinone ring of 10-CF3CO-DDACTHF is tilted about 15° relative to the
quinazoline ring of 10-formyl-TDAF, which places N2 within hydrogen bonding range
(3.1 Å) of the backbone carbonyl oxygen of Glu141. The diaminopyrimidinone ring conserves all
of the key interactions that were previously observed with the quinazoline ring of 10-formyl-TDAF
and provides additional key hydrogen bonds with the enzyme. Several hydrophobic residues
encircle a deep cavity holding the heterocycle. The hydrophobic pocket consists of Leu85, Ile91,
Leu92, Phe96, and Val97 lining one end and the folate-binding loop of residues 141-146 at the
other. The diaminopyrimidinone ring makes six hydrogen bonds to the main chain amides and
carbonyls of Arg90, Leu92, Ala140, Glu141, and Asp144, and two hydrogen bonds to ordered
waters (W18 and W70). In the quinazoline ring of 10-formyl-TDAF, N8 of the folate pteridine
ring is replaced with a carbon. This nitrogen has been proposed to play a key role in the recognition
and interaction with folate-binding enzymes and forms

one end of an H-bond

donor-acceptor-donor array. While its replacement with carbon does not preclude the
binding to GARFTase, its presence appears to contribute to substrate recognition by the
folate transport system and/or FPGS. The diaminopyrimidinone ring of 10-CF 3CO- DDACTHF,
however, preserves this nitrogen (N8).
Glutamate Tail. In the 10-CF3CO-DDACTHF complex, the p-aminobenzoate
moiety locates in a hydrophobic pocket sandwiched between the side chains of Ile91
and Ser118.

The electron density of the carbonyl group is well-defined and in the same

- 25 -

plane as the phenyl ring. The glutamate tail is oriented almost perpendicular to the paminobenzoate plane and parallel to the aliphatic stem of the diaminopyrimidinone ring. In the
complex structure of 10-CF3CO-DDACTHF with human GARFTase, the glutamate moiety is
solvent-exposed, but exhibits a remarkably well-ordered structure, in contrast to its flexibility in
E. coli GARFTase complex structures. A salt bridge (2.7 Å) is formed between the glutamate αcarboxylate and Arg64 so that the γ-carboxylate points to the solvent. An additional interaction
observed here includes a hydrogen bond between the Ile91 backbone amide and the α-glutamate
carboxylate (2.8 Å).
Formyl Transfer Region and the Gem-Diol Structure. Key interactions for tight binding of
inhibitor 10-CF3CO-DDACTHF to GARFTase are found in the formyl transfer region. Strong
density next to the ketone oxygen indicates that the ketone is hydrated to a gem-diol, similar to the
10-formyl-TDAF and β-GAR complex with the E.coli GARFTase (PDB ID 1C2T). The gem-diol
forms extensive interactions with the formyl transfer region, especially with Asp144 and His108,
two essential residues in the formyl transfer reaction. The Asp144 carboxylate hydrogen bonds
bind (2.5 and 2.7 Å) to each of the hydroxyl groups of the gem-diol. N3 in the imidazole ring of
His108 also forms hydrogen bonds with both hydroxyls of the gem-diol [OA1 (2.7 Å) and OA2
(3.1 Å)]. Moreover, OA2 also makes a potential hydrogen bond (3.0 Å) with the backbone
carbonyl oxygen of Gly117.
Recently X-ray crystal structure of hGARTFase with pemetrexed and 6-substituted
pyrrolo[2,3-d] pyrimidine antifolate (Figure 13) and β-GAR substrate were determined.133 Based
on the crystallographic models antifolates form six hydrogen bond interactions with hGARFTase
peptide backbone atoms via the pyrrolo[2,3-d] pyrimidine moiety. In addition, two hydrogen bonds
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with the peptide backbone, a bidentate polar interaction with Arg871, and three long distance
charge–charge interactions with Arg897 and Lys844 are mediated via the glutamyl tail.

Figure 13 Crystal structure of hGARTFase. (PDB: 4ZZ1)133
3.4. GARFTase Inhibitors
Three types of GARFTase inhibitors are reviewed. These are listed in Table 1, Table 2 and
Table 3 below:
3.4.1. 5,6,7,8-Tetrahydropyrido[2,3-d]pyrimidines and 7,8-dihydropyrimido[5,4b][1,4]thiazines (Table 1)
3.4.2. Pyrimidines (Table 2)
3.4.3. Pyrrolo[2,3-d]pyrimidines and thieno[2,3-d]pyrimidines (Table 3)
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3.4.1. 5,6,7,8-Tetrahydropyrido[2,3-d]pyrimidines and 7,8-dihydropyrimido[5,4b][1,4]thiazines (Table 1)
Lometrexol. In 1985 Taylor and coworker139 synthesized the first GARFTase inhibitor to
Structure

Compound
Lometrexol
(DDATHF)

Biological
Activity
hGARFTase (Ki)
6 nM

LY-222306
(6-R,S)

hGARFTase (Ki)
0.77 nM
CCRF-CEM
(IC50) 27 nM

LY-254155
(6-R,S)
LY-309887
(6-R)

hGARFTase (Ki)
2.1 nM
CCRF-CEM
(IC50) 27 nM

AG-2034

AG-2037
(pelitrexol)

Ref.
134

135

136

hGARFTase (Ki)
28 nM
CCRF-CEM
(IC50) 2.9 nM

137

hGARFTase (Ki)
0.5 nM

138

enter clinical trials, the 6-(R)-isomer of 5, 10-dideazatetrahydrofolic acid (DDATHF), termed
lometrexol (LMTX, Table 1). This discovery established GARFTase and the purine de novo
biosynthetic pathway as viable targets for antineoplastic intervention. LMTX is a poor inhibitor of
both DHFR and TS, but a potent inhibitor of GARFTase (Ki = 6 nM) and a substrate for FPGS.140
The diastereomers were separated and found to be equipotent as inhibitors of cell growth and as
substrates for FPGS.134 The (6R)-diastereomer, which corresponds to the configuration found in
natural tetrahydrofolates, was chosen for further development. Patients treated with LMTX in
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phase I clinical trials developed severe and cumulative myelosuppression and mucositis. The
cumulative toxicity of LMTX is thought to be due in part to its ability to be
transported by both the RFC and FRs, resulting in increased cellular levels and a lack of selectivity
for tumor cells.141,142
(2S)-2-[[5-[2-[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6yl]ethyl]thiophene-2-carbonyl]amino]pentanedioic acid (LY309887). Unexpected observations of
delayed cumulative toxicity with LMTX led to a search for a second-generation antimetabolite
with a more favorable toxicological, biochemical and pharmacological profile. In 1994, Habeck et
al.135 reported a novel class of classical antifolates that replaced the 1’,4’-phenyl group of LMTX
with a 2’,5’-furan (LY222306) and a 2’,5’-thiophene (LY254155) (Table 2). Both LY222306 and
LY254155 (mixtures of diastereomers) were found to be potent inhibitors of CCRF-CEM cell
growth (IC50 = 27 and 2.3 nM, respectively) and tight binders of human GARFTase (Ki = 0.77 and
2.1 nM, respectively). Further evaluation of LY254155 was restarted in 1996 after the compound
was

resolved

into

its

two

diastereomers.136,143

LY309887

(6R-2’,5’-thienyl-5,10-

dideazatetrahydrofolic acid, Table 1) was more potent than LMTX at inhibiting tumor growth in
the murine C3H mammary tumor model and several tumor xenografts. LY309887 displayed a 9fold greater inhibitory potency against GARFTase compared to LMTX. In preclinical models,
LY309887 was more active than LMTX against two pancreatic xenografts and in the human LX1 lung carcinoma model. In two preliminary reports of phase I studies with LY309887, all patients
received concurrent folic acid but still suffered from cumulative toxicity, suggesting that, like
LMTX, cumulative toxicity remains a property of LY309887.144,145
AG-2034 and AG-2037. AG-2034 (Table 1) was designed from the X-ray structure of the
GARFTase domain of the human trifunctional enzyme. The only difference between AG-2034 and
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LY-309887 is the 5-sulfur in the pteridine ring. AG-2034 inhibits hGARFTase (Ki = 28 nM) and
is a substrate for rat liver FPGS, with similar efficacy as LMTX, while AG-2034 is a more effective
ligand for FRs than LMTX. AG-2034 inhibited cell growth (IC 50 = 4.0 and 2.9 nM, respectively,
against L1210 and CCRF-CEM cells) and exhibited in vivo antitumor activity against lung
carcinomas, lymphosarcomas, mammary and colon adenocarcinomas and melanoma. In phase I
clinical studies, AG-2034 displayed much less cumulative myelosuppression than LMTX, but like
LMTX did result in mucositis and diarrhea.146 AG-2037 (pelitrexol) is currently in phase I clinical
development (Table 1).147 The configuration at C-6 is reversed compared to LMTX and the
thiophene is methylated at the 4-position of AG-2037. AG-2037 is a potent inhibitor of GARFTase
(Ki = 0.5 nM) and exhibits significant antiproliferative effects against tumor cells in vitro and in
vivo.148 Several phase I studies have been completed that indicate that AG-2037 is well tolerated
and its maximum tolerated dose and schedule for phase II studies have been determined. 149,150
4.2. Pyrimidines (Table 2)
Structure

Structure

Compound
7-DMDDATHF
X = CH2

CCRF-CEM (IC50)
0.13 µM

151

5-DACTHF
X = NH

hog liver
GARTFase (IC50)
2.6 µM

152

Compound
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Biological Activity Ref.

Biological Activity Ref.

hog liver
GARTFase (IC50)
2.06 µM
hog liver
GARTFase (IC50)
0.14 µM

153

10-CHODDACTHF
R=H

hGARTFase (Ki)
14 nM
CCRF-CEM (IC50)
60 nM

122

10-CF3CODDACTHF
R = CF3

rhGARTFase (Ki)
15 nM
CCRF-CEM (IC50)
16 nM

129

(10R)-CH3SDDACTHF

rhGARTFase (Ki)
210 nM
CCRF-CEM (IC50)
80 nM

155

(10S)-CH3SDDACTHF

rhGARFTase (Ki)
180 nM
CCRF-CEM (IC50)
50 nM
hGARFTase (Ki)
4.8 µM
CCRF-CEM (IC50)
inactive

155

hGARFTase (Ki)
56 nM
CCRF-CEM (IC50)
300 nM

156

1 X = CH

2X=N

α-CH2-10CF3CODDACTHF
R1=COONH2
R2=COOH
γ-CH2-10CF3CODDACTHF
R1=COOH
R2=COONH2

154

156

γ -Tetrazole- hGARFTase (Ki) 157
10-CF3CO130 nM
DDACTHF
CCRF-CEM (IC50)
R1=COOH
40 nM
R2=tetrazole
7-DM-DDATHF. During the development and evaluation of LMTX, open-chain
analogs of LMTX were synthesized and evaluated.151,152 These analogs did not possess a
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stereocenter and were therefore less challenging to synthesize. 7-DesmethyleneDDATHF (7-DMDDATHF)

(Table

2)

is

approximately

8-fold

less

potent

than

LMTX

against human leukemia CCRF-CEM cells (IC50 = 130 nM vs. 16 nM) and only 3-fold
less active against GARFTase isolated from murine leukemia L1210 cells. 7-DMDDATHF is also
a

substrate

inhibitors

for

of

FPGS

and

its

GARFTase

than

the

polyglutamated
parent

conjugates

compound.

Removal

are
of

more
the

potent

annulated

tetrahydropyridine ring of LMTX had minimal effect on binding to GARFTase. A similar
compound 5-DACTHF (Table 2) was reported by Kelley and coworkers 152 in 1990. 5DACTHF showed an IC50 of 2.6 μM against GARFTase isolated from hog liver, and
slight inhibition of AICARFTase (IC 50 = 200 μM in L1210 cells). Further SAR studies
afforded the thienyl and thiazolyl analogs of 5-DACTHF.153 The thiophene analog 1 (Table 2) was
equal in activity to 5-DACTHF in controlling MCF7 breast cancer cell growth, while thiazole 2
(Table 2) was 9-fold more active than 5-DACTHF and 4-times more active than LMTX.
Compound 2 and LMTX have very similar activity against hog liver GARFTase.
10-CF3CO-DDACTHF.

Boger

and

coworkers122

reported

the

synthesis

and

evaluation of 10-formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-CHODDACTHF,
Table

2),

an

acyclic

analog

of

LMTX

bearing

a

nontransferable

C-10

formyl

group. 10-CHO-DDACTHF inhibited cell growth (IC50 = 60 nM, CCRF-CEM) and
hGARFTase (Ki = 14 nM), but suffered from instability due to a facile oxidative
deformylation. Continued development of such GARFTase inhibitors was accomplished
by combining the 2,4-diaminopyrimidone core of 10-CHO-DDACTHF with a more
stable

trifluoromethyl

ketone

moiety.13010-(Trifluoroacetyl)-5,10-dideaza-acyclic-

5,6,7,8-tetrahydrofolic acid (10-CF3CO-DDACTHF, Table 3) is a potent inhibitor of
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tumor cell proliferation, with an IC50 of 16 nM against CCRF-CEM cells, which
represents

a

10-fold

improvement

over

LMTX.

10-CF3CO-DDACTHF

specifically

inhibits recombinant hGARFTase (Ki = 15 nM), and is stable, displaying no competitive
oxidative deacylation.
10-CH3S-DDACTHF. Further exploration of analogs containing alternative tetrahedral
intermediate mimics continued with the synthesis and evaluation of 10-CH 3SDDACTHF (Table
2).158 10-CH3S-DDACTHF proved to be potent, exhibiting an IC50 of 100 nM against CCRF-CEM
cells. A follow-up asymmetric synthesis of (10R)- and (10S)- diastereomers of 10-CH3SDDACTHF was recently reported in 2008.158 Both diastereomers are potent and selective
inhibitors of rhGARFTase (Ki = 210 and 180 nM, respectively, for 10R and 10S) and effective
inhibitors of cell growth (IC50 = 80 and 50 nM, respectively, against CCRF-CEM cells), which is
dependent on intracellular polyglutamation by FPGS but not transport by RFC.
γ-CONH2-10-CF3CO-DDACTHF and γ-tetrazole-10-CF 3CO-DDACTHF.A further area
of examination in these efforts was the glutamic acid portion of 10-CF 3CO-DDACTHF. As stated
previously, folates and many antifolates are polyglutamylated by FPGS after entering cells. Most
FPGS, including human FPGS, attach additional glutamates to the γ-carboxylic acid of folates and
antifolates. Polyglutamation of folates and antifolates increases their affinity for some enzymes
(e.g. TS and GARFTase) and makes them less susceptible to cellular efflux, providing a long-lived
cellular supply of the molecules. However, this long-term enhanced intracellular accumulation of
antifolates, due to their polyglutamation, contributes to their cumulative toxicity. Therefore, the
strategy that preventing polyglutamylation, while maintaining potent enzyme binding, is
considered a therapeutic asset. γ-CONH2-10-CF3CO-DDACTHF (Table 2) exhibited potent
inhibitory activity against rhGARFTase (Ki = 56 nM) and purine sensitive cytotoxic activity (IC 50
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= 300 nM, CCRF-CEM), whereas α-CONH2-10-CF3CO-DDACTHF showed decreased affinity
(Ki = 4.8 μM) and was inactive in cellular functional assays.155 Another potent
nonpolyglutamatable inhibitor γ-tetrazole-10-CF3CO-DDACTHF (Table 2) exhibited purinesensitive cytotoxic activity (IC50 = 40 nM) and was a selective inhibitor of hGARFTase (Ki = 130
nM).156 As anticipated, both γ-CONH2-10-CF3CO-DDACTHF and γ-tetrazole-10-CF3CODDACTHF are not dependent on FPGS for acitivty, and hence not susceptible to resistance
mediated by FPGS.
4.3. Pyrrolo[2,3-d]pyrimidines and thieno[2,3-d]pyrimidines (Table 3)
Structure
O

COOH
N
H

Compound

Biological Activity (IC50)

Ref.

3 n=3

hGARFTase
KB
IGROV1

18 nM
1.7 nM
2.2 nM

96

4 n=4

hGARFTase
KB
IGROV1
hGARFTase
KB
IGROV1

6.8 nM
1.9 nM
3.6 nM
13.8 nM
23 nM
4.7 nM

hGARFTase
KB
IGROV1
hGARFTase
KB
IGROV1

13.3 nM
4.9 nM
5.9 nM
0.69 nM
0.26 nM
0.55 nM

hGARFTase
KB
IGROV1

1.96 nM
0.55 nM
0.97 nM

O
COOH

HN
H2N

N

N
H

n
n = 1-6
O

COOH
N
H

O
COOH

HN
H2N

N

S

5 n=3
6 n=4

n
n = 2-8

7 n=3

8 n=4

5

63

1. SAR of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines with para substituted benzoyl
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aromatic rings as side chain in whole cell assay as GARTFase inhibitors with selectivity for FRs
and/or PCFT over RFC.96
Table 4. IC50’s (in nM) for 6-Substituted Pyrrrolo[2,3-d]pyrimidine Antifolates 3,4 and classical
Antifolates in hRFC, hPCFT, and FR-Expressing Cell Lines. (+F (folic acid) = 200 nM, plus/minus
SEM in parentheses, ND not determined).96

Engineered CHO (Chinese Hamster Ovary) Cell Line (IC50S in nM)
hRFC

NIL

PC43-10

R2

RT16

3

304

448

4.1

>1000

5.6

4

>1000

>1000

6.3

>1000

138(13)

894 (93)

42 (9)

MTX

12 (1.1)

216 (8.7) 114 (31)

RTX

6.3(1.3)

PMX

>1000

hFRα

15(5)

hFRβ

hPCFT

NIL

R2/hPCFT4

R2(VC)

>1000

23

>1000

10

>1000

213

>1000

388 (68)

60 (8)

254 (78)

13.2 (2.4)

461(62)

106 (11)

211 (43)

120.5 (16.8)

>1000

>1000

22 (10)

746 (138)

99.5 (11.4)

>1000

RT16+F

D4

D4+F

974.0
(18.1)

Gangjee and coworkers5,63,95, recently described novel 6-substituted classical pyrrolo[2,3d]pyrimidine and thieno[2,3-d]pyrimidine as cytotoxic antifolates with varying lengths of the
carbon bridge region (Table 3), that are characterized by selective FR and PCFT transport over
RFC transport. For every series, the three- and four-carbon bridge analogs were the most active
toward FR-expressing human tumors (KB and IGROV1) and the cytotoxicity was primarily due
to potent inhibition of GARFTase, although for the thieno[2,3-d]pyrimidine antifolates, a
secondary target, most likely AICARFTase, was also implied at higher concentration.
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The 6-substituted classical pyrrolo[2,3-d]pyrimidine with a para substituted benzoyl side
chain compound 3 and 4 were highly potent against tumor cells (3, IC50s of 1.7 nM for KB and
2.2 nM IGROV1 and 4, IC50s of 1.9 nM for KB and 3.6 nM IGROV1) . These compounds are
highly selective towards FRs and PCFT over RFC (Table 4). The selectivity of compound 3 is
slightly compromised by its RFC transport, however compound 4 has excellent selectivity for FRs
and PCFT over RFC. These in vitro cytotoxicity results establish that the growth inhibitory effects
of 3 and 4 are dependent on their cellular accumulation via FRs rather than RFC and that there is
no apparent difference in the activity of these drugs toward cells that express the FRα isoform from
cells that express FRβ.
2. SAR of 2-amino-4-oxo-6-substituted pyrrrolo[2,3-d]pyrimidines with para substituted thieno
rings as side chain in whole cell assay as GARTFase inhibitors with selectivity for FRs and/or
PCFT over RFC.5
The 6-substituted classical thieno[2,3-d]pyrimidines with a para substituted thieno side
chain 7 and 8 were highly potent against tumor cells (Table 5) . These compounds showed high
selective towards FRs over RFC and PCFT (Table 5). These compounds do not use RFC for
transport into the cell.
Table 5. IC50’s (in nM) for 6-Substituted pyrrrolo[2,3-d]pyrimidines Antifolates 7, 8 and
Classical Antifolates in hRFC, hPCFT, and FR-Expressing Cell Lines. (+F (folic acid) = 200 nM,
plus/minus SEM in parentheses, ND not determined) 5
Table 5.
Engineered CHO (Chinese Hamster Ovary) Cell Line (IC50S in nM)
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hRFC
PC43-10

NIL
R2

hFRα
RT16

hFRβ

RT16+F

D4

D4+F

hPCFT

NIL

R2/hPCFT4

R2(VC)

7

101

273

0.31

>1000

0.17

>1000

3.34

>1000

8

>1000

>1000

1.82

>1000

0.57

>1000

43.4

>1000

138(13)

894
(93)

42 (9)

388 (68)

60 (8)

254
(78)

13.2 (2.4)

974.0
(18.1)

12(1.1)

216
(8.7)

114 (31)

461(62)

106
(11)

211
(43)

120.5 (16.8)

>1000

6.3(1.3)

>1000

15(5)

>1000

22
(10)

746
(138)

99.5 (11.4)

>1000

PMX

MTX

RTX

4. Aminoimidazole-4-carboxamide ribonucleotide transformylase (AICARFTase)
AICARFTase catalyzes the penultimate reaction in the de novo purine biosynthetic
pathway, producing formyl-AICAR (FAICAR) from AICAR using N10-formyltetrahydrofolate
(N10-CHOFH4) as the formyl donor. It exists as one domain of a bifunctional enzyme that also
contains IMP cyclohydrolase (IMP CHase) that catalyzes the final reaction of the pathway (Figure
4). Because of the large demand for purines by cancer cells, AICARFTase has been targeted by
antifolate inhibitors in chemotherapy along with GARFTase. 160-161
4.1. Structure of AICARFTase
AICARFTase is highly conserved from E. coli to human but has no sequence homology
with other folate-dependent enzymes, such as GARFTase.162 Thus, folate based inhibitors of
GARFTase do not usually inhibit AICARFTase because of different interactions within the two
active sites.163 For example, lometrexol potently inhibits GARFTase but not AICARFTase. 164
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Wilson

and

coworkers161,163,165-167have

previously

reported

several

crystals

structures of human and avian ATIC (the bifunctional enzyme, aminoimidazole-4carboxamide

ribonucleotide

(AICAR)

transformylase

(AICARFTase)/IMP

cyclohydrolase (IMPCH)) in both unliganded and complexed forms. The ATIC forms an
intertwined symmetrical homodimer (each monomer being composed of 393 residues)
with the IMPCH domain at the N terminus (residues 1–199) and the AICARFTase
domain at the C terminus (residues 200-593). The IMPCH active sites are contained
within each monomer of the dimer, but the AICARFTase active site is located at the
dimer interface with key active-site residues being contributed from both monomers.
4.2. AICARFTase catalytic mechanism
The catalytic mechanism of AICARFTase was evaluated with pH dependent kinetics, sitedirected mutagenesis, and quantum chemical calculations. 168-170 The results indicated that the
amide-assisted mechanism is concerted such that the proton transfers from the 5-amino group to
the formamide are simultaneous with nucleophilic attack by the 5-amino group. Because this
process does not lead to a kinetically stable intermediate, the intramolecular proton transfer from
the 5-amino group through the 4-carboxamide to the formamide proceeds via the same transition
state. Collectively, these experimental and theoretical analyses lead to a proposed mechanism for
AICARFTase catalysis shown in Figure 14.
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Figure 14 A proposed mechanism of AICARFTase.170
In this proposed mechanism, Lys266, with the aid of His267, acts as a general acid catalyst
to interact with the N3 of the imidazole ring of AICAR. His267 aids Lys266 to be in the right
position for a hydrogen-bonding interaction. The 4-carboxamide mediates proton shuttling from
the 5-amino to 4-carboxamide and then to the nitrogen of the leaving group with simultaneous
nucleophilic attack of the 5-amino group on the formyl group of folate cofactor. The first proton
transfer is facilitated by the intramolecular hydrogen bond in the ground-state AICAR and the
protonated 4-carboxamide species is only present transiently. The theoretical results suggest that
protonation of the nitrogen of the leaving group is critical in the aminolysis reaction between
AICAR and the formyl group rather than the nucleophilic attack on the carbonyl group. The central
role assigned to proton transfer compensates for the weak nucleophilicity of the AICAR 5-amino
group.
4.3. AICARFTase inhibitors
Burroughs Wellcome (Research Triangle Park, NC) had designed and synthesized two
antifolates that are specific inhibitors (nM) for human AICARFTase, as compared with other folate
dependent

enzymes,

GARFTase,

DHFR,

sulfamido-bridged 5,8-dideazafolate analogs

and

TS.162 These

compounds

are

both

identified as BW1540U88UD (BW1540)
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and BW2315U89UC (BW2315) (Fig. 15) that differ only in the disposition of the imido
and sulfonyl groups within the bridge region. BW1540 and BW2315 have approximate Ki
values against human ATIC of 8 and 6 nM, respectively, whereas the Ki values against
GARFTase, DHFR and TS are within the micromolar range, except for BW1540, which
showed low nanomolar inhibition against DHFR. BW1540 and BW2315 were co-crystallized at
2.55 and 2.60 Å with human ATIC in the presence of substrate AICAR to elucidate their
mechanism of inhibition. It was found both of compounds bound to the AICARFTase active site
of ATIC and the sulfonyl groups dominate inhibitor binding and orientation through
interaction with the proposed oxyanion hole. Moreover, interaction of the sulfonyl oxygens with
the oxyanion hole of the AICARFTase active site suggests that it is the driving force behind the
high affinity for these sulfonyl-containing antifolates (The Km of 10-f-THF is 100 µM170, whereas
the Ki values for BW1540 and BW2315 are 8 and 6 nM, respectively).162 Thus, these two
antifolates bind more strongly to the AICARFTase active site, by at least 1000-fold, than the
natural co-factor N10-formyltetrahydrofolate.

Figure 15 AICARFTase inhibitors.162
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Figure 15 AICARFTase inhibitors.162
b. NSC37173 and NSC30171
NSC30171 had nanomolar inhibition (Ki = 154 nM, IC50 = 600 nM), and NSC37173 (IC50
= 4.1 µM) against human AICARFTase.171 The human AICARFTase /BW1540 complex (PDB
1P4R) was selected as the docking template. NSC30171 was selected via NSC37173 similarity
search. Docking with and without AICAR substrate in the active site strongly indicates that this
nonfolate competes with the AICAR substrate for the AICAR binding site. Key interactions with
the AICARFTase active site residues appear to be the electrostatic and H-bonding interactions
between its sulfate and the enzyme “oxyanion hole”, and the aromatic stacking of the NSC30171
naphthalene ring with the Phe590 benzyl ring.
c. TNP-351
TNP-351, characterized by a pyrrolo[2,3-d]pyrimidine ring, exhibits potent antitumor
activities against mammalian solid tumors.172 The mechanism of action of TNP-351 was evaluated
using methotrexate-resistant CCRF-CEM human lymphoblastic leukemia cell lines as well as
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partially purified FPGS, AICARFTase, and GARFTase from parent CCRF-CEM cells. TNP-351
was found to significantly inhibit the growth of L1210 and CCRF-CEM cells in culture, with the
doses effective against 50% of the cells (ED50 values) being 0.79 and 2.7 nM, respectively. The
methotrexate-resistant CCRFCEM cell line, which has an impaired methotrexate transport,
showed less resistance to TNP-351 than to methotrexate. Inhibitory activities of TNP-351 and its
polyglutamatesGn (n=1–6) for AICARFTase were found to be significantly enhanced with
increasing glutamyl chain length (inhibition constants (Ki): G1, 52 μM; G6, 0.07 μM). Neither TNP351 nor its polyglutamates were very potent AICARFTase inhibitors.
d. Pemetrexed (PMX, Alimta)
Pemetrexed (PMX) is currently in widespread clinical use as the first line therapy for
mesothelioma and non–small cell lung cancer (NSCLC) and is also currently being evaluated for
the treatment of a variety of other solid tumors in the US. 173 Thymidylate synthase (TS) was
identified originally as the primary intercellular target174 of PMX. However, it is possible start that
PMX is a multitargeted antifolate that inhibits DHFR, GARFTase and AICARFTase in addition
to TS.175 However, TS Iis the pricipal target.
7. Multiple targeted antifolates in combinational anticancer chemotherapy
It

has

been

of

interest

not

only

to

design

potent

antifolates

against

specific

enzymes of DHFR, TS, GARFTase and AICARFTase but also to design and synthesize
single agents that have potent multiple inhibitory activities against these enzymes. 176,

177

This strategy is particularly promising in anticancer chemotherapy against the multiple
drug resistant cancers.178 Such a single agent could act at more than one active site and
provide “combination chemotherapy”. The benefits of single agents are the following: 1)
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circumvent the pharmacokinetic problems of multiple agents, 2) avoid of drug-drug interactions,
3) used at lower doses to alleviate toxicity, 4) devoid of overlapping toxicities, and most
importantly delay or prevent cancer drug resistance.178,179 Other advantages of such single agents
are cost reduction and patient compliance. In addition, the clinical success of pemetrexed
provided a good example of multiple targeted antifolates used in combinational anticancer
chemotherapy.179
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II. CHEMICAL REVIEW
The chemistry related to the present work is reviewed and includes synthetic approaches to the
following 5-substituted, 6-substituted pyrrolo[2,3-d]pyrimidines and relevant reactions:
1. Synthesis of pyrrolo[2,3-d]pyrimidines
2. Sonogashira coupling in antifolate synthesis
3. Heck coupling reaction in one-step aldehyde synthesis
1. Synthesis of pyrrolo[2,3-d]pyrimidine
A large body of literature exists for the synthesis of pyrrolo[2,3-d] pyrimidines because
of their application as deazapurine analogs. The synthetic strategies to this ring system have
three broad classifications for synthesis from:
1.1 Pyrimidine precursors
1.2 Pyrrole precursors
1.3 Furan precursors
1.1. From pyrimidine precursors
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Scheme 1 Synthesis of pyrrolo[2,3-d]pyrimidines 11and 13.
Noell and Robins180 first reported the synthesis of pyrrolo[2,3-d]pyrimidines 11 and 13 by
the reaction of chloroacetaldehyde 10 with 2-amino-6-alkylamino-4-hydroxypyrimidines 9 and
6-amino-1,3-dimethyluracil 12 respectively (Scheme 1).

Scheme 2 Synthesis of pyrrolo[2,3-d]pyrimidine 15
Noell and Robins180 also reported the synthesis of pyrrolo[2,3-d]pyrimidine 15 from 2methylthio-6-amino-4-pyrimidone 14 and chloroacetaldehyde 10 (Scheme 2)
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Scheme 3 Synthesis of pyrrolo[2,3-d] pyrimidines 20
In 1998, Gibson et al.181 reported a synthetic approach to prepare 2-amino-4oxopyrrolo[2,3-d]pyrimidines 20 (Scheme 3). In this method, 2,6-diamino-4-hydroxypyrimidine
16 was reacted with a biselectrophile, an oxime 17, in the presence of a weak base (sodium
carbonate, sodium acetate, or triethylamine) to afford the C-5 alkylated pyrimidine derivatives 19.
No side products resulting from substitution at any other position were isolated. Cyclization of
pyrimidine derivatives 19 at 120 °C under acid-catalyzed transoximation with benzaldehyde or
acetaldehyde afforded substituted pyrrolo[2,3-d]pyrimidines 20.

Scheme 4 Synthesis of furo[2,3-d]pyrimidines 22 and pyrrolo[2,3-d]pyrimidines 23.
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In 1973, Fumio et al.182 reported that the reaction of 6-amino-1,3-dimethyluracil 12 with
phenacyl bromides 21 in DMF afforded 1,3-dimethyl-6-phenylpyrrolo[2,3-d]pyrimidines 23 in 6974% yields (Scheme 4). The reaction of 12 and 21 in acetic acid afforded the isomeric 1,3dimethyl-5-phenylfuro[2,3-d]pyrimidine-2,4(1H,3H)-diones 22 as a byproduct in addition to 23.

Scheme 5 Synthesis of pyrrolo[2,3-d] pyrimidines 27.
Davoll and coworker183 reported the synthesis of various pyrrolo[2,3-d]pyrimidines 27
(Scheme 5) by an acid mediated cyclization of suitable pyrimidine 5-acetone or acetaldehyde
side-chains 26 onto the neighboring amino group. The pyrimidines were in turn obtained from
the acetals ethyl(2,2-diethoxyethyl)acetate 24, or 2,2-diethoxyethylmalonodinitrile, or their ketal
derivatives respectively and cyclization with guanidine, urea or thiourea.
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Scheme 6 Synthesis of pyrrolo[2,3-d]pyrimidines 29 and furo[2,3-d]pyrimidines 30.
Secrist and Liu184 provided a detailed study of the reaction of 2,6-diamino-4hydroxypyrimidine 16 with various -halo aldehydes and ketones (Scheme 6). They reported that
the cyclization occurred via two different route to produce either the pyrrolo[2,3-d]pyrimidine
and/or the furo[2,3-d]pyrimidine. Thus -halo ketones, chloroacetone 10 and 3-bromo-2-butanone
28, afforded both the furo[2,3-d]pyrimidine 30 and the pyrrolo[2,3-d]pyrimidine 29, whereas 16
afforded only the pyrrolo[2,3-d]pyrimidine 30 on reaction with 28. It was concluded that a critical
electron density is necessary at the C5 of the pyrimidine nucleus for it to react with the -carbon
atom of the -halo aldehydes or ketones to afford exclusively pyrrolo[2,3-d]pyrimidines.
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Scheme 7 Synthesis of pyrrolo[2,3-d]pyrimidines 34.
Seela and Luepke185 first reported the synthesis of 6-substituted 2-amino-3,7dihydropyrrolo[2,3-d]pyrimidin-4-one 34 from 1,3-dioxolane-2-propanoic acid 33, α-cyano-2methyl-ethyl ester 31 and guanidine 32 (Scheme 7).

Scheme 8. Synthesis of 5,6-disubstituted pyrrolo[2,3-d]pyrimidine 39.
Gibson et al.186 also reported the synthesis of 5,6-disubstituted-pyrrolo[2,3-d]pyrimidine.
2-Chloro-2-cyanoethanal 36 was reacted with 35 to afford exclusively the 7-cyano-7-deazaguanine
37. Substituents at C-5 and C-6 were obtained by brominating the primary deazaguanine 37 with
N-bromosuccinimide in DMF to afford the 7-cyano-8-bromo derivative 39. These transformations
establish methods for the synthesis of a wide range of 5,6-disubstituted pyrrolo[2,3-d]pyrimidine.

- 49 -

Scheme 9 Synthesis of 2-amino-4-methyl pyrrolo[2,3-d]pyrimidine 45.
In 2000, Gangjee, et al.,187 reported the synthesis of 2-amino-4-methylpyrrolo[2,3d]pyrimidine 45 (Scheme 9) via a novel ring closure method. The synthesis started with
condensation of 2-acetylbutyrolactone 40 with guanidine carbonate 32 to afford the substituted
pyrimidine 41. Chlorination with POCl3 provided the dichloro compound 42 which was in turn
condensed

with

benzylamine

to

afford

2-amino-4-methyl-7-(N-benzyl)piperidinyl[2,3-

d]pyrimidine 43. Oxidative aromatization of this compound with MnO2 provided the N7benzylated compound 44. Compound 45 was obtained following debenzylation of 44 with metallic
sodium in ammonia.
In 2001, Gangjee, et al.,188 reported the synthesis of 2-(2-amino-4-oxo- 4,7-dihydro-1Hpyrrolo[2,3-d]pyrimidin-6-yl)acetic acid 47 from the condensation of 2,6-diaminopyrimidin4(1H)-one 16 with ethyl 4-chloro-3-oxobutanoate 46 in the presence of sodium acetate (Scheme
10).
In another report of 2001, Gangjee, et al., also reported the synthesis of 2-amino-4-oxo4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 49 (Scheme 11) from the condensation
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of compound 16 with 2-chloro-3-oxopropanenitrile 48 under basic conditions.189

Scheme 10 Synthesis of 2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d] pyrimidin-6yl)acetic acid 47.

Scheme 11 Synthesis of 2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidine-5- carbonitrile
49.
In 1991, Miwa and coworkers190 reported a series of 2,4-diamino-5-arylalkyl substituted
classical pyrrolo[2,3-d]pyrimidine antifolates. In this synthetic approach (Scheme 12), the ring
system was constructed by the spontaneous lactam formation of the tert-butyl ester of (2,4,6triamino-pyrimidin-5-yl)-acetic acid which was in turn generated in situ by the condensation of
guanidine 32 and the malonodinitrile derivative 51. The resulting lactam 52 was subjected to
borane reduction to afford the pyrrolo[2,3-d] pyrimidine intermediate 54 along with its 5,6-dihydro
analog 53, which were separated by flash chromatography in 45% and 46% yields, respectively.
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Scheme 12 Synthesis of pyrrolo[2,3-d]pyrimidine 54.
Taylor et al.191reported a novel synthesis of PMX (Scheme 13) which involved the
spontaneous cyclization of 6-amino-5-pyrimidylacetaldehydes 58 which in turn was generated
utilizing the Nef reaction with compound 58 onto the adjacent amino group. 2,6-Diamino-4-oxopyrimidine, 16 was known to form Michael adducts at its unsubstituted C-5 position. 192-196 The
synthesis of 58 thus involved a Michael addition reaction between the Michael acceptor 56 and
compound 16. The Michael acceptor 56 was in turn synthesized in three steps that involved a
palladium-catalyzed cross-coupling197 between methyl 4-iodobenzoate 56 and allyl alcohol, aldol
condensation with nitromethane followed by dehydration with methanesulfonyl chloride in the
presence of triethylamine.198 As expected, the condensation between 56 and 16 afforded the nitro
derivative 57 in high yield. Compound 58 was converted to 4-[2-(2-amino-4-oxo-7H-pyrrolo[2,3d]pyrimidin-5-yl]ethylbenzoic acid 59 by the Nef reaction in a one-pot, five-step procedure.
Conversion of acid 59 to PMX involved standard peptide coupling with diethyl L-glutamate using
2-chloro-4,6-dimethoxy-1,3,5-triazine as the coupling agent in presence of N-methylmorpholine
and final saponification.
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Scheme 13 Synthesis of pyrrolo[2,3-d]pyrimidine 59 from 6-amino-5-pyrimidylacetalde-hydes 58.

Scheme 14 Synthesis of PMX from α-bromo aldehyde 64.
Barnett and coworkers also reported199 in 1999 a practical synthesis of PMX (Scheme 14)
which involved the cyclization of 2-bromo-4-arylbutanal 63 with 2,4-diamino-6-oxo-pyrimidine
16 regioselectively provided 5-substituted pyrrolo[2,3-d]pyrimidine 64 as shown in Scheme 14.
The key intermediate α-bromo aldehyde 63 was synthesized from aryl bromide 60 and alkyne 61
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with Sonogashira coupling followed by reduction of the triple bond, oxidation to aldehyde and
corresponding bromination of the aldehyde 62.

Scheme 15 Synthesis of pyrrolo[2,3-d]pyrimidines 71.
Legraverend and coworkers200 reported the synthesis of pyrrolo[2,3-d]pyrimidines 71 from
2-amino-4,6-dichloro-5-(2,2-diethoxyethyl)pyrimidine 68 (Scheme 15). Thus, 5-allyl-2-amino4,6-dihydroxypyrimidine 65, prepared by the reaction of guanidine hydrochloride with diethyl
allylmalonate, was converted to the 4,6-dichloro derivative 66 by treatment with POCl3, and
diethylaniline in the presence of PCl5. The (2-amino-4,6-dichloropyrimidin-5-yl)acetaldehyde 67
was obtained from 66 by ozonolysis of the allyl group (Scheme 15). The diethylacetal derivative
69 of 68 was prepared by using standard methods. The acetal 69 was cyclized to 2-amino-4-chloro7-alkyl-7H-pyrrolo-[2,3-d]pyrimidine 70 by treatment with dilute aqueous HCl at room
temperature. Compound 71 was then obtained by hydrolysis of the 4-chloro group of 70 using 1
N HCl at 100 °C.
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Kondo et al.201 reported the synthesis of 4-methyl pyrrolo[2,3-d]pyrimidine 74 via a
palladium(0)

catalyzed

cross-coupling

of

terminal acetylenes

73

with

N-(5-halo-4-

pyrimidinyl)methane sulfonamides 72 (Scheme 16).

Scheme 16 Synthesis of 4-methyl pyrrolo[2,3-d]pyrimidines 74.
In the same report, Kondo and coworkers201 also reported the synthesis of 2,4-dimethyl
pyrrolo[2,3-d]pyrimidine 80 via a photoinduced or thermal cyclization of 4-azidopyrimidines 79
containing an olefinic functionality at the 5-position (Scheme 17). Intermediates 79 were obtained
by a palladium catalyzed cross-coupling between the 5-iodopyrimidine 75 and appropriate
stannanes 76, followed by nucleophilic displacement of the 4-chloro in pyrimidine 78 in the
presence of sodium azide.

Scheme 17 Synthesis of 2,4-dimethyl pyrrolo[2,3-d]pyrimidines 80
Sakamoto and coworkers202 reported in 1993 the synthesis of pyrrolo[2,3-d]pyrimidines 84
by utilizing an intramolecular cyclization of protected 5-acetaldehyde pyrimidines 83 (Scheme 18).
Compounds 83 were synthesized by palladium (0) catalyzed coupling of the appropriate 2,4disubstituted-5-bromo-6-acetamido pyrimidine 81 with (Z)-1-ethoxy-2-(tributylstannyl)ethane 82.
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The same methodology was also applicable for the synthesis of pyrrolo[3,2-d]pyrimidines, except
that, 5-acetylamino-4-iodopyrimidine was used as the starting material.

Scheme 18 Synthesis of pyrrolo[2,3-d]pyrimidines 84.
Wright, et al.203 reported acid-catalyzed (Fisher indole cyclization) cyclization of 6(phenylhydrazino) uracils 86 to 9H-pyrimido[4,5-b]indole-2,4-diones 85. Several authors have
employed the Fischer indole cyclization of 4-pyrimidinylhydrazones 87 (Scheme 19) to afford the
pyrrolo[2,3-d]pyrimidine ring system 88.204-208The applicability of the Fischer-indole cyclization
to the synthesis of pyrrolo[2,3-d]pyrimidines, however is limited by the high reaction temperatures
and the steric constraints for the [3,3] sigmatropic rearrangement involved in the mechanism.

Scheme 19. Synthesis of pyrrolo[2,3-d]pyrimidines via Fischer indole cyclization.
Gangjee, et al.209 reported the synthesis of 2-amino-4-methylpyrrolo[2,3-d]pyrimidine.
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Compound 89 (Scheme 20) and guanidine carbonate were refluxed with absolute ethanol in the
presence of triethylamine or sodium methoxide to afford 90. Compound 90 was converted to 91
by refluxing with phosphorus oxychloride. Condensation of benzylamine with 91 in the presence
of triethylamine under reflux in n-BuOH afforded the bicyclic compound 92. Compound 92 was
oxides to aromatic compound 93 using MnO2. Sodium in liquid ammonium at -78 °C afforded 94.

Scheme 20. Synthesis of pyrrolo[2,3-d]pyrimidines 94
1.2 From Pyrroles precursors
in 1965, Taylor, et al.210 reported the synthesis of 4-amino-5-cyano-pyrrolo[2,3d]pyrimidine 100 (Scheme 21) starting from the tetracyanoethylene 95 via 2-mercapto-3,4dicyano-5-aminopyrrole 97.211 Reaction of 98 with triethylorthoformate followed by ammonia
results in the formation of a formamidine intermediate which then cyclizes to 99. The mercapto
group of 99 could be removed by Raney nickel (RaNi) to afford 100. Formamidine acetate 98 also
condensed with 97 to give 99 but in lower yields.
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Scheme 21 Synthesis of 4-amino-5-cyanopyrrolo[2,3-d]pyrimidine 100.

Scheme 22 Synthesis of 4-amino-5-substituted pyrrolo[2,3-d]pyrimidines 105
In the same report, Taylor, et al.210 synthesized 4-amino-5-methyl-pyrrolo[2,3d]pyrimidine 105 (Scheme 22) from 2-amino-3-cyano-5-substituted pyrroles 104 which in turn
were obtained from malonodinitrile 103 and the appropriate -aminoketones 101. Treatment of
pyrrole 104 with triethylorthoformate followed by ammonia resulted in the imidine intermediates
104 which underwent cyclization with sodium methoxide in pyridine to afford the pyrrolo[2,3- 58 -

d]pyrimidine 105. The fact that pyrroles 103, did not cyclize to pyrrolo[2,3-d]pyrimidine 105 in
ethanolic ammonia was attributed to the absence of the second nitrile group in the pyrrole 103.
Tolman and coworkers211 reported the synthesis of pyrrolo[2,3-d]pyrimidine 107 by
cyclization of 2-amino-5-bromo-3,4-dicyanopyrrole 106 with formamidine acetate (Scheme 23).
Ramasamy and coworkers212 have also utilized the pyrrole 106 to form the pyrrolo[2,3d]pyrimidine ring system for use in nucleoside synthesis. The versatility of the pyrrole 106
prompted Swayze et al213 to synthesize it in an efficient one-step reaction from tetracyanoethylene
95. On controlled addition of HBr in acetic acid 95 undergoes an intramolecular self-condensation
to afford 106.

Scheme 23 Synthesis of 5,6-disubstitutedpyrrolo[2,3-d]pyrimidine 107

Scheme 24 Synthesis of 2,5,6-trimethyl pyrrolo[2,3-d]pyrimidine 111
Eger and coworkers214,215reported the synthesis of 2,5,6-trimethylpyrrolo[2,3-d]pyrimidine
111 (Scheme 24) from 1-(1-phenylethyl)-2-amino-3-cyano-4,5-dimethylpyrrole 110 by heating
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with a mixture of acetonitrile and sodium methoxide. The pyrrole 110 was in turn obtained by
cyclocondensation of 3-hydroxy-2-butanone 108, 1-phenyl-ethylamine 109 and malonodinitrile
102.
Chen, et al.216 reported an efficient synthesis of pyrrolo[2,3-d]pyrimidine 118 (Scheme 25).
Acetone 112 was condensed with malonodinitrile 102 to afford 113. Bromination of 113 using
NBS and benzoyl peroxide in chloroform afforded 114. Cyclization of 114 with aryl amine 115
afforded the substituted pyrrole intermediate 116. Compound 116 was then elaborated to the
pyrrolo[2,3-d]pyrimidine 118.

Scheme 25 Synthesis of 2,5,-dimethyl-N7-substitutedpyrrolo[2,3-d]pyrimidine 118.
Barnett, et al.217 reported the synthesis of a 2-amino-4-oxo-5,6-dihydropyrrolo[2,3d]pyrimidine 123 via a guanidine cyclization of a preformed 3-carbethoxy-2-thiopyrrolidine
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intermediate 121 as the key step (Scheme 26). This intermediate was in turn prepared in several
steps from 4-propionaldehyde benzoic acid tert-butyl ester 120. Compound 122 was oxidized to
the pyrrolo[2,3-d]pyrimidine intermediate 123, 123 which was then elaborated to PMX in several
steps.

Scheme 26 Synthesis of pyrrolo[2,3-d]pyrimidine 123.
Taylor and coworkers218 reported the synthesis of a pyrrolo[2,3-d]pyrimidine analog of
PMX by a novel route (Scheme 27). A manganic triacetate dihydrate mediated radical cyclization
of

racemic

methyl

N-crotyl-N-[1-(3,4-phenyl)-eth-1-yl)malonamide

128,

afforded

a

diastereomeric mixture of the 3-carbomethoxy-2-pyrrolidinone 129. Compound 128 was in turn
obtained by alkylation of racemic 1-(3,4-dimethoxy-phenyl)-ethylamine 124 with crotyl bromide
132 followed by a DMAP catalyzed acylation with methyl malonyl chloride 127. The
pyrrolidinone 129 was converted to the thiolactam 130 with P2S5 followed by cyclocondensation
with guanidine to afford the N7-protected 5,6-dihydro-5-allyl-pyrrolo[2,3-d]pyrimidine131.
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Palladium catalyzed cross-coupling with diethyl-4-iodobenzoyl-L-glutamate fortuitously afforded
the ethano-bridged derivatives, and not the expected vinyl-bridged derivatives, by double bond
migration. This compound was then elaborated to analogs of PMX.
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Scheme 27 Synthesis of N7-substituted analogs of PMX 131.
Pedersen and coworkers219 reported the synthesis of 2,5-dimethyl pyrrolo[2,3-d]pyrimidine
136 (Scheme 28) from 2-acetylamino-3-cyano-4-methylpyrrole 135 by heating with 85%
phosphoric acid. The pyrrole 135 was in turn obtained by acetylation of 2-amino-3-cyano-4methylpyrrole 134 using acetic anhydride. Cyclocondensation of 132 or 133 with malonodinitrile
102 using sodium hydroxide afforded the precursor pyrrole 134.220,221
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Scheme 28 Synthesis of 2,5-dimethylpyrrolo[2,3-d]pyrimidine 136.
In

2005,

Bookser

and

coworkers222 reported

the

synthesis

of

pyrrolo[2,3-

d]pyrimidine 137 (Scheme 29) via the condensation between substituted pyrrole 138 and
triethylorthoformate 139 under acidic conditions.

Scheme 29 Synthesis of 5-substituted 2-des-4-oxo-pyrrolo[2,3-d]pyrimidine 139.
1.3 From Furans precursors
A general method to 2,5,6-trisubstituted-4-amino-pyrrolo[2,3-d]pyrimidines 143 was
reported by Taylor and coworkers223 (Scheme 30). Condensation of appropriate -hydroxyketones
140 with malonodinitrile 102 afforded the corresponding 2-amino-3-cyanofurans 141 which on
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cyclization with amidines 142 afforded the corresponding pyrrolo[2,3-d]pyrimidines 143 by an
unexpected ring transformation/ring annulation sequence.

Scheme 30 Synthesis of 2,5,6-trisubstitutedpyrrolo[2,3-d]pyrimidines 143.
2. Sonogashira coupling in antifolate synthesis

Scheme 31 A general transformation of Sonogashira coupling. 224, 225
In 1975, Sonogashira and coworkers226 reported the synthesis of symmetrically substituted
alkynes via a coupling reaction between acetylene gas and aryl iodides or vinyl bromides in the
presence of catalytic amounts of Pd(PPh3)Cl2 and CuI under mild conditions (Scheme 31). Thus,
the copper-palladium catalyzed coupling of terminal alkynes with aryl and vinyl halides to give
enynes is named the Sonogashira crosscoupling. Typically, two catalysts, a zerovalent palladium
complex and a halide salt of copper (I), are necessary for the reaction. Copper (I) salts, such as
copper (I) iodide, react with the terminal alkyne and produce a copper (I) acetylide, which acts as
an activated species to increase the rate of the coupling reactions. 224 However, the copper-free
- 64 -

Sonogashira coupling of aryl iodides with terminal acetylenes has been developed recently. 227-229
The Sonogashira coupling reaction also requires a base to neutralize the hydrogen halide produced
as the byproduct of this coupling reaction. The reactivity order of the aryl and vinyl halides is as:
I ≈ OTf > Br >> Cl.224, 225
Sonogashira

coupling

is

believed

to

involve

oxidative

addition-reductive

elimination pathway (Scheme 32), although the mechanism is not clearly understood.

Scheme 32 Mechanism of Sonogashira cross-coupling.230
Gangjee and coworkers reported231 in 2007 the synthesis of N-(7-benzyl-4-methyl-5(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-N-pivaloylpivalamide 146 from N-(7-benzyl5-iodo-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-N-pivaloylpivalamide 144 and phenylacetylene 145 via a Sonogashira cross-coupling in the presence of tetrakis (triphenylphosphine)
palladium(0) and CuI as catalysts in dichloromethane (Scheme 33).
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Scheme 33 Synthesis of pyrrolo[2,3-d]pyrimidin-2-yl)-N-pivaloylpivalamide 146.
In

2010,

Wang,

et

al.101 reported

the

synthesis

of

classical

2-amino-4-

oxo-6-substituted-pyrrolo[2,3-d]-pyrimidines 147a-c (Scheme 34) from terminal alkynes
149a-c and thiophenyl bromide 148 via a Sonogashira cross-coupling in the presence of
tetrakis(triphenylphosphine)palladium(0) and CuI as catalysts in DMF.

Scheme34 Synthesis of classical 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]-pyrimidines by
Sonogashira coupling.
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3. Heck coupling reaction in one-step aldehyde synthesis

Scheme 35 General transformation of Heck coupling
The Heck coupling reaction (also called the Mizoroki-Heck reaction) is the
chemical reaction of an aryl or vinyl halide (or triflate) with an alkene and a base and
palladium catalyst to form a substituted alkene.231,232 Together with the other palladium catalyzed
cross-coupling reactions, this reaction is of great importance in modern organic
synthesis as reviewed.233,234 Richard F. Heck was awarded the 2010 Nobel Prize in
Chemistry for the discovery and development of this reaction. A General transformation
of Heck coupling is shown in Scheme 35.

Scheme 36 Heck coupling to synthesis aldehyde 152 and 153.
In 1968, Heck disclosed the formation of 3-aryl aldehydes and ketones by the reaction of
primary and secondary allylic alcohols with aryl palladium complexes prepared in situ from
arylmercuric chlorides or acetates and either an equimolecular amount of a palladium (II) salt, or
a catalytic amount of this salt with an equimolecular amount of copper (II) chloride to regenerate
the palladium after each reaction cycle.235 The teams of Heck and Chalk reported in 1976
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simultaneously, but independently, a strong improvement in these couplings by disclosing that
such compounds are also obtained using aryl iodides or bromides and, furthermore, with a catalytic
amount of a palladium catalyst (Scheme 36). 236, As shown in Scheme 36, this reaction was carried
out with catalytic amount of palladium acetate at 100 C in MeCN for 0.5 hour to afford aldehydes
152 with good yield (60%) from phenyl iodide 150 and allyl alcohol 151. 236,237 This kind of Heck
coupling reactions with unsaturated alcohols has been widely used to synthesize aldehydes from
aryl halides in one step reaction.
A possible mechanism of this Heck coupling to synthesize aldehydes from phenyl iodide
and allyl alcohol was proposed in Scheme 37.

Scheme 37 A proposed mechanism of Heck coupling to synthesis aldehyde
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In 1989, Larock and coworkers239 reported an improved Heck coupling to synthesis
aldehyde 152 with much better yield (90%) and lower temperature (70 C). (Scheme 38). This
reaction between phenyl iodide 150 and allyl alcohol 151 is carried out successfully with assistance
of palladium acetate as the key catalyst, Bu4NCl as the phase transfer catalyst and lithium acetate
as the base. The easy availability of the reactants and catalysts plused the excellent yield and mild
condition made this reaction very attractive to synthesize aldehydes as versatile intermediates. 239241

However, the applications of this condition to heterocycle (such as thiophene and furan) halides

other than phenyl halides were not reported, which highly limited the application of this reaction.
239

Scheme 38 Improved Heck coupling to synthesis aldehyde 152
In 1977 Yoshida and coworkers reported242,243 a improved Heck coupling with thiophenyl
bromides as shown in Scheme 39. 2-Bromothiophene 154 was alkylated in the 2 position by
reaction with allylic alcohol 151 in the presence of Pd(OAc)2, NaI, NaHCO3 at 90 C under Ar2
for 4 h gave 76% 3-(thiophen-2-yl)propanal 155. Although this is a successful example of Heck
coupling with thiophenyl bromides, the drawbacks of this reaction are obvious: Only thiophenyl
bromide without any substitutions on the thiophenyl ring was demonstrated; the reaction tolerance
of different functional groups (e.g. –COOMe, -C=O) on the thiophene ring is not known; the
reaction condition is pretty hash: high temperature (90 C) and argon protection needed. Due to its
potential

use

in

synthesis

of

classical

antifolates
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and

analogs

such

as

RTX

and PMX,244 the mild conditioned and wide functional group tolerant Heck coupling of thiophenyl
halides with allyl alcohols to afford aldehydes in one step is highly attractive.

Scheme 39 Heck coupling with thiophenyl bromide 155
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III.

STATEMENT OF THE PROBLEM

1. Methylated (S)-2-({5-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)alkyl]-thiophene-2-carbonyl}-amino)-pentanedioic acids regio-isomers (156 -159) as
GARFTase inhibitors with selectivity for FRs and/or PCFT over RFC.

Figure 16 The structures of classical 2-amino-4-oxo-6-substituted pyrrolo[2,3-d]pyrimidine
antifolates (7,8 and 156-159).
Classical antifolates are all anions at physiologic pH, their ability to cross cell membranes
by passive diffusion is limited, so specific transporters are required for folates. There are three
major uptake systems involved in the transport of reduced folates system, all of which are shared
by antifolates.2-4 Reduced folate carrier is the major transport system for folates in mammalian
cells and tissues at physiologic pH.2-4 Folate receptor α and Folate receptor β are
glycosylphosphatidylinositol-anchored proteins that transport folates by receptor-mediated
endocytosis.5, 6 Finally, proton coupled folate transporter functions optimally at acidic pH. 7, 8
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Classical antifolates continue to serve a key role in the therapy of cancer as well as for
other diseases.245 Clinically relevant antifolates (Figure 1) such as methotrexate (MTX),
pemetrexed (PMX), and raltitrexed (RTX) are all substrates for the ubiquitously expressed reduced
folate carrier (RFC), which is the major folate transport system in tissues and tumors. RFC levels
and activities are important determinants of drug efficacy, and loss of RFC is a common mode of
antifolate drug resistance.62 However, RFC is also expressed in normal tissues and it is likely to
be a determinant of dose-limiting drug toxicity. Along with RFC, other folate membrane
transporters are recognized as important for physiologic functions in relation to in vivo folate
homeostasis and likely contribute to assorted clinical manifestations of folate deficiency. For
instance, FRα is expressed in epithelial tissues such as the renal tubules and cerebral
microvasculature where it is important in folate reabsorption and folate transport across the
bloodbrain barrier, respectively.6 A folate-proton symporter, PCFT is expressed in the upper small
intestine (e.g., jejunum) where it represents the primary mode of dietary folate absorption, and its
loss is causal in the autosomal recessive folate-deficient condition termed hereditary folate
malabsorption.4
Interestingly, these non-RFC transport mechanisms have also attracted attention for their
potentials in chemotherapy drug targeting, particularly for cancer, since FRs are expressed in a
subset of malignancies such as ovarian and endometrial cancers, 65 and PCFT is present at high
levels in assorted solid tumors (including lung cancers, ovarian cancer, and hepatomas). 246 Further,
PCFT is maximally active at pHs approximating those attained in the solid tumor
microenvironment.63 In response to the patterns of expression and function of FRs and PCFT in
tumors and normal tissues, new cytotoxic agents are being developed, by virtue of their
specificities for FRs and/or PCFT over RFC for selective tumor targeting.
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Gangjee et al.101 recently reported 6-substituted classical pyrrolo[2,3-d]pyrimidines with
varying lengths of the carbon bridge region as cytotoxic tumor-targeted antifolates (Table 3).
Pyrrolo[2,3-d]pyrimidines and thieno[2,3-d]pyrimidines (Table 3)
Structure
O

COOH
N
H

Compound

Biological Activity (IC50)

Ref.

3 n=3

hGARFTase
KB
IGROV1

18 nM
1.7 nM
2.2 nM

96

4 n=4

hGARFTase
KB
IGROV1
hGARFTase
KB
IGROV1

6.8 nM
1.9 nM
3.6 nM
13.8 nM
23 nM
4.7 nM

hGARFTase
KB
IGROV1
hGARFTase
KB
IGROV1

13.3 nM
4.9 nM
5.9 nM
0.69 nM
0.26 nM
0.55 nM

hGARFTase
KB
IGROV1

1.96 nM
0.55 nM
0.97 nM

O
COOH

HN
H2N

N

N
H

n
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O

COOH
N
H

O
COOH

HN
H2N

N

S

5 n=3
6 n=4

n
n = 2-8

7 n=3

8 n=4

5

63

These compounds were characterized by selective transport via FRα, FRβ and PCFT over
RFC. Three- and four-carbon bridge analogs were most active toward FR-expressing human
tumors and cytotoxicity was primarily due to the potent inhibition of GARFTase, the first folatedependent reaction in de novo purine nucleotide biosynthesis. The three-carbon pyrrolo[2,3d]pyrimidine derivative, 7 was subsequently reported122 to also be a substrate for PCFT, thus
providing an additional selective means of tumor targeting. Further structural optimization of
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compounds such as 7, for improved drug efficacy due to selective cellular uptake by non-RFC
transport mechanisms, and as a sbustrate for folylpolyglutamate synthase for polyglutamylation
and binding to GARFTase to inhibit purine nucleotide biosynthesis, requires a systematic variation
of individual structural features. For example, although compound 7 is highly potent, its selective
tumor-targeting via FRs and PCFT is lower than compound 8 (Table 3).
Thus, it is of interest to further explore the structure−activity relationships (SAR) for this
series to determine if absolute selectivity over RFC along with high potency for FRα, FRβ, and/or
PCFT expressing cells over RFC would be possible. In this study, we consider the SAR for cellular
uptake and inhibition of cell proliferation for the pyrrolo[2,3-d]pyrimidine scaffold of 7 and 8 in
which the thienoyl ring was replaced by methylated thienoyl regioisomers. Our goal was to explore
the SAR for novel 6-substituted pyrrolo[2,3-d]pyrimidine methylated thienoyl antifolates related
to 7 and 8 (Figure 16), the most potent compounds of our series for inhibiting proliferation of FRαand PCFT-expressing cells with substantially reduced inhibitory effects toward RFC expressing
cells. Thus, 6-substituted pyrrolo[2,3-d]pyrimidine classical antifolates with methylated thienoyl
regioisomers in the side chain 156-159 (Figure 20) were designed and synthesized to evaluate the
effect of methylation in the side chain on transport by RFC, FR and PCFT and as inhibitors of
proliferation of human KB tumor cells (IC50) via inhibition of GARFTase. Methylated thienoyl
regioisomers analogues could provide metabolic stability and perhaps alter the conformation of
the molecule to allow FRα, FRβ, PCFT, and GARFTase and/or AICARFTase for better binding at
the required active sites.
1.1 Molecular Modeling Studies
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A

Figure 17. (A) Superimposition of docked poses of 7(red) and 156 (green) in FRα (PDB:
12

5IZQ).

B

Figure 17. (B) Superimposition of docked poses of 7(green) and 157 (red) in FRα (PDB:
12

5IZQ). Modeled using MOE 2014.08.
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A

Figure 18. (A) Superimposition of docked poses of 7 (green) and 156 (red) in GARFTase (PDB:
4ZZ1).

12

B

Figure 18. (B) Superimposition of docked poses of 7 (green) and 157 (red) in GARFTase (PDB:
4ZZ1).14 Modeled using MOE 2014.08.

13

Figures 17 and 18 show the docked poses of methylated thienoyl regioisomers 156 and 157
in FRα (PDB: 5IZQ) and GARFTase (PDB ID: 4ZZ1), respectively. In FRα and GARFTase, 156
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maintains the interaction patterns of the bicyclic scaffold and L-glutamate side chain moiety as 7.
The meta-methyl group in compound 157 decreases the distance (6.94 Å) between the scaffold
and the L-glutamate side chain moiety, when compareing with that of 7 (8.15 Å), resulting in the
loss of the interaction pattern of the L-glutamate side chain. In GARFTase, compound 157 with
the methyl group shifts away from the scaffold binding region, owing to the change in its linker
conformation (due to the steric clash with the methyl group). This results in a loss of the interaction
pattern of the bicyclic scaffold, when compared to the parent 7. Though the molecular modeling
of 157 predicts a lower activity for FRα, modeling in RFC and PCFT is not currently possible due
to an absence of crystal structures. Thus, it was of interest to determine the effects of methylation
on the thiophene ring to RFC and PCFT activity.
Figures 17 and 18 show the docked poses of methylated thienoyl regioisomers 156 and 157
in FRα (PDB: 5IZQ) and GARFTase (PDB ID: 4ZZ1), respectively. In FRα and GARFTase, 156
maintains the interaction patterns of the bicyclic scaffold and L-glutamate side chain moiety as 7.
The meta-methyl group in compound 157 decreases the distance (6.94 Å) between the scaffold
and the L-glutamate side chain moiety when compared with that of 7 (8.15 Å), resulting in the loss
of the interaction pattern of the L-glutamate side chain. In GARFTase, compound 157 with the
methyl group shifts away from the scaffold binding region, owing to the change in its linker
conformation (due to the steric clash with the methyl group). This results in a loss of the interaction
pattern of the bicyclic scaffold, when compared to the parent 7. Though the molecular modeling
of 157 predicts a lower activity for FRα, modeling in RFC and PCFT is not currently possible due
to an abance of crystal structures. Thus, it was of interest to determine the effects of methylation
on the thiophene ring to RFC and PCFT activity.
Figures 19 and 20 show the docked poses of methylated thienoyl regioisomers 158 and
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159 in FRα (PDB: 5IZQ) and GARFTase (PDB ID: 4ZZ1), respectively. In FRα, 158, 159 retain
the interaction patterns of the bicyclic scaffold but loss of the interaction patterns of the Lglutamate side chain moiety as 8. However, in GARFTase, both 158 and 159 overlap with 8 and
maintain the interaction patterns of the bicyclic scaffold and L-glutamate side chain moiety as 8.

A

Figure 19. (A) Superimposition of docked poses of 8 (yellow) and 158 (purple) in FRα (PDB:
12

5IZQ).

B

Figure 19. (B) Superimposition of docked poses of 8 (yellow) and 159 (blue) in FRα (PDB:
5IZQ).

- 78 -

A

Figure 20. (A) Superimposition of docked poses of 8 (red) and 158 (green) in GARFTase (PDB:
4ZZ1).

12

B

Figure 20. (B) Superimposition of docked poses of 8 (red) and 159 (yellow) in GARFTase (PDB:
4ZZ1).14 Modeled using MOE 2014.08.

13
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2. 6-substituted pyrrolo[2,3-d]pyrimidine with three atom chain length having a nitrogen in the
bridge and fluorinated benzoyl regioisomers as GARTFase inhibitors with selectivity for FRs
and/or PCFT over RFC.

Figure 21 6-substituted pyrrolo[2,3-d]pyrimidine with three atom chain length having nitrogen
bridge and fluorinated benzoyl regioisomers compounds design.
Gangjee et al.96 previously described novel 6-substituted pyrrolo[2,3-d]pyrimidine benzoyl
antifolates with selective cellular uptake by FRs and/or PCFT over RFC, resulting in potent
inhibitory activity toward human tumor cells.96 The most active analog of this series, 3 included
a 3-carbon bridge (Table 3), showed high level activity toward KB human tumors (IC 50 = 1.7 nM)
expressing FRα and PCFT. Compound 4 has a 4-carbon atom bridge and showed better selectivity
than 3 for both FR and PCFT over RFC.63
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The natural substrate for GARFTase, N10-formyl tetrahydrofolate (10-CHOTHF, Figure 3),
is a 6-substituted pteridine with a –CH2-N-2-atom bridge. The N10 a formyl (CHO) moiety forms
a hydroxylated, tetrahedral intermediate prior to transfer of the formyl group. 129 Thus, replacement
of the benzylic CH2 of the 6-substituted pyrrolo[2,3-d] pyrimidine 3 (Table 3) with a NH would
afford “mimics” of the natural substrate side chain with a three-atom rather than two-atom bridge.
Gangjee et al.247 synthesized the 6-substituted three-atom bridged NH function as potent inhibitors
of human GARFTase rather than as substrates. The X-ray crystal structures of 161

248

with FRα

and GARFTase showed that the bound conformations of 161 were different and required flexibility
for attachment to both FRα and GARFTase. Compound 161 showed high potency against FRα and
GARFTase, but its potency and selective tumor- targeting via PCFT is lower than 3.
Recently, Gangjee et al.249report that for 160 (Figure 21), fluorine incorporation on the
aromatic group adjacent to the L-glutamate amide had better selectivity, as well as potency, toward
FR- and PCFT-expressing CHO and KB cells than its des-fluorine compound 4 (Figure 21). We
proposed that fluorine substitution could improve the selectivity in antifolates through electrostatic
molecular interactions, such as those involving fluorine hydrogen bonding and dipole interactions.
Thus, it is of interest to further explore the SAR for this series to determine if fluorinated benzoyl
regioisomers 162 and 163 (Figure 21) could have absolute selectivity along with high potency for
FRα, FRβ, and/or PCFT over RFC.
2.1 Molecular Modeling
The docked poses of 162 (Figure 22A, 23A) in FRα and GARFTase retain the hydrogen
bonding and hydrophobic interactions seen in the docked pose of the lead compound 161. In
addition, the fluorine meta to the L-glutamate side chain in 162 facilitated the interaction with the
polar hydrophobic amino acid Phe 62 and results increased potency toward against FRα-expressing
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cells. Comparing to the parent 162, fluorine ortho to the L-glutamate side chain in 163 (Figure 22B,
23B)results in a loss of interaction patterns of the L-glutamate region in FRα and GARFTase,
which causes a lower inhibitory activity toward cells expressing FRα. Alought the molecular
modeling predicts lower activity for FRα, modeling in RFC and PCFT is not currently possible
due to lack of crystal structures. Thus, it was of interest to determine the effects of fluorine on the
benzyl ring in relation to RFC, FRs and PCFT anti-proliferative activities.

A

Figure 22. (A) Superimposition of docked poses of 161 (red) and 162 (green) in FR(PDB:
247

5IZQ).

B

Figure 22. (B) Superimposition of docked poses of 161 (red) and 163 (green) in FR(PDB:
247

5IZQ).

Modeled using MOE 2014.08.

12
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A

Figure 23. (A) Superimposition of docked poses of 161 (green) and 162 (red) in GARFTase (PDB:
4ZZ1).

247

B

Figure 23. (B) Superimposition of docked poses of AGF161 (green) and 163 (red) in GARFTase
3. 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)-2fluorobenzoyl)-L-glutamic acid 167 as GARFTase inhibitors with potential selectivity for
FRs and/or PCFT over RFC
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Figure 24 5-substituted pyrrolo[2,3-d]pyrimidine antifolates with three bridge carbons and
fluorinated benzoyl ring compound 167 as antitumor agent.
As mentioned above, pemetrexed (PMX) is clinically used for the treatment of
mesothelioma and non–small cell lung cancer (NSCLC) and is currently being evaluated for the
treatment of a variety of other solid tumors in the US.172 More recently, PMX has been approved
in combination with cisplatin as a first-line treatment for patients with locally advanced or
metastatic NSCLC other than squamous cell histology.174 PMX is a multitargeted antifolate that is
protected to several folate metabolism enzymes: TS, DHFR, AICARFTase and GARFTase. 174
However, its potentional target is TS. PMX suffers from dose-limiting toxicity due to its transport
by RFC which is ubiquitously expressed in normal cells.248 To determine if altering the length of
the side chain of PMX would maintain the multitarget attributes of PMX and perhaps provide
selectivity for FR over RFC, Gangjee et al.249synthesized and evaluated the one to six carbon chain
homologs of PMX. Compound 164 and 166 (Figure 24) the 4- and 3- carbon chain homologs of
PMX, respectively have better KB cell inhibitiory potency than PMX. Compound 164 inhibits KB
cells at an IC50 of 3.6 nM, about 20-fold greater than PMX. However, 164 and 166 have poor
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PCFT inhibition potency and poor KB tumor cell inhibitiory potency. Recently, Gangjee et al.247
reported that for 165 (Figure 24), with a fluorine in the benzene adjacent to the L-glutamate amide
had better potency for PCFT and FRs, as well as better selectivity, than its des-fluoro 164 (Figure
24). Based on this result, we designed and synthesized the fluorinated benzoyl analog 167 to
evaluate the effect of fluorine in the side chain on transport by RFC, FR and PCFT, and as
inhibitors of human KB tumor cells (IC50).
4. 5-Substituted pyrrolo[2,3-d]pyrimidine with two- to- four- bridge carbons and thienoyl
regioisomers 172-174 in the side chain as GARFTase inhibitors with selectivity for FRs
and/or PCFT over RFC.

Figure 25 5-substituted pyrrolo[2,3-d]pyrimidine antifolates with two- to- four- bridge carbons
and thienoyl regioisomers in the side chain as antitumor agents.
Gangjee and coworkers101 recently reported a series of 6-substituted pyrrolo[2,3d]pyrimidine thienoyl antifolates (Figure 25). The best characterized of this series, compound 8
included a 4- carbon bridge and was selectively transported into cells by FRs and PCFT (but not
RFC) whereupon it inhibited de novo purine biosynthesis at the level of GARFTase. Compound 8
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was highly active toward both KB (IC50 = 3.17 nm) and IGROV1 (IC50 = 176 nm) tumors. In vivo
in SCID mice with KB tumor xenograft, 8 was highly active against both early and advanced stage
tumors. Based on the 5-substituted pyrrolo[2,3-d]pyrimidine structure of PMX and our results with
the 6-substituted compound 8, it was of interest to synthesize 5-substituted pyrrolo[2,3d]pyrimidine thienoyl analogs with 2 to 4- carbon atoms in the bridge (169-171) as hybrid
molecules of PMX and 8. These analogs were expected to afford the multi-targeted attributes of
PMX, while preserving FRα and/or PCFT specificity of the 6-substituted analogs previously
reported. However, 171 showed less activity against KB tumor cell, FRs and PCFT than 8.
Knowing that compound 863 is an excellent lead analog for further structure optimization for
inhibition of GARFTase and as for transport selectivity by FRs and/or hPCFT over RFC.
Compound 168 was designed to probe the importance of the regio-positions of the 4-carbon bridge
and the L-glutamate moiety on the side chain thienoyl ring of 8. The biological result showed that
168 had 10-fold more FRα activity than 8. Based on this result, compounds 172-174 were designed
to improve the potency and selectivity of 5-substituted pyrrolo[2,3-d]pyrimidine thienoyl
antifolates against FRs, PCFT and KB tumor cells.

IV.

CHEMICAL DISCUSSION

1. The synthesis of methylated (S)-2-({5-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-methyl]-thiophene-2-carbonyl}-amino)-pentanedioic acid isomers 156 and
157.
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177 X = H, Y= CH3 (73%)
178 X = CH3, Y = H (71%)
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193 X = H, Y= CH3, R2 = C2H5 (53%)
194 X = CH3, Y = H, R2 = C2H5 (64%)
h
156 X = H, Y= CH3, R2 = H (75%)
157 X = CH3, Y = H, R2 = H (76%)

191 X = H, Y= CH3, R1 = H (95%)
192 X = CH3, Y = H, R1 = H (97%)

Scheme 40a Synthesis of classical three carbon atoms side chain methylated thiophene 2-amino4-oxo-6-substitutedpyrrolo[2,3-d]pyrimidine isomers 156,157.
a

Conditions: (a) but-3-yn-ol, CuI, PdCl2, PPh3, Et3N, CH3CN, microwave,100 0C,10 min;

(b)10% Pd/C, H2, 55 psi, MeOH, overnight; (c) H5IO6, pyridinium chlorochromate, 0 0C, 3h; (d)
oxalyl chloride, CH2Cl2, reflux, 1h; (e) diazomethane, Et2O, RT, 1h; (f) HBr, reflux, 2h; (g) 2,6diamino-3H-pyrimidin-4-one, DMF, RT, 3 days; (h) i. 1 N NaOH, RT, overnight; ii. 1 N HCl; (i)
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N-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate diethyl ester
hydrochloride, DMF, RT, overnight.
The synthesis of target compound 156 and 157 followed a modification of a reported
procedure101 as shown in Scheme 40. A palladium-catalyzed Sonogashira coupling of 5-bromo-3methylthiophene-2-carboxylate 175 and 5-bromo-4-methylthiophene-2-carboxylate 176, with but3-yn-1-ol respectively, afforded butynyl alcohols 177, 178 (73%, 71%) respectively, which were
catalytically hydrogenated to give the saturated alcohols 179, 180 respectively in quantitative yield.
Subsequent oxidation of 179 and 180 using Jones reagent afforded the carboxylic acids 181, 182
(94%, 83%) respectively, which were converted to the acid chlorides 183 and 184 and immediately
reacted with diazomethane followed by 48% HBr to give the desired α-bromomethyl ketones 187
and 188. Condensation of 2,6-diamino-3H-pyrimidin-4-one, with 187, 188 at room temperature
for 3 days afforded the 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines 189, 190 (41%,
30%) respectively. Hydrolysis of 189 and 190 afforded the corresponding free acids 191, 192 (95%,
97%). Subsequent coupling with L-glutamate diethyl ester using 2-chloro-4,6-dimethoxy-1,3,5triazine as the activating agent afforded the diesters 193, 194. Final saponification of the diesters
gave the desired compounds 156 and157.
In this study, one of the most important and difficult challenge is to characterize the
stuructures of these two regioisomers, compound156 and 157. Although the starting materials for
synthesis 156 and 157 are commercially available, it is still necessary to distinguish between
regioisomer 5-bromo-3-methylthiophene-2-carboxylate 175 and 5-bromo-4-methylthiophene-2carboxylate 176 (Figure 26).
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Figure 26 Structure of 5-bromo-3-methylthiophene-2-carboxylate 175 and 5-bromo-4methylthiophene-2-carboxylate 176
Compound 175 and 176 have two electongeative founctional group are attached to the same
position of thiophene ring. These two electron withdrawing groups, bromine and carboxylic ester,
can affect chemical shift of the adjacent proton to be desheilded. The higher electonegativity
difference between H and its surrounding atoms results a higher chemical shift. This is because
the higher the electronegativity difference between H and another atom, the lower the electron
density is around the H (proton), and thus the more deshielding the proton experiences. In fact, the
electronegativity of the carboxylic ester is greater than bromine. Therefore, the proton ortho to the
bromine should have a lower chemical shift than the proton ortho to the carboxylic ester. The 1H
NMR data showed that the chemical shift of C3-H (δ 6.83 ppm) of 175 is less than the chemical
shif of the C3-H (δ 7.56 ppm) of 176. The chemical shift of the methyl group of 175 is greater than
the methyl group of 176. Based on this difference in 1H NMR chemical shifts in the thiophene ring,
the structure of 175 and 176 can be assigned.
In this study, the current synthetic method was optimized and simplified via synthetic steps,
separation procedure, shorte the reaction time and increased yield. Firstly, optimization the
reaction conditions of the palladium-catalyzed Sonogashira reaction. Without changing the
reaction regents, a microwave reaction replaced the high temperature reflux reaction (80 0C, 6-8h)
afforoded alcohols 177, 178 (73%, 71%) respectively. Comparing with the reflux condition,
microwave reaction shortened the Sonogashira reaction from 8 hours to 10 minutes. Instead of
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generation multiple spots on TLC, this microwave reaction generated one clear spot. Therefore,
this microwave reaction significantly simplified the separation step and save cost of separation. In
addition, the microwave reacrion increased the yield from 54%, 58% to 73%, 71% respectively.
Since microwave reaction took 10 minutes to complete the Sonogashira coupling, it could be a
potential methodology for scale-up synthesis.
In the alcohol oxidation step, different reaction regents were selected to increase the yield
and shorton the reaction time. Instead of chromium trioxide as the oxidation regents (CrO 3, H2SO4,
24h, rt), periodic acid with pyridinium chlorochromate (H 5IO4, PCC, 3h, rt) was used to convert
the alcohol to the carboxylic acids 181, 182 (94%, 83%) respectively. This optimization shortened
the reaction time more than 21 hours and doubled the yield.
For the synthesis of the key intermediate α-bromomethyl ketones 187 and 188 step, fresh
diazomethane was used to convert acid chlorides 183 and 184 into the haloketones. Comparing
with the equivalent reagent trimethylsilyldiazomethane, freshly produced diazomethane works
much faster to generate the desired haloketone.The only limition of diazomethane is that it is
hazardous on an industrial scale without special precautions. However, it is a popular methylating
agent in the laboratory. It is universally used as a solution in diethyl ether and kept at lower
temperature.
2. The synthesis of methylated (S) -5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3d]pyrimidin-6-yl)butyl)thiophene-2-carbonyl)-L-glutamic acid isomers 158 and 159.
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Scheme 41a Synthesis of classical four carbon atoms side chain methylated thiophene2-amino-4oxo-6-substituted pyrrolo[2,3-d]pyrimidine isomers 158,159.
a

Conditions: (a) pent-4-yn-ol, CuI, PdCl2, PPh3, Et3N, CH3CN, microwave,100 0C,

10 min; (b)10%Pd/C, H2, 55psi, MeOH, overnight; (c) H5IO6, pyridinium chlorochromate, 0 0C,
3h; (d) oxalyl chloride, CH2Cl2, reflux, 1h; (e) diazomethane, Et2O, RT, 1h; (f) HBr, reflux, 2h;
(g) 2,6-diamino-3H-pyrimidin-4-one, DMF, RT, 3days; (h) i. 1N NaOH, RT, overnight; ii. 1 N
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HCl; (i) N-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate diethyl ester
hydrochloride, DMF, RT, overnight.
The synthesis of target compound 158 and 159 followed a modification of a reported
procedure101as shown in Scheme 41. A palladium-catalyzed Sonogashira coupling of methyl 5bromo-3-methylthiophene-2-carboxylate

175

and

methyl

5-bromo-4-methylthiophene-2-

carboxylate 176, with pent-4-yn-ol, afforded butynyl alcohols 195, 196 (72%, 78%) respectively,
which was catalytically hydrogenated to give the saturated alcohol 197, 198 in quantitative yield.
Subsequent oxidation of 197 and 198 using Jones reagent afforded the carboxylic acid 199, 200
(80%, 80%) respectively, which was converted to the acid chloride 201 and 202 and immediately
reacted with diazomethane followed by 48% HBr to give the desired α-bromomethylketone203
and 204 respectively. Condensation of 2,6-diamino-3H-pyrimidin-4-one, with 203, 204 at room
temperature for 3 days afforded the 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines 205,
206 (38%, 33%) respectively. Hydrolysis of 205, 206 afforded the corresponding free acid 207,
208 (81%, 87%) respectively. Subsequent coupling with L-glutamate diethyl ester using 2-chloro4,6-dimethoxy-1,3,5-triazine as the activating agent afforded the diesters 209, 210 respectively.
Final saponification of the diesters gave the desired compound 158 and 159.

3 .The synthesis of (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)fluorobenzoyl)-L-glutamic acid isomers 162 and 163.
The retro synthetic route A was proposed as shown in Scheme 42. From route A (Scheme
42), it was anticipatied that nucleophilic substitution of 217 and 218 would afford the ketone 216.
Ketone 216 could then can be converted to the α-bromoketone compound 215. Sequential
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condensation with 2,6-diamino-3H-pyrimidin-4-one 214, hydrolysis, L-glutamate peptide
coupling, and saponification would afford the desired compound 213.

Scheme 42. Retro synthetic route A.
Synthesis of compounds 225 and 226 were attempted (Scheme 43). Compound 219 and
220 were reacted with the α, β- unsaturated methyl ketone 217 to afford 221 and 222 respectivly.
Compound 221, 222 reacted with 33% HBr in acetic acid and bromine afforded the α-bromoketo
compounds 223, 224 respectivly. Condensation of 223, 224 with compound 214 failed to provide
compounds 225, 226. TLC of the reaction shows multiple spots at R f = 0.5 (5:1, Chloroform:
Methanol), separation of these spot could not be achieved. This could be because of the instability
of the α-bromomehtyl ketone in the presence of a secondary or tertiary nitrogen. Protection of the
nitrogen was considered as the next strategy to obtain the target compounds.
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Scheme 43. Condensation recation between 223, 224 and 214.
The synthesis of target compound 162 and 163 followed a modification of a reported
procedure291as shown in Scheme 44. Commercially available methyl 4-amino-3- fluorobenzoate
219 and methyl 4-amino-2-fluorobenzoate 220 were reacted with methyl vinyl ketone through a
Michael addition to afford the β-keto amines 221 and 222 respectively. Selective bromination of
the α-carbon of 221 and 222 under acidic condition using 33% HBr in acetic acid/Br2 afforded the
α-bromoketone 223 and 224. Trifluroacetic anhydride was converted without protection of the αbromoketones 223 and 224. Subsequently, the protected amine was reacted with 2,6-diamino-3Hpyrimidin-4-one in DMF at room temperature for 3 days to afford the 2-amino-4-oxo-6substituted-pyrrolo[2,3-d] pyrimidines 227 and 228. Hydrolysis of 227 and 228 gave the
corresponding free acids 229 and 230 respectively. Subsequent coupling with L-glutamate di- tertbutyl ester using 2-chloro-4,6-dimethoxy-1,3,5-triazine as the activating agent afforded the di-tertbutyl esters 231 and 232 respectively. Deprotection of di-tert-butyl ester using trifluroacetic acid
afforded the corresponding final compounds 162 and 163 respectively.
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Scheme 44a Synthesis of classical 6-substituted pyrrolo[2,3-d]pyrimidine with a three atom chain
length with a nitrogen atom and fluorinated benzoyl regioisomers 162 and 163.
a

Conditions: (a) but-3-en-2-one, ethanol, reflux, 5 h; (b) 33% HBr in CH 3COOH, Br2, rt,

2.5 h; (c) (CF3CO)2O, rt, overnight; (d) 2,6-diaminopyrimidin-4(3H)-one, DMF, rt, 3 d; (e) 1N
NaOH, rt, 10 h; (f) N-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate
diethyl ester hydrochloride, DMF, RT, overnight; (g) CF3COOH, CH2Cl2, rt, 2 h
4. The synthesis of (S)- (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)propyl)-2-fluorobenzoyl)-L-glutamic acid 167.

- 95 -

Scheme 45. Synthetic route A of 167.
The retro synthetic route A was proposed as shown in Scheme 45. The proposed synthesis
followed a modification of a reported procedure.101A palladium-catalyzed Sonogashira coupling
of methyl 4-bromo-3-fluorobenzoate 233 with but-3-yn-1-ol 234, afforded alcohol 235, which was
catalytically hydrogenated to give the saturated alcohol 236. Subsequent oxidation of 236 afforded
the aldehyde 237. However, over three steps, the total yield of the aldehyde was less than 20%.
Starting from the Sonogashira coupling to afford aldehyde 237, usually takes three steps and more
than three days. To improve the yield and simplify the reaction, the synthesis of the aldehyde 237
was optimized by designing a Heck coupling instead of the Sonogashira coupling. Another
methodology optimization in the synthesis of 167 is to optimize the synthsis step of the key
intermediate α-bromoaldehyde 238. Bromine and 1,4-dioxane as a mild brominating agent was
used to convert the aldehyde 237 into the α-bromoaldehyde 238 (82%). Compared with other
brominating

agents,

such

as

5,5-dibromo-2,2-dimethyl-1,3-dioxane-4,6-dione,
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this

dioxanedibromide shortened the bromination reaction from 36 hours to 3 hours and increased the
yield from 30% to 82%.
The synthesis of target compound 167 followed a modidification of a reported
procedure290as shown in Scheme 46. A palladium-catalyzed Heck coupling reaction of 233 with
pent-4-en-1-ol 234 in DMF 85 0C afforded the aldehyde 237. Reaction of 237 with bromine in
dioxane at 0 0C afforded the corresponding α-bromoaldehyde 238. The α-bromoaldehyde 238
reacted with 2,6-diamino-3H-pyrimidin-4-one in DMF at 45 0C in the presence of sodium acetate
to afford 5-substituted-pyrrolo[2,3-d]pyrimidine 239. Subsequent hydrolysis of 239 with 1 N
NaOH followed by coupling with L-glutamate dimethyl ester using N-methyl morpholine and 2,4dimethoxy-6-chlorotriazine as the activating agents afforded the diester 241. Final saponification
of the diester with 1 N NaOH gave the target compound 167.
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Scheme 46a Synthesis of classical 5-substituted pyrrolo[2,3-d]pyrimidine antifolates with three
bridge carbons and fluorinated benzoyl 167.
a

Conditions: (a) pent-4-en-1-ol, Pd(OAc)2, n-Bu4NCl, LiOAc, LiCl, ACN, 85 0C, 4h; (b)

Br2, Dioxane, 3h, 0C; (c) 2,6-diamino-3H-pyrimidin-4-one, CH3COONa, H2O/MeOH (1:1), 45
0

C, 4h; (d) i. 1N NaOH, RT, overnight; ii. 1 N HCl; (e) N-methylmorpholine, 2-chloro-4,6-

dimethoxy-1,3,5-triazine, L-glutamate diethyl ester hydrochloride, DMF, RT, overnight. (d) i. 1N
NaOH, RT, overnight; ii. 1 N HCl;
5. The synthesis of (S)-5-substituted pyrrolo[2,3-d]pyrimidine with two- to- four bridge carbons
and thienoyl regioisomers 172-174.
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Scheme 47a Synthesis of classical 5-substituted pyrrolo[2,3-d]pyrimidine antifolates 172-174.
a

Conditions: (a) 3-buten-1-ol, 5-hexen-1-ol, pent-4-en-1-ol, Pd(OAc) 2, n-Bu4NCl, LiOAc,

LiCl, ACN, 85 0C, 4h; (b) 5,5-dibromo-2,2-dimethyl-1,3-dioxane-4,6-dione, 2N HCl, 24 h, RT;
(c) 2,6-diamino-3H-pyrimidin-4-one, CH3COONa, H2O/MeOH (1:1), 45 0C, 4h; (d) i. 1N NaOH,
RT, overnight; ii. 1 N HCl; (e) N-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, Lglutamate diethyl ester hydrochloride, DMF, RT, overnight. (d) i. 1N NaOH, RT, overnight; ii. 1
N HCl;
The synthesis of target compounds 172-174 followed a modidication of a reported
procedure290 as shown in Scheme 47. A palladium-catalyzed Heck coupling reaction of methyl 4bromothiophene-2-carboxylate 242 with 3-buten-1-ol, 5-hexen-1-ol, pent-4-en-1-ol in DMF 85 0C
afforded the aldehydes 243-245 respectively. Compounds 243-245 reacted with 5,5- dibromo-2,2dimethyl-4,6-dioxo-1,3-dioxane at room temperature afforded the corresponding α-bromo
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aldehydes 246-248. Subsequently, the α-bromoaldehydes 246-248 were eacted with 2,6-diamino3H-pyrimidin-4-one in DMF at 45 0C in the presence of sodium acetate to afford 5-substitutedpyrrolo[2,3-d] pyrimidines 249-251. Hydrolysis 249-251 with 1 N NaOH followed by coupling
with L-glutamate dimethyl ester using N-methyl morpholine and 2,4-dimethoxy-6-chlorotriaine as
the activating agents afforded the diester 255-257. Final saponification of the diester with 1 N
NaOH gave the target compounds 172-174.
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V. SUMMARY
The design and synthesis of classical 6-substituted pyrrolo[2,3-d]pyrimidines and 5substituted pyrrolo[2,3-d]pyrimidines as potential antifolates have been described. As a part of
this study, a series of new compounds have been synthesized and characterized. Of these, over
ten compounds were submitted for biological evaluation.
The target compounds synthesized as part of this study are as follows:
1．

The synthesis of (S) -(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6yl)propyl)-3-methylthiophene-2-carbonyl)-L-glutamic acid 156

2.

The synthesis of (S) -(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6yl)propyl)-4-methylthiophene-2-carbonyl)-L-glutamic acid 157

3.

The synthesis of (S) -5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6yl)butyl)-3-methylthiophene-2-carbonyl)-L-glutamic acid 158

4.

The synthesis of (S) -5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6yl)butyl)thiophene-2-carbonyl)-L-glutamic acid 159

5.

The synthesis of (S)- 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6yl)ethyl)amino)-3-fluorobenzoyl)-L-glutamic acid 162

6.

The synthesis of (S)-4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6yl)ethyl)amino)-2-fluorobenzoyl)-L-glutamic acid 163

7.

The synthesis of (S)- (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)propyl)-2-fluorobenzoyl)-L-glutamic acid 167

8.

The synthesis of (S)- (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl)thiophene-2-carbonyl)-L-glutamic acid 172

9.

(S)- (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)propyl)thiophene-2-carbonyl)-L-glutamic acid 173
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10.

The synthesis of (S)- (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)thiophene-2-carbonyl)-L-glutamic acid 174
During this study, a synthetic procedure for synthesizing 6-substituted pyrrolo[2,3-

d]pyrimidines was successfully exploited. In addition a synthetic method leading to novel 5substituted pyrrolo[2,3-d]pyrimidines was accomplished. The classic analog 157 showed excellent
potent activities for FRα, FRβ and PCFT, and high selectivity for FRα, FRβ and PCFT over RFC.
Compound 157 further demonstrated potent inhibition of tumor cells in culture (IC 50 = 0.3 nM
toward KB cells).
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VI . EXPERIMENTAL
All evaporations were carried out in vacuum with a rotary evaporator. Analytical samples
were dried in vacuo (0.2 mmHg) in a CHEM-DRY drying apparatus over P 2O5 at 60 °C. Melting
points were determined on a MEL-TEMP II melting point apparatus with FLUKE 51 K/J
electronic thermometer and are uncorrected. Nuclear magnetic resonance spectra for proton (1H
NMR) were recorded on Bruker Avance II 400 (400 MHz) and 500 (500 MHz) spectrometer. The
chemical shift values are expressed in ppm (parts per million) relative to tetramethylsilane as an
internal standard: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet. Thinlayer chromatography (TLC) was performed on Whatman Sil G/UV254 silica gel plates with a
fluorescent indicator, and the spots were visualized under 254 and 366 nm illumination.
Proportions of solvents used for TLC are by volume. Column chromatography was performed on
a 230-400 mesh silica gel (Fisher, Somerville, NJ) column. The amount (weight) of silica gel for
column chromatography was in the range of 50-100 times the amount (weight) of the crude
compounds being separated. Columns were dry-packed unless specified otherwise. Elemental
analyses were performed by Atlantic Microlab, Inc., Norcross, GA. Element compositions are
within ±0.4% of the calculated values. Fractional moles of water or organic solvents frequently
found in some analytical samples of antifolates could not be prevented despite 24-48 h of drying
in vacuo and were confirmed where possible by their presence in the 1H NMR spectra. All solvents
and chemicals were purchased from Aldrich Chemical Co. and Fisher Scientific and were used as
received.
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Methyl 5-(4-hydroxybut-1-yn-1-yl)-3-methylthiophene-2-carboxylate 177.
To a 20-mL vial for microwave reaction, was added a mixture of palladium chloride (71
mg, 0.4 mmol), triphenylphosphine (131 mg, 0.4 mmol), copper iodide (304 mg, 1.6 mmol),
triethylamine (10.1 g, 100 mmol), methyl 5-bromo-4-methylthiophene-2-carboxylate 175 (2.35 g,
10 mmol) and anhydrous acetonitrile (10 mL). To the stirred mixture, was added but-3-yn-ol (1.05
g, 10.5 mmol), and the vial was sealed and placed into the microwave reactor at 100 0C for 10 min.
Then, silica gel (5 g) was added, and the solvent was evaporated to afford a plug under reduced
pressure. The resulting plug was loaded on to a silica gel column (3.5 × 12 cm) and eluted with
hexane followed by 40% EtOAc in hexane. The desired fraction (TLC) were pooled and
evaporated to afford 177 (1.63 g), yield 73% as yellow oil. TLC Rf = 0.37 (hexane/ EtOAc, 1:1); 1
H NMR (400 MHz, DMSO-d6) δ 2.43 (s, 3H, ArCH3), 2.60-2.62 (t, 2H, CH2CH2OH, J = 6.4 Hz),
3.57-3.59 (t, 2H, CH2CH2OH, J = 6.4 Hz), 3.79 (s, 3H, OCH3), 4.96-4.98 (t, 1H, OH, exch, J =
5.6 Hz), 7.16 (s, 1H, Ar).
Methyl 5-(4-hydroxybut-1-yn-1-yl)-4-methylthiophene-2-carboxylate 178.
To a 20-mL vial for microwave reaction, was added a mixture of palladium chloride (71
mg, 0.4 mmol), triphenylphosphine (131 mg, 0.4 mmol), copper iodide (304 mg, 1.6 mmol),
triethylamine (10.1 g, 100 mmol), methyl 5-bromo-4-methylthiophene-2-carboxylate 176 (2.35 g,
10 mmol) and anhydrous acetonitrile (10 mL). To the stirred mixture, was added but-3-yn-ol (1.05
g, 10.5 mmol), and the vial was sealed and placed into the microwave reactor at 100 0C for 10 min.
Then, silica gel (5 g) was added, and the solvent was evaporated to afford a plug under reduced
pressure. The resulting plug was loaded on to a silica gel column (3.5 × 12 cm) and eluted with
hexane followed by 40% EtOAc in hexane. The desired fraction (TLC) were pooled and
evaporated to afford 178 (1.58 g), yield 71% as yellow oil. TLC Rf = 0.35 (hexane/ EtOAc, 1:1); 1
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H NMR (400 MHz, DMSO-d6) δ 2.23 (s, 3H, ArCH3), 2.63-2.66 (t, 2H, CH2CH2OH, J = 6.4 Hz),
3.57-3.60 (t, 2H, CH2CH2OH, J = 6.4 Hz), 3.80 (s, 3H, OCH3), 4.96-4.98 (t, 1H, OH, exch, J =
5.6 Hz), 7.63 (s, 1H, Ar).
Methyl 5-(4-hydroxybutyl)-3-methylthiophene-2-carboxylate 179
To a parr flask was added 177 (1.20 g, 7.14 mmol), 10% palladium on active carbon (50%
w/w), and MeOH (25 mL). Hydrogenation was carried out at 55 psi of H2 for overnight. The
reaction mixture was filtered through Celite, washed with MeOH (100 mL) and concentrated under
reduced pressure to give 179 (1.01 g,) yield 84% as yellow oil. TLC Rf = 0.35 (hexane/ EtOAc,
1:1);

1

H NMR (400 MHz, DMSO-d6) δ 1.44-1.49 (m, 2H, ArCH2CH2), 1.60-1.65 (m, 2H,

CH2CH2OH), 2.42 (s, 3H, ArCH3), 2.75-2.78 (t, 2H, ArCH2, J = 7.3 Hz), 3.40-3.42 (t, 2H, CH2OH,
J = 6.0 Hz), 3.75 (s, 3H, OCH3), 4.42-4.43 (t, 1H, OH, exch, J = 4.8 Hz), 6.83 (s, 1H, Ar).
Methyl 5-(4-hydroxybutyl)-4-methylthiophene-2-carboxylate 180
To a parr flask was added 178 (2.24 g, 10 mmol), 10% palladium on active carbon (50%
w/w), and MeOH (25 mL). Hydrogenation was carried out at 55 psi of H2 for overnight. The
reaction mixture was filtered through Celite, washed with MeOH (100 mL) and concentrated under
reduced pressure to give 180 (2.0 g,) yield 88% as yellow oil. TLC Rf = 0.35 (hexane/ EtOAc, 1:1);
1

H NMR (400 MHz, DMSO-d6) δ 1.45-1.50 (m, 2H, ArCH2CH2), 1.59-1.63 (m, 2H, CH2CH2OH),

2.13 (s, 3H, ArCH3), 2.72-2.76 (t, 2H, ArCH2CH2, J = 7.6 Hz), 3.39-3.42 (t, 2H, CH2OH, J = 6.0
Hz), 3.77 (s, 3H, OCH3), 4.42-4.44 (t, 1H, OH, exch, J = 5.2 Hz), 7.54 (s, 1H, Ar).
4-(5-(methoxycarbonyl)-3-methylthiophen-2-yl) butanoic acid 181
To MeCN (40 mL) was added H5IO6 (2.20 g, 9.65 mmol) and the mixture was stirred
vigorously at room temperature for 15 min. 179 (1 g, 4.38 mmol) was then added in iced-water
bath followed by addition of pyridinium chlorochromate (19 mg, 2 mol%) in MeCN (10 mL) and
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the reaction mixture was stirred for 3 h. The reaction mixture was then diluted with EtOAc (100
mL) and washed with brine-water (1:1), sat. aq NaHSO 3 solution, and brine, respectively, dried
over anhydrous Na2SO4 and concentrated to give the clean carboxylic acid 181 (1.0 g) yield 94%
as yellow oil. TLC Rf = 0.56 (hexane/ EtOAc, 1:1).

1

H NMR (400 MHz, DMSO-d6) δ 1.81-1.85

(m, 2H, ArCH2CH2), 2.25-2.29 (t, 2H, CH2COOH, J = 7.6 Hz), 2.43 (s, 3H, ArCH3), 2.77-2.80 (t,
2H, ArCH2, J = 7.6 Hz), 3.76 (s, 3H, OCH3), 6.84 (s, 1H, Ar), 12.15 (br, 1H, COOH, exch).
4-(5-(methoxycarbonyl)-3-methylthiophen-2-yl) butanoic acid 182
To MeCN (40 mL) was added H5IO6 (1.48 g, 6.49 mmol) and the mixture was stirred
vigorously at room temperature for 15 min. 180 (673 mg, 2.95 mmol) was then added in icedwater bath followed by addition of pyridinium chlorochromate (12.7 mg, 2 mol%) in MeCN (10
mL) and the reaction mixture was stirred for 3 h. The reaction mixture was then diluted with EtOAc
(100 mL) and washed with brine-water (1:1), sat. aq NaHSO3 solution, and brine, respectively,
dried over anhydrous Na2SO4 and concentrated to give the clean carboxylic acid 182 (590 mg)
yield 83% as yellow oil. TLC Rf = 0.55 (hexane/ EtOAc, 1:1). Mp 113.10C.

1

H NMR (400 MHz,

DMSO-d6) δ 1.79-1.82 (m, 2H, ArCH2CH2), 2.27-2.30 (m, 2H, CH2COOH), 2.13 (s, 3H, ArCH3),
2.74-2.76 (t, 2H, ArCH2, J = 7.6 Hz), 3.78 (s, 3H, OCH3), 7.55 (s, 1H, Ar), 12.14 (br, 1H, COOH,
exch).
Methyl 5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3methylthiophene-2-carboxylate 189
To 181 (0.65 g, 2.69 mmol) in a 100 mL flask was added oxalyl chloride (2.0 g, 15.9 mmol)
and anhydrous CH2Cl2 (15 mL). The resulting solution was refluxed for 1 h and then cooled to the
room temperature. After evaporating the solvent under reduced pressure, the residue was dissolved
in 15 mL Et2O. The resulting solution was added dropwise to an ice-cooled diazomethane
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(generated in stiu from 4.1 g of diazald by using Aldrich Mini Diazald Apparatus) in an ice bath
for over 10 min. The resulting mixture was allowed to stand for 30 min and then stirred for an
additional 1 h. To this solution was added 48% HBr (6 mL). The resulting mixture was refluxed
for 1.5 h. After cooling to room temperature, the organic layer was separated, and aqueous layer
extracted with Et2O (3 × 50 mL). The organic layer was washed with 10% Na2CO3 solution and
dried over Na2SO4. To this residue anhydrous DMF (15 mL) was added 2,6-diamino-3Hpyrimidin-4-one (338 mg, 2.68 mmol). The resulting mixture was stirred under N 2 at room
temperature for 3 days. Silica gel (1.0 g) was then added, and the solvent was evaporated under
reduced

pressure.

The

resulting

plug

was

loaded

on

to

a

silica

gel

column

(1.5 × 12 cm) and eluted with CHCl3 and then CHCl3 followed by 5% MeOH in CHCl3. The desired
fraction (TLC) was collected, and the solvent was evaporated under reduced pressure to
afford 189 (380 mg) yield 41% as yellow power. TLC Rf = 0.66 (CHCl3/MeOH, 6:1). Mp 189.3
0

C.

1

H NMR (400 MHz, DMSO-d6) δ 1.90-1.96 (m, 2H, ArCH2CH2CH2Ar), 2.43 (s, 3H, CH3),

2.53-2.55 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.76-2.79 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz),
3.76 (s, 3H, COOCH3), 5.90 (s, 1H, C5-CH), 5.99 (s, 2H, 2-NH2, exch), 6.85 (s, 1H, Ar), 10.16 (s,
1H, 3-NH, exch), 10.85 (s, 1H, 7-NH, exch).
Methyl5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3methylthiophene-2-carboxylate 190
To 182 (580 mg, 2.4 mmol) in a 100 mL flask was added oxalyl chloride (1.8 g, 14.4 mmol)
and anhydrous CH2Cl2 (15 mL). The resulting solution was refluxed for 1 h and then cooled to the
room temperature. After evaporating the solvent under reduced pressure, the residue was dissolved
in 15 mL Et2O. The resulting solution was added dropwise to an ice-cooled diazomethane
(generated in stiu from 10 g of diazald by using Aldrich Mini Diazald Apparatus) in an ice bath
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for over 10 min. The resulting mixture was allowed to stand for 30 min and then stirred for an
additional 1 h. To this solution was added 48% HBr (20 mL). The resulting mixture was refluxed
for 1.5 h. After cooling to room temperature, the organic layer was separated, and aqueous layer
extracted with Et2O (3 × 50 mL). The organic layer was washed with 10% Na2CO3 solution and
dried over Na2SO4. To this residue anhydrous DMF (15 mL) was added 2,6-diamino-3Hpyrimidin-4-one (301 mg, 2.5 mmol). The resulting mixture was stirred under N 2 at room
temperature for 3 days. Silica gel (1.0 g) was then added, and the solvent was evaporated under
reduced pressure. The resulting plug was loaded on to a silica gel column (1.5 × 12 cm) and eluted
with CHCl3 and then CHCl3 followed by 5% MeOH in CHCl3. The desired fraction (TLC) was
collected, and the solvent was evaporated under reduced pressure to afford 190 (250 mg) yield
30% as yellow power. TLC Rf = 0.63 (CHCl3/MeOH, 6:1). Mp 181.4 0C.

1

H NMR (400 MHz,

DMSO-d6) δ 1.88-1.92 (m, 2H, ArCH2CH2CH2Ar), 2.56-2.54 (t, 2H, ArCH2CH2CH2Ar, J = 7.6
Hz), 2.11 (s, 3H, ArCH3), 2.76-2.74 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 3.78 (s, 3H, OCH3),
5.90 (s, 1H, C5-CH), 6.00 (s, 2H, 2-NH2, exch), 7.66 (s, 1H, Ar), 10.17 (s, 1H, 3-NH, exch), 10.86
(s, 1H, 7-NH, exch).
5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3methylthiophene-2-carboxylic acid 191
To a solution of 189 (370 mg, 1.06 mmol) in MeOH (15 mL) was added 1 N NaOH (10
mL) and the mixture was stirred under N2 at room temperature for overnight. TLC showed the
disappearance of the starting material and one major spot at the origin. The reaction mixture was
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4.
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed
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with 20-40 mL cold water and dried in dried in vacuum using P 2O5 to afford 191 (343 mg) yield
97% as yellow power. Mp 188.40C.

1

H NMR (400 MHz, DMSO-d6) δ 1.90-1.93 (m, 2H,

ArCH2CH2CH2Ar), 2.40 (s, 3H, ArCH3), 2.55-2.57 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.742.77 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 5.90 (s, 1H, C5-CH), 6.01 (s, 2H, 2-NH2, exch), 6.80
(s, 1H, Ar), 10.17 (s, 1H, 3-NH, exch), 10.85 (s, 1H, 7-NH, exch), 12.74 (br, 1H, COOH, exch).
5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3methylthiophene-2-carboxylic acid 192
To a solution of 190 (346 mg, 1 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL)
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the
disappearance of the starting material and one major spot at the origin. The reaction mixture was
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4.
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed
with 20-40 mL cold water and dried in dried in vacuum using P 2O5 to afford 192 (315 mg) yield
95% as yellow power. Mp 181.4 0C.

1

H NMR (400 MHz, DMSO-d6) δ 1.87-1.90 (m, 2H,

ArCH2CH2CH2Ar), 2.55-2.57 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.13 (s, 3H, ArCH3), 2.722.75 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 5.90 (s, 1H, C5-CH), 5.99 (s, 2H, 2-NH2, exch), 7.46
(s, 1H, Ar), 10.16 (s, 1H, 3-NH, exch), 10.86 (s, 1H, 7-NH, exch).
Diethyl (5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6-yl)propyl)-4methylthiophene-2-carbonyl)glutamate 193
To a solution of 191 (330 mg, 1.0 mmol) in anhydrous DMF (10 mL) was added Nmethylmorpholine (180 mg, 1.8 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (314 mg, 1.8
mmol). The resulting mixtures were stirred at room temperature for 2 h. To this
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mixture were added N-methylmorpholine (180 mg, 1.8 mmol) and L-glutamate diethyl ester
hydrochloride (360 mg, 1.5 mmol). The reaction mixture was stirred for overnight at room
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 ×
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were
pooled, and the solvent evaporated to dryness to afford 193 (274 mg) yield 53 % as yellow power.
TLC Rf = 0.42 (CHCl3/ MeOH, 6:1); Mp 143.8 0C.

1

H NMR (400 MHz, DMSO-d6) δ 1.10-1.15

(m, 6H, COOCH2CH3), 1.82-1.84 (m, 2H, β-CH2), 1.87-1.93 (m, 2H, ArCH2CH2CH2Ar), 2.03 (s,
3H, CH3), 2.35-2.37 (t, 2H, J = 7.2 Hz, γ-CH2), 2.49-2.52 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz),
2.68-2.71 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 4.97-4.05 (m, 4H, COOCH2CH3), 4.30-4.34 (m,
1H, α-CH), 5.90 (s, 1H, C5-CH), 6.02 (s, 2H, 2-NH2, exch), 7.60 (s, 1H, Ar), 8.57-8.56 (d, 1H, J =
4.0 Hz, CONH, exch), 10.18(s, 1H, 3-NH, exch), 10.86 (s, 1H, 7-NH, exch).
Diethyl (5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6-yl)propyl)-4methylthiophene-2-carbonyl)glutamate 194
To a solution of 192 (420 mg, 1.26 mmol) in anhydrous DMF (20 mL) was added Nmethylmorpholine (230 mg, 2.28 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (400mg, 2.28
mmol). The resulting mixtures were stirred at room temperature for 2 h. To this
mixture were added N-methylmorpholine (230 mg, 2.28 mmol) and L-glutamate diethyl ester
hydrochloride (458 mg, 1.9 mmol). The reaction mixture was stirred for overnight at room
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 ×
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were
pooled, and the solvent evaporated to dryness to afford 194 (417 mg) yield 64% as yellow power.
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TLC Rf = 0.42 (CHCl3/ MeOH, 6:1); Mp 143.8 0C.

1

H NMR (400 MHz, DMSO-d6) δ 1.10-1.15

(m, 6H, COOCH2CH3), 1.82-1.84 (m, 2H, β-CH2), 1.87-1.93 (m, 2H, ArCH2CH2CH2Ar), 2.03 (s,
3H, ArCH3), 2.35-2.37 (t, 2H, γ-CH2, J = 7.2 Hz), 2.40-2.44 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz),
2.70-2.74 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 4.04-4.11 (m, 4H, COOCH2CH3), 4.30-4.34 (m,
1H, α-CH), 5.90 (s, 1H, C5-CH), 5.98 (s, 2H, 2-NH2, exch), 7.60 (s, 1H, Ar), 8.55-8.57 (d, 1H,
CONH, exch, J = 4.0 Hz,), 10.15(s, 1H, 3-NH, exch), 10.86 (s, 1H, 7-NH, exch).
5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6-yl)propyl)-4methylthiophene-2-carbonyl)glutamic acid 156
To a solution of 193 (90 mg, 0.17 mmol) in MeOH (20 mL) was added 1 N NaOH (10 mL).
The mixture was then stirred under N2 at room temperature overnight. TLC showed the
disappearance of the starting material and one major spot at the origin (CHCl 3/ MeOH, 6:1). The
reaction mixture was then evaporated to dryness under reduced pressure. The residue was
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was
adjusted to 3-4 with dropwise addition of 1 N acetic acid. The resulting suspension was stored in
a 4-5 0C refrigerator and filtered. The residue was washed with 30-40 mL cold water and dried in
vacuum using P2O5 to afford 60 mg (76%) of 156 as a yellow powder. Mp 163.5 0C. 1 H NMR
(400 MHz, DMSO-d6) δ 1.90-2.08 (m, 4H, β-CH2), 2.32-2.34 (t, 2H, J = 7.2 Hz, γ-CH2), 2.36 (s,
3H, ArCH3), 2.54-2.59 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.71-2.73 (t, 2H, ArCH2CH2CH2Ar,
J = 7.6 Hz), 4.29-4.33 (m, 1H, α-CH), 5.91 (s, 1H, C5-CH), 5.99 (s, 2H, 2-NH2, exch), 6.74 (s, 1H,
Ar), 7.98-8.00 (d, 1H, J = 6.6 Hz, CONH, exch), 10.17 (s, 1H, 3-NH, exch), 10.85 (s, 1H, 7-NH,
exch). Anal. (C20H23N5O6S. 2.5573 H2O) C, H, N, S.
5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6-yl)propyl)-4methylthiophene-2-carbonyl)glutamic acid 157
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To a solution of 194 (155 mg, 0.3 mmol) in MeOH (20 mL) was added 1 N NaOH (10 mL).
The mixture was then stirred under N2 at room temperature overnight. TLC showed the
disappearance of the starting material and one major spot at the origin (CHCl 3/ MeOH, 6:1). The
reaction mixture was then evaporated to dryness under reduced pressure. The residue was
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was
adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5
0

C refrigerator and filtered. The residue was washed with 30-40 mL cold water and dried in

vacuum using P2O5 to afford 105 mg (75%) of 157 as a yellow powder. Mp 167.8 0C. 1 H NMR
(400 MHz, DMSO-d6) δ 1.89-1.93 (m, 4H, β-CH2), 2.09 (s, 3H, ArCH3), 2.30-2.34 (t, 2H, γ-CH2,
J = 7.2 Hz), 2.54-2.58 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.71-2.73 (t, 2H, ArCH2CH2CH2Ar,
J = 7.6 Hz), 4.29-4.32 (m, 1H, α-CH), 5.89 (s, 1H, C5-CH), 5.97 (s, 2H, 2-NH2, exch), 7.58 (s, 1H,
Ar), 8.41-8.42 (d, 1H, CONH, exch, J = 8.0 Hz), 10.14(s, 1H, 3-NH, exch), 10.84 (s, 1H, 7-NH,
exch), 12.42 (br, 2H, COOH, exch). Anal. (C 20H23N5O6S. 2.5573 H2O) C, H, N, S.
Methyl 5-(5-hydroxypent-1-yn-1-yl)-3-methylthiophene-2-carboxylate 195
To a 20-mL vial for microwave reaction, was added a mixture of palladium chloride (71
mg, 0.4 mmol), triphenylphosphine (131 mg, 0.4 mmol), copper iodide (304 mg, 1.6 mmol),
triethylamine (10.1 g, 100 mmol), methyl 5-bromo-3-methylthiophene-2-carboxylate 175 (2.35 g,
10 mmol) anhydrous acetonitrile (10 mL). To the stirred mixture, was added pent-4-yn-ol (0.88 g,
10.5 mmol), and the vial was sealed and placed into the microwave reactor at 100 0C for 10 min.
Then, silica gel (5 g) was added, and the solvent was evaporated to afford a plug under reduced
pressure. The resulting plug was loaded on to a silica gel column (3.5 × 12 cm) and eluted with
hexane followed by 40% EtOAc in hexane. The desired fraction (TLC) were pooled and
evaporated to afford 195 (1.7 g), yield 71.4 % as yellow oil. TLC Rf = 0.57 (hexane/ EtOAc, 1:1);
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1

H NMR (400 MHz, DMSO-d6) δ 1.64-1.71 (m, 2H, CH2CH2CH2OH), 2.43 (s, 3H, ArCH3), 2.51-

2.54 (t, 2H, CH2CH2CH2OH, J = 7.1 Hz), 3.47-3.51 (t, 2H, CH2CH2CH2OH, J = 6.2 Hz), 3.78 (s,
3H, COOCH3), 4.57 (s, 1H, OH, exch), 7.15 (s, 1H, Ar-H).
Methyl 5-(5-hydroxypent-1-yn-1-yl)-4-methylthiophene-2-carboxylate 196
To a 20-mL vial for microwave reaction, was added a mixture of palladium chloride (71
mg, 0.4 mmol), triphenylphosphine (131 mg, 0.4 mmol), copper iodide (304 mg, 1.6 mmol),
triethylamine (10.1 g, 100 mmol), methyl 5-bromo-4-methylthiophene-2-carboxylate 176 (2.35 g,
10 mmol) and anhydrous acetonitrile (10 mL). To the stirred mixture, was added pent-4-yn-ol
(0.88 g, 10.5 mmol), and the vial was sealed and placed into the microwave reactor at 100 0C for
10 min. Then, silica gel (5 g) was added, and the solvent was evaporated to afford a plug under
reduced pressure. The resulting plug was loaded on to a silica gel column (3.5 × 12 cm) and eluted
with hexane followed by 40% EtOAc in hexane. The desired fraction (TLC) were pooled and
evaporated to afford 196 (1.87 g), yield 78% as yellow oil. TLC Rf = 0.51 (hexane/ EtOAc, 1:1); 1
H NMR (400 MHz, DMSO-d6) δ 1.68-1.73 (m, 2H, CH2CH2CH2OH), 2.24 (s, 3H, ArCH3), 2.542.58 (t, 2H, CH2CH2CH2OH, J = 7.2 Hz), 3.50-3.53 (t, 2H, CH2CH2CH2OH, J = 6.2 Hz), 3.80 (s,
3H, OCH3), 4.58 (Br, 1H, OH, exch), 7.64 (s, 1H, Ar-H).
Methyl 5-(5-hydroxypentyl)-3-methylthiophene-2-carboxylate 197
To a parr flask was added 195 (2.4 g, 9.67 mmol), 10% palladium on active carbon (50%
w/w), and MeOH (25 mL). Hydrogenation was carried out at 55 psi of H2 for overnight. The
reaction mixture was filtered through Celite, washed with MeOH (100 mL) and concentrated under
reduced pressure to give 197 g (1.90 g,) yield 82% as green oil. TLC Rf = 0.37 (hexane/ EtOAc,
1:1);

1

H NMR (400 MHz, DMSO-d6) δ 1.31-1.33 (m, 2H, ArCH2CH2CH2), 1.42-1.45 (m, 2H,

CH2CH2 OH), 1.59-1.63 (m, 2H, ArCH2CH2CH2), 2.42 (s, 3H, ArCH3), 2.74-2.78 (t, 2H, ArCH2,
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J = 7.5 Hz), 3.35-3.38 (t, 2H, CH2OH, J = 6.0 Hz), 3.75 (s, 3H, OCH3), 4.35-4.37 (t, 1H, OH, exch,
J = 4.8 Hz), 6.82 (s, 1H, Ar-H).
Methyl 5-(5-hydroxypentyl)-4-methylthiophene-2-carboxylate 198
To a parr flask was added 196(600 mg, 2.5 mmol), 10% palladium on active carbon (50%
w/w), and MeOH (25 mL). Hydrogenation was carried out at 55 psi of H2 for overnight. The
reaction mixture was filtered through Celite, washed with MeOH (100 mL) and concentrated under
reduced pressure to give 198 (485 mg,) yield 80% as yellow oil. TLC Rf = 0.53 (hexane/ EtOAc,
1:1);

1

H NMR (400 MHz, DMSO-d6) δ 1.35-1.37 (m, 2H, Ar CH2CH2CH2CH2CH2OH), 1.43-

1.46 (m, 2H, ArCH2CH2CH2CH2CH2OH), 1.57-1.60 (m, 2H, ArCH2CH2CH2CH2CH2OH), 2.12
(s, 3H, ArCH3), 2.72-2.75 (t, 2H, ArCH2CH2, J = 7.5 Hz), 3.37-3.39 (t, 2H, CH2OH, J = 5.9 Hz),
3.78 (s, 3H, COOOCH3), 4.37-4.39 (t, 1H, OH, J = 5.0 Hz exch), 7.54 (s, 1H, Ar-H).
5-(5-(methoxycarbonyl)-4-methylthiophen-2-yl)-pentanoic acid 199
To MeCN (40 mL) was added H5IO6 (3.94 g, 17.4 mmol) and the mixture was stirred
vigorously at room temperature for 15 min. 197 (1.90 g, 7.85 mmol) was then added in iced-water
bath followed by addition of pyridinium chlorochromate (34 mg, 2 mol%) in MeCN (10 mL) and
the reaction mixture was stirred for 3 h. The reaction mixture was then diluted with EtOAc (100
mL) and washed with brine-water (1:1), sat. aq NaHSO 3 solution, and brine, respectively, dried
over anhydrous Na2SO4 and concentrated to give the clean carboxylic acid 199 (1.6 g) yield 80%
as yellow oil. TLC Rf = 0.56 (hexane/ EtOAc, 1:1).

1

H NMR (400 MHz, DMSO-d6) δ 1.51-1.62

(m, 4H, ArCH2CH2CH2CH2Ar), 2.22-2.26 (t, 2H, CH2COOH, J = 7.2 Hz), 2.42 (s, 3H, ArCH3),
2.75-2.79 (t, 2H, ArCH2, J = 7.3 Hz), 3.75 (s, 3H, OCH3), 6.83(s, 1H, Ar-H), 12.15 (br, 1H, COOH,
exch).
5-(5-(methoxycarbonyl)-3-methylthiophen-2-yl) pentanoic acid 200
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To MeCN (60 mL) was added H5IO6 (5.18 g, 22.7 mmol) and the mixture was stirred
vigorously at room temperature for 15 min. 198 (2.5 g, 10.3 mmol) was then added in iced-water
bath followed by addition of pyridinium chlorochromate (44.7 mg, 2 mol%) in MeCN (10 mL)
and the reaction mixture was stirred for 3 h. The reaction mixture was then diluted with EtOAc
(100 mL) and washed with brine-water (1:1), sat. aq NaHSO3 solution, and brine, respectively,
dried over anhydrous Na2SO4 and concentrated to give the clean carboxylic acid 200 (2.1 g) yield
80% as yellow oil. TLC Rf = 0.55 (hexane/ EtOAc, 1:1). 1 H NMR (400 MHz, DMSO-d6) δ 1.561.61 (m, 4H, ArCH2CH2CH2CH2COOH), 2.13 (s, 3H, ArCH3), 2.24-2.27 (t, 2H, CH2COOH, J =
5.9 Hz), 2.74-2.77 (t, 2H, ArCH2, J = 6.9 Hz), 3.78 (s, 3H, COOCH3), 7.55 (s, 1H, Ar-H), 12.05
(br, 1H, COOH, exch).
Methyl 5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3methylthiophene-2-carboxylate 207
To 199 (1.60 g, 6.25 mmol) in a 100 mL flask was added oxalyl chloride (4.85 g, 38.2
mmol) and anhydrous CH2Cl2 (15 mL). The resulting solution was refluxed for 1 h and then cooled
to the room temperature. After evaporating the solvent under reduced pressure, the residue was
dissolved in 15 of mL Et2O. The resulting solution was added dropwise to an ice-cooled
diazomethane (generated in stiu from 9.3 g of diazald by using Aldrich Mini Diazald Apparatus)
in an ice bath for over 10 min. The resulting mixture was allowed to stand for 30 min and then
stirred for an additional 1 h. To this solution was added 48% HBr (13 mL). The resulting mixture
was refluxed for 1.5 h. After cooling to room temperature, the organic layer was separated, and
aqueous layer extracted with Et2O (3 × 50 mL). The organic layer was washed with 10% Na2CO3
solution and dried over Na2SO4. To this residue in anhydrous DMF (15 mL) residue and 2,6diamino-3H-pyrimidin-4-one (788 mg, 5.08 mmol) was added The resulting mixture was stirred
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under N2 at room temperature for 3 days. Silica gel (1.0 g) was then added, and the solvent was
evaporated under reduced pressure. The resulting plug was loaded on to a silica gel column (1.5 ×
12 cm) and eluted with CHCl3 and then CHCl3 followed by 5% MeOH in CHCl3. The desired
fraction (TLC) was collected, and the solvent was evaporated under reduced pressure to afford 207
(855 mg) yield 38% as yellow oil. TLC Rf = 0.50 (CHCl3/MeOH, 6:1).

1

H NMR (400 MHz,

DMSO-d6) δ 1.58-1.68 (m, 4H, ArCH2CH2CH2CH2Ar), 2.38-2.41 (t, 2H, ArCH2CH2CH2CH2Ar,
J = 9.3 Hz), 2.41 (s, 3H, ArCH3), 2.76-2.80 (t, 2H, ArCH2CH2CH2CH2Ar, J = 9.3 Hz), 3.75 (s,
3H, COOCH3), 5.86 (s, 1H, C5-CH), 5.99 (s, 2H, 2-NH2, exch), 6.81 (s, 1H, Ar-H), 10.16 (s, 1H,
3-NH, exch), 10.82 (s, 1H, 7-NH, exch).
Methyl 5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-4methylthiophene-2-carboxylate 208
To 200 (2.13 g, 8.3 mmol) in a 100 mL flask was added oxalyl chloride (4.7 g, 37.6 mmol)
and anhydrous CH2Cl2 (15 mL). The resulting solution was refluxed for 1 h and then cooled to the
room temperature. After evaporating the solvent under reduced pressure, the residue was dissolved
in 15 of mL Et2O. The resulting solution was added dropwise to an ice-cooled diazomethane
(generated in stiu from 10 g of diazald by using Aldrich Mini Diazald Apparatus) in an ice bath
for over 10 min. The resulting mixture was allowed to stand for 30 min and then stirred for an
additional 1 h. To this solution was added 48% HBr (12 mL). The resulting mixture was refluxed
for 1.5 h. After cooling to room temperature, the organic layer was separated, and aqueous layer
extracted with Et2O (3 × 50 mL). The organic layer was washed with 10% Na2CO3 solution and
dried over Na2SO4. To this residue in anhydrous DMF (15 mL) was added 2,6-diamino-3Hpyrimidin-4-one (301 mg, 2.5 mmol). The resulting mixture was stirred under N 2 at room
temperature for 3 days. Silica gel (1.0 g) was then added, and the solvent was evaporated under
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reduced pressure. The resulting plug was loaded on to a silica gel column (1.5 × 12 cm) and eluted
with CHCl3 and then CHCl3 followed by 5% MeOH in CHCl3. The desired fraction (TLC) was
collected, and the solvent was evaporated under reduced pressure to afford 208 (1. 01 g) yield 34%
as yellow power. TLC Rf = 0.53 (CHCl3/MeOH, 6:1).

1

H NMR (400 MHz, DMSO-d6) δ 1.57-

1.64 (m, 4H, ArCH2CH2 CH2CH2Ar), 2.12 (s, 3H, ArCH3), 2.51-2.54 (t, 2H, ArCH2CH2CH2Ar, J
= 6.9 Hz), 2.73-2.76 (t, 2H, ArCH2CH2CH2Ar, J = 6.9 Hz), 3.80 (s, 3H, COOCH3), 5.87 (s, 1H,
C5-CH), 6.06 (s, 2H, 2-NH2, exch), 7.45 (s, 1H, Ar-H), 10.21 (s, 1H, 3-NH, exch), 10.85 (s, 1H,
7-NH, exch).
5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-ethylthiophene2-carboxylic acid 209
To a solution of 207 (360 mg, 1.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL)
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the
disappearance of the starting material and one major spot at the origin. The reaction mixture was
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4.
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed
with 20-40 mL cold water and dried in dried in vacuum using P 2O5 to afford 209 (280 mg) yield
81% as yellow oil.

1

H NMR (400 MHz, DMSO-d6) δ 1.53-1.63 (m, 4H, ArCH2CH2CH2CH2Ar),

2.40 (s, 3H, ArCH3), 2.47-2.51 (t, 2H, ArCH2CH2CH2CH2Ar, J = 7.6 Hz), 2.74-2.77 (t, 2H,
ArCH2CH2CH2CH2Ar, J = 7.6 Hz), 5.86 (s, 1H, C5-CH), 6.00 (s, 2H, 2-NH2, exch), 6.77(s, 1H,
Ar-H), 10.16 (s, 1H, 3-NH, exch), 10.81 (s, 1H, 7-NH, exch), 12.63 (br, 1H, COOH, exch).
5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-4methylthiophene-2-carboxylic acid 210
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To a solution of 208 (400 mg, 1.1 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL)
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the
disappearance of the starting material and one major spot at the origin. The reaction mixture was
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4.
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed
with 20-40 mL cold water and dried in vacuum using P 2O5 to afford 210 (330 mg) yield 87% as
yellow power. Mp 179.5 0C.

1

H NMR (400 MHz, DMSO-d6) δ 1.57-1.64 (m, 4H, ArCH2CH2

CH2CH2Ar), 2.12 (s, 3H, ArCH3), 2.51-2.54 (t, 2H, ArCH2CH2CH2Ar, J = 6.9 Hz), 2.73-2.76 (t,
2H, ArCH2CH2CH2Ar, J = 6.9 Hz), 5.87 (s, 1H, C5-CH), 6.06 (s, 2H, 2-NH2, exch), 7.45 (s, 1H,
Ar-H), 10.21 (s, 1H, 3-NH, exch), 10.85 (s, 1H, 7-NH, exch).
Diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3methylthiophene-2-carbonyl)-L-glutamate 211
To a solution of 209 (340 mg, 1.0 mmol) in anhydrous DMF (10 mL) was added Nmethylmorpholine (180 mg, 1.8 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (314 mg, 1.8
mmol). The resulting mixture was stirred at room temperature for 2 h. To this
mixture were added N-methylmorpholine (180 mg, 1.8 mmol) and L-glutamate diethyl ester
hydrochloride (360 mg, 1.5 mmol). The reaction mixture was stirred for overnight at room
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 ×
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were
pooled, and the solvent evaporated to dryness to afford 211 (260 mg) yield 53 % as yellow oil.
TLC Rf = 0.42 (CHCl3/ MeOH, 6:1).

1

H NMR (400 MHz, DMSO-d6) δ 1.15-1.21(m, 6H,
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COOCH2CH3), 1.88-1.97 (m, 2H, β-CH2), 1.60-1.65 (m, 2H, ArCH2CH2CH2CH2Ar), 2.34 (s, 3H,
ArCH3), 2.38-2.42 (t, 2H, J = 7.2 Hz, γ-CH2), 2.49-2.52 (t, 2H, ArCH2CH2CH2CH2Ar, J = 7.6 Hz),
2.75-2.78 (t, 2H, ArCH2CH2CH2CH2Ar, J = 7.6 Hz), 4.06-4.11 (m, 4H, COOCH2CH3), 4.33-4.35
(m, 1H, α-CH), 5.87 (s, 1H, C5-CH), 5.99 (s, 2H, 2-NH2, exch), 6.70 (s, 1H, Ar-H), 8.13-8.15 (d,
1H, J = 4.0 Hz, CONH, exch), 10.18(s, 1H, 3-NH, exch), 10.86 (s, 1H, 7-NH, exch).
Diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-4methylthiophene-2-carbonyl)-L-glutamate 212
To a solution of 210 (500 mg, 1.45 mmol) in anhydrous DMF (20 mL) was added Nmethylmorpholine (263 mg, 2.61 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (452mg,
2.61mmol). The resulting mixture was stirred at room temperature for 2 h. To this
mixture were added N-methylmorpholine (263 mg, 2.61 mmol) and L-glutamate diethyl ester
hydrochloride (518 mg, 2.15 mmol). The reaction mixture was stirred for overnight at room
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 ×
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were
pooled, and the solvent evaporated to dryness to afford 212 (510 mg) yield 66% as yellow power.
TLC Rf = 0.45 (CHCl3/ MeOH, 6:1); Mp 152.6 0C.

1

H NMR (400 MHz, DMSO-d6) δ 1.10-1.15

(m, 6H, COOCH2CH3), 1.58-1.63 (m, 2H, β-CH2), 1.93-1.98 (m, 4H, ArCH2CH2CH2CH2Ar), 2.15
(s, 3H, ArCH3), 2.35-2.38 (t, 2H, γ-CH2, J = 7.2 Hz), 2.38-2.43 (t, 2H, ArCH2CH2CH2Ar, J = 7.6
Hz), 2.70-2.74 (t, 2H, ArCH2CH2 CH2CH2Ar, J = 7.6 Hz), 4.04-4.11 (m, 4H, COOCH2CH3), 4.304.34 (m, 1H, α-CH), 5.86 (s, 1H, C5-CH), 5.97 (s, 2H, 2-NH2, exch), 7.58 (s, 1H, Ar), 8.55-8.57
(d, 1H, CONH, exch, J = 4.0 Hz,), 10.14(s, 1H, 3-NH, exch), 10.81 (s, 1H, 7-NH, exch).
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5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3methylthiophene-2-carbonyl)-L-glutamic acid 158
To a solution of 211 (200 mg, 0.38 mmol) in MeOH (20 mL) was added 1 N NaOH (10
mL). The mixture was then stirred under N2 at room temperature overnight. TLC showed the
disappearance of the starting material and one major spot at the origin (CHCl 3/ MeOH, 6:1). The
reaction mixture was then evaporated to dryness under reduced pressure. The residue was
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was
adjusted to 3-4 with dropwise addition of 1 N acetic acid. The resulting suspension was
stored in a 4-5 0C refrigerator and filtered. The residue was washed with 30-40 mL cold water and
dried in vacuum using P2O5 to afford 140 mg (81%) of 158 as a yellow powder.Mp 130.8 0C. 1 H
NMR (400 MHz, DMSO-d6) δ 1.60-2.62 (m, 4H, ArCH2CH2CH2CH2Ar), 1.88-1.96 (m, 2H, βCH2), 2.31-2.34 (t, 2H, J = 7.2 Hz, γ-CH2), 2.35 (s, 3H, ArCH3), 2.51-2.54 (t, 2H,
ArCH2CH2CH2CH2Ar, J = 7.6 Hz), 2.75-2.78 (t, 2H, ArCH2CH2CH2CH2Ar, J = 7.6 Hz), 4.284.33 (m, 1H, α-CH), 5.86 (s, 1H, C5-CH), 5.98 (s, 2H, 2-NH2, exch), 6.74 (s, 1H, Ar), 7.97-7.99
(d, 1H, J = 6.6 Hz, CONH, exch), 10.14 (s, 1H, 3-NH, exch), 10.82 (s, 1H, 7-NH, exch), 12.25 (br,
2H, COOH, exch). Anal. (C21H25N5O6S. 0.9246 H2O. 0.7945CH3CO2H) C, H, N, S.
(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-4methylthiophene-2-carbonyl)-L-glutamic acid 159
To a solution of 212 (130 mg, 0.24 mmol) in MeOH (20 mL) was added 1 N NaOH (10
mL). The mixture was then stirred under N2 at room temperature overnight. TLC showed the
disappearance of the starting material and one major spot at the origin (CHCl 3/ MeOH, 6:1). The
reaction mixture was then evaporated to dryness under reduced pressure. The residue was
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was
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adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was
stored in a 4-5 0C refrigerator and filtered. The residue was washed with 30-40 mL cold water and
dried in vacuum using P2O5 to afford 87 mg (74%) of 159 as a yellow powder. Mp 190.2 0C. 1 H
NMR (400 MHz, DMSO-d6) δ 1.56-1.65 (m, 4H, ArCH2CH2CH2Ar), 1.87-1.93 (m, 2H, β-CH2),
1.99-2.09 (m, 2H, CH2), 2.12 (s, 3H, ArCH3), 2.35-2.32 (t, 2H, γ-CH2, J = 7.4 Hz), 2.54-2.71-2.75
(t, 2H, ArCH2CH2CH2CH2Ar, J = 7.2 Hz), 4.29-4.32 (m, 1H, α-CH), 5.87 (s, 1H, C5-CH), 5.98 (s,
2H, 2-NH2, exch), 7.58 (s, 1H, Ar-H), 8.43-8.45 (d, 1H, CONH, exch, J = 7.7 Hz), 10.15(s, 1H, 3NH, exch), 10.82 (s, 1H, 7-NH, exch), 12.42 (br, 2H, COOH, exch). Anal. (C 20H23N5O6S. 1.2735
H2O. 0.8361 CH3CO2H) C, H, N, S.
Methyl 3-fluoro-4-((3-oxobutyl) amino) benzoate 221
To a solution of methyl 4-amino-3-fluorobenzoate 219 (10.14 g, 60 mmol) in in anhydrous
absolute ethanol (70 mL), methyl vinyl ketone (4.2 g, 60 mmol) was added. The reaction mixture
was stirred under reflux for 4.5 hours, and the resultant mixture was cooled to 0 °C. The
precipitated crystalline product was collected and washed with precooled ethanol and dried to
afford 221, yield 35 % as yellow power; Mp 98 °C; TLC Rf = 0.6 (hexane/ EtOAc, 1:1); 1 H NMR
(400 MHz, DMSO-d6) δ 2.21 (s, 3H, CH2COCH3), 2.80-2.83(t, 2H, CH2CH2O, J = 6.1 Hz), 3.513.55 (t, 2H, CH2CH2O, J = 6.3 Hz), 3.88 (s, 3H, OCH3), 5.54 (bs, Ar-NH, exch), 6.65-6.70 (t, 1H,
Ar-CH, J = 8.4 Hz), 7.62-7.65 (d, 1H, Ar-CH, J = 7.0 Hz), 7.74-7.76 (d, 1H, Ar-CH, J = 7.0 Hz).
Methyl 2-fluoro-4-((3-oxobutyl)amino)benzoate 222
To a solution of methyl 4-amino-3-fluorobenzoate 220 (9.15 g, 50 mmol) in in anhydrous
absolute ethanol (10 mL), methyl vinyl ketone (3.4 g, 50 mmol) was added. The reaction mixture
was stirred under reflux for 4.5 hours, and the resultant mixture was cooled to 0 °C. The
precipitated crystalline product was collected and washed with precooled ethanol and dried to
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afford 222 (6.9 g), yield 54 % as yellow power; Mp 86.8 0C. TLC Rf = 0.5 (hexane/ EtOAc, 1:1);
1

H NMR (400 MHz, DMSO-d6) δ 2.21 (s, 3H, CH2COCH3), 2.78-2.80 (t, 2H, CH2CH2O,

J = 5.9 Hz), 3.45-3.48 (t, 2H, CH2CH2O, J = 5.9 Hz), 3.88 (s, 3H, OCH3), 5.54 (bs, Ar-NH, exch),
6.27-6.30 (d, 1H, Ar-CH, J = 13.6 Hz), 6.37-6.39 (d, 1H, Ar-CH, J = 10.7 Hz), 7.78-7.80 (t, 1H,
Ar-CH, J = 8.5 Hz).
Methyl 4-((4-bromo-3-oxobutyl)amino)-3-fluorobenzoate 223
A suspension of 221 (8 g, 33.5 mmol) in 21 mL of 33% hydrogen bromide-glacial acetic
acid solution was treated with 2.6 mL of bromine in 5.24 mL of glacial acetic acid and stirred for
2.5 h at 25 °C. Ether (100 mL) was added to the reaction mixture with swirling until separation of
the syrupy hydrobromide was complete. The ether was decanted, and any ether remaining was
evaporated from the syrup along with excess hydrogen bromide. After further drying by
evaporation (bath 35 °C) of a solution in an equal volume of dichloromethane, the syrup
weighed 8.0 g. The syrup was then stirred with cold water and filtered to afford yellow solid.
Yellow solid obtained was then washed with water (3 × 20 mL) and dissolved in dichloromethane.
The solution was dried over sodium sulfate. Removal of solvent under reduced
pressure at room temperature gave a beige colored semisolid. The crude product was thoroughly
triturated with precooled ether, and the solid product was collected by filtration to afford 223 (4.2
g, yield 43%). 223 wasn’t stable. Used directly for the next step without purification.
Methyl 4-((4-bromo-3-oxobutyl)amino)-2-fluorobenzoate 224
A suspension of 222 (7 g, 29.0 mmol) in 18 mL of 33% hydrogen bromide-glacial acetic
acid solution was treated with 2.2 mL of bromine in 4.4 mL of glacial acetic acid and stirred for
2.5 h at 25 °C. Ether (100 mL) was added to the reaction mixture with swirling until separation of
the syrupy hydrobromide was complete. The ether was decanted, and any ether remaining was

- 122 -

evaporated from the syrup along with excess hydrogen bromide. After further drying by
evaporation (bath 35 °C) of a solution in an equal volume of dichloromethane, the syrup
weighed 3.3 g. The syrup was then stirred with cold water and filtered to afford yellow solid.
Yellow solid obtained was then washed with water (3 × 20 mL) and dissolved in dichloromethane.
The solution was dried over sodium sulfate. Removal of solvent under reduced
pressure at room temperature gave a beige colored semisolid. The crude product was thoroughly
triturated with precooled ether, and the solid product was collected by filtration to afford 224 (2.7
g) yield 33 % as yellow oil. 224 wasn’t stable. Used directly for the next step without purification.
Methyl 4-(N-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)-2,2,2trifluoroacetamido)-3-fluorobenzoate 227
A suspension of α-bromoketone 223 (3.15 g, 10 mmol) in trifluoroacetic anhydride (30 mL)
was stirred for overnight at room temperature and then evaporated to dryness under reduced
pressure to remove the excess trifluoroacetic anhydride. The residue was dissolved in
dichloromethane (30 mL). The reaction solution was washed with cold 2% HCl (100 mL), 5%
NaHCO3 (100 mL) and extraction with cold water (100 mL) and dried over Na2SO4. After
evaporation of solvent, the residue was dried in vacuo using P 2O5 to afford amine protected αbromoketone 225 (3.1 g). 225 was then added to a suspension of 2,6-diaminopyrimidin-4-one (1.26
g, 10 mmol) in anhydrous DMF (25 mL). The resulting mixture was stirred under anhydrous
condition at room temperature for 3 days. After evaporation of the solvent under reduced pressure,
methanol (10 mL) was added followed by silica gel (5 g). The resulting plug was loaded on to a
silica gel column (3.5 cm × 12 cm) and eluted with CHCl 3 followed by 5% MeOH in CHCl3 and
then 8% MeOH in CHCl3. The desired fraction (TLC) were pooled and evaporated to afford 227
(1.5 g), yield 34% as red power. Mp : 213 0C TLC Rf = 0.23 (CHCl3/ MeOH, 6:1); 1 H NMR (400
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MHz, DMSO-d6) δ 2.76-2.80 (t, 2H, CH2CH2N, J = 7.3 Hz), 3.89 (s, 3H, OCH3), 4.09-4.12 (t, 2H,
CH2CH2N, J = 7.3 Hz), 5.96 (s, 2H, 2-NH2, exch), 6.02 (s, 1H, C5-CH), 7.51-7.55 (t, 1H, Ar-CH,
J = 7.9 Hz), 7.82-7.84 (d, 1H, Ar-CH, J = 8.3 Hz), 7.90-7.93 (d, 1H, Ar-CH, J = 10.2 Hz), 10.18
(s, 1H, 3-NH, exch), 10.83 (s, 1H, 7-NH, exch).
Methyl 4-(N-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)-2,2,2trifluoroacetamido)-2-fluorobenzoate 228
A suspension of α-bromoketone 224 (3.0 g, 10 mmol) in trifluoroacetic anhydride (30 mL)
was stirred for overnight at room temperature and then evaporated to dryness under reduced
pressure to remove the excess trifluoroacetic anhydride. The residue was dissolved in
dichloromethane (30 mL). The reaction solution was washed with cold 2% HCI (100 mL), 5%
NaHCO3 (100 mL) and extraction with cold water (100 mL) and dried over Na2SO4. After
evaporation of solvent, the residue was dried in vacuo using P 2O5 to afford amine protected αbromoketone 226 (3.20 g, 10 mmol). 226 was then added to a suspension of 2,6-diaminopyrimidin4-one (1.26 g, 10 mmol) in anhydrous DMF (25 mL). The resulting mixture was stirred under
anhydrous condition at room temperature for 3 days. After evaporation of the solvent under
reduced pressure, methanol (10 mL) was added followed by silica gel (5 g). The resulting plug
was loaded on to a silica gel column (3.5 cm × 12 cm) and eluted with CHCl 3 followed by 5%
MeOH in CHCl3 and then 8% MeOH in CHCl3. The desired fraction (TLC) were pooled and
evaporated to afford 228 (1.59g), yield 43 % as brown power. Mp 178.4 0C. TLC Rf = 0.23 (CHCl3/
MeOH, 6:1); 1 H NMR (400 MHz, DMSO-d6) δ 2.75-2.78 (t, 2H, CH2CH2N, J = 7.3 Hz), 3.89 (s,
3H, OCH3), 3.97-4.01 (t, 2H, CH2CH2N, J = 7.3 Hz), 5.95 (s, 1H, C5-CH), 6.02 (s, 2H, 2-NH2,
exch), 7.26-7.28 (d, 1H, Ar-CH, J = 10.1 Hz), 7.34-7.37 (d, 1H, Ar-CH, J = 10.1 Hz), 7.93-7.96
(t, 1H, Ar-CH, J = 8.1 Hz), 10.20 (s, 1H, 3-NH, exch), 10.85 (s, 1H, 7-NH, exch).
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4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)amino)-3fluorobenzoic acid 229
To a solution of 227 (440 mg, 1.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL)
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the
disappearance of the starting material and one major spot at the origin. The reaction mixture was
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4.
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed
with 20-40 mL cold water and dried in dried in vacuum using P 2O5 to afford 229 (284 mg) yield
86 % as yellow power. Mp 204.4 0C.

1

H NMR (400 MHz, DMSO-d6) δ 2.76-2.80 (t, 2H,

CH2CH2N, J = 7.3 Hz), 3.37-3.40 (t, 2H, CH2CH2N, J = 7.3 Hz), 5.99 (s, 2H, 2-NH2, exch), 6.02
(s, 1H, C5-CH), 6.34 (s, 1H, NH), 6.82-6.87 (t, 1H, Ar-CH, J = 8.5 Hz), 7.45-7.49 (d, 1H, Ar-CH,
J = 12.6 Hz), 7.59-7.62 (d, 1H, Ar-CH, J = 8.2 Hz), 10.20 (s, 1H, 3-NH, exch), 10.96 (s, 1H, 7NH, exch).
4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)amino)-2fluorobenzoic acid 230
To a solution of 228 (444 mg, 1.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10
mL) and the mixture was stirred under N2 at room temperature for overnight. TLC showed the
disappearance of the starting material and one major spot at the origin. The reaction mixture was
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 34. The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was
washed with 20-40 mL cold water and dried in dried in vacuum using P 2O5 to afford 230 (264
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mg) yield 84 % as brown power. Mp 213.3 0C.

1

H NMR (400 MHz, DMSO-d6) δ 2.74-2.77 (t,

2H, CH2CH2N, J = 7.2 Hz), 3.30-3.33 (t, 2H, CH2CH2N, J = 7.3 Hz), 6.03 (s, 2H, 1H, C5-CH),
6.12 (s, 2H, 2-NH2, exch), 6.34 (s, 1H, NH), 6.35-6.40 (d, 1H, Ar-CH, J = 14.5 Hz), 6.45-6.47
(d, 1H, Ar-CH, J = 10.6 Hz), 7.54-7.62 (t, 1H, Ar-CH, J = 8.8 Hz), 10.69 (s, 1H, 3-NH, exch),
11.26 (s, 1H, 7-NH, exch).
Di-tert-butyl (4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6yl)ethyl)amino)-3-fluorobenzoyl)-L-glutamate 231
To a solution of 229 (800 mg, 2.4 mmol) in anhydrous DMF (10 mL) was added Nmethylmorpholine (483 mg, 4.8 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (845 mg, 4.8
mmol). The resulting mixture was stirred at room temperature for 2 h. To this
mixture were added N-methylmorpholine (483 mg, 4.8 mmol) and L-glutamate di-tert-butyl
hydrochloride (1.04 g, 3.53 mmol). The reaction mixture was stirred for overnight at room
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 ×
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were
pooled, and the solvent evaporated to dryness to afford 231 (678 mg) yield 49% as yellow power.
TLC Rf = 0.63 (CHCl3/ MeOH, 6:1); Mp 202.3 0C.

1

H NMR (400 MHz, DMSO-d6) δ 1.39 (s, 9H,

C(CH3)3), 1.40 (s, 9H, C(CH3)3), 1.87 -2.04 (m, 2H, β-CH2), 2.30-2.34 (t, 2H, γ-CH2, J = 7.5 Hz),
2.77-2.81 (t, 2H, CH2CH2N, J = 7.5 Hz), 3.36-3.40 (t, 2H, CH2CH2N, J = 7.5 Hz), 4.22-4.31 (m,
1H, α-CH), 6.00 (s, 1H, NH), 6.02 (s, 2H, 2-NH2, exch), 6.08 (s, 1H, C5-CH), 6.82-6.87 (t, 1H,
Ar-CH, J = 8.6 Hz), 7.57-7.63(d, 2H, Ar-CH, J = 10.3 Hz), 8.26-8.28 (d, 1H, CONH, exch, J =
7.2 Hz), 10.19 (s, 1H, 3-NH, exch), 10.96 (s, 1H, 7-NH, exch).
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Di-tert-butyl (4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6yl)ethyl)amino)-2-fluorobenzoyl)-L-glutamate 232
To a solution of 230 (331 mg, 1.0 mmol) in anhydrous DMF (10 mL) was added Nmethylmorpholine (182 mg, 1.8 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (320 mg, 1.8
mmol). The resulting mixture was stirred at room temperature for 2 h. To this
mixture were added N-methylmorpholine (182 mg, 1.8 mmol) and L-glutamate di-tert-butyl
hydrochloride (442mg, 1.5 mmol). The reaction mixture was stirred for overnight at room
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 ×
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were
pooled, and the solvent evaporated to dryness to afford 232 (245 mg) yield 43% as brown power.
TLC Rf = 0.78 (CHCl3/ MeOH, 6:1); Mp 158.9 0C.

1

H NMR (400 MHz, DMSO-d6) δ 1.38 (s, 9H,

C(CH3)3), 1.40 (s, 9H, C(CH3)3), 1.86 -2.01 (m, 2H, β-CH2), 2.29-2.32 (t, 2H, γ-CH2, J = 7.5 Hz),
2.73-2.76 (t, 2H, CH2CH2N, J = 7.5 Hz), 3.28-3.30 (t, 2H, CH2CH2N, J = 7.5 Hz), 4.22-4.31 (m,
1H, α-CH), 5.99 (s, 1H, C5-CH), 6.01 (s, 2H, 2-NH2, exch), 6.39-6.42 (d, 1H, Ar-CH, J = 8.6 Hz),
6.45-6.49 (d, 1H, Ar-CH, J = 8.6 Hz), 6.61 (s, 1H, NH), 7.44-7.50 (t, 1H, Ar-CH, J = 8.8 Hz),
7.74-7.78 (t, 1H, CONH, exch, J = 7.2 Hz), 10.27 (s, 1H, 3-NH, exch), 11.20 (s, 1H, 7-NH, exch).
4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)amino)-3fluorobenzoyl)-L-glutamic acid 162
To a solution of 231 (109 mg, 0.19 mmol) in MeOH (10 mL) was added trifluoroacetic
acid (2 mL). The mixture was then stirred under N 2 at room temperature for 2 h. TLC showed the
disappearance of the starting material and one major spot at the origin (CHCl 3/ MeOH, 6:1). The
reaction mixture was then evaporated to dryness under reduced pressure. The residue was
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dissolved in 1 N NaOH, the resulting solution was cooled in an ice bath, and the pH was adjusted
to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5 0C
refrigerator and filtered. The residue was washed with 10-20 mL cold water and dried in vacuum
using P2O5 to afford 60 mg (68%) of 162 as a yellow powder. Mp 222.9 0C. 1 H NMR (400 MHz,
DMSO-d6) δ 1.91 -2.04 (m, 2H, β-CH2), 2.32-2.36 (t, 2H, γ-CH2, J = 7.5 Hz), 2.77-2.82 (t, 2H,
CH2CH2N, J = 7.5 Hz), 3.36-3.40 (t, 2H, CH2CH2N, J = 7.5 Hz), 4.37-4.34 (m, 1H, α-CH), 6.00
(s, 1H, NH), 6.02 (s, 1H, C5-CH), 6.19 (s, 2H, 2-NH2, exch), 6.81-6.87 (t, 1H, Ar-CH, J = 8.6 Hz),
7.57-7.63(d, 2H, Ar-CH, J = 10.3 Hz), 8.29-8.31 (d, 1H, CONH, exch, J = 7.2 Hz), 10.33 (s, 1H,
3-NH, exch), 11.04 (s, 1H, 7-NH, exch). Anal. (C20H21FN6O6. 1.40447 H2O. 0.0582CF3COOH)
C, H, N, F.
4-((2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl)amino)-2fluorobenzoyl)-L-glutamic acid 163
To a solution of 232 (100 mg, 0.17 mmol) in MeOH (10 mL) was added trifluoroacetic
acid (2 mL). The mixture was then stirred under N 2 at room temperature for 2 h. TLC showed the
disappearance of the starting material and one major spot at the origin (CHCl 3/ MeOH, 6:1). The
reaction mixture was then evaporated to dryness under reduced pressure. The residue was
dissolved in 1 N NaOH, the resulting solution was cooled in an ice bath, and the pH was adjusted
to

3-4

with

dropwise

addition

of

1

N

HCl.

The

resulting

suspension

was

stored in a 4-5 0C refrigerator and filtered. The residue was washed with 10-20 mL cold water and
dried in vacuum using P2O5 to afford 60 mg (76%) of 163 as a yellow powder. Mp 187.3 0C. 1 H
NMR (400 MHz, DMSO-d6) δ1.86 -2.01 (m, 2H, β-CH2), 2.30-2.33 (t, 2H, γ-CH2, J = 7.3 Hz),
2.72-2.76 (t, 2H, CH2CH2N, J = 7.1 Hz), 3.28-3.32 (t, 2H, CH2CH2N, J = 6.8 Hz), 4.37-4.41 (m,
1H, α-CH), 6.00 (s, 1H, C5-CH), 6.14 (s, 2H, 2-NH2, exch), 6.38-6.42 (d, 1H, Ar-CH, J = 8.6 Hz),
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6.48-6.50 (d, 1H, Ar-CH, J = 8.6 Hz), 6.61 (s, 1H, NH), 7.47-7.51 (t, 1H, Ar-CH, J = 8.8 Hz),
7.74-7.78 (t, 1H, CONH, exch, J = 7.2 Hz), 10.28 (s, 1H, 3-NH, exch), 11.00 (s, 1H, 7-NH, exch).
Anal. (C20H21FN6O6. 1.6967 H2O) C, H, N, F.
Methyl 3-fluoro-4-(5-oxopentyl) benzoate 237
To a solution of methyl 4-bromo-3-fluorobenzoate 233 (4.66 g, 20 mmol) in 20mL
anhydrous DMF was added pent-4-en-1-ol (2.06 g, 24 mmol), LiCl (840 mg, 20 mmol), LiOAc
(3.4 g, 50 mmol), n-Bu4NCl (3.36g, 10 mmol), Pd(OAc)2 (240 mg, 1.2 mmol) and the mixture was
stirred at 85 0C for 3 hours. Then, silica gel (5 g) was added, and the solvent was evaporated to
afford a plug under reduced pressure. The resulting plug was loaded on to a silica gel column (3.5
× 12 cm) and eluted with hexane followed by 20% EtOAc in hexane. The desired fraction (TLC)
were pooled and evaporated to afford 237 (2.38 g), yield 50 % as yellow oil. TLC Rf = 0.50
(hexane/ EtOAc, 1:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.54-1.59 (m, 4H, ArCH2CH2CH2), 2.442.47 (t, 2H, CH2CHO, J = 7.0 Hz), 2.62-2.65 (t, 2H, ArCH2CH2, J = 7.3 Hz), 3.82 (s, 3H, OCH3),
7.13-7.19 (t, 2H, Ar, J = 10.9 Hz), 7.77-7.81 (t, 1H, Ar, J = 7.8 Hz), 9.63-9.65 (s, 1H, CHO, J =
5.6 Hz).
Methyl 4-(4-bromo-5-oxopentyl)-3-fluorobenzoate 238
To a solution of aldehyde 237 (2.38 g, 10 mmol) in 10 mL dichloromethane was added the
Br2(0.66 g, 7.7 mmol), dioxane in dichloromethane solution dropwise and the mixture was stirred
at ice bath for 3 hours. TLC (hexane/ EtOAc, 1:1) showed the disappearance of the starting material
(Rf = 0.50) and formation of one major spot at Rf = 0.40 (hexane/ EtOAc, 1:1). The reaction solution
was washed with 5% NaHCO3 solution and extraction with H2O and dried over Na2SO4. After
evaporation of solvent the residue was dried in vacuo using P 2O5 to afford 238 (3g). 238 wasn’t
stable. Used directly for the next step without purification.
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Methyl 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)-2fluorobenzoate 239
To a solution of 2,6-diamino-3H-pyrimidin-4-one 214 (1.25g, 10 mmol) and sodium
acetate (1.7 g, 20 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo aldehyde
238 (3.17, 10 mmol). The reaction mixture was stirred at 45 0C for 3 hours. TLC showed the
disappearance of starting materials and the formation of one major spot at R f = 0.73 (CHCl3/ MeOH,
6:1) After evaporation of solvent, CH3OH was added followed by silica gel (3 g). Evaporation of
the solvent afforded a plug, which was loaded onto a silica gel column (3.5 cm × 15 cm) and eluted
with CHCl3 followed by 8% MeOH in CHCl3. The desired fraction (TLC) were pooled and
evaporated to afford 239 (2.01g), yield 61 % as green power. Mp : 171.4 0C TLC Rf = 0.73 (CHCl3/
MeOH, 6:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.91-1.95 (m, 2H, ArCH2CH2CH2), 2.56-2.59 (t,
2H, ArCH2CH2CH2Ar, J = 7.0 Hz), 2.64-2.68 (t, 2H, ArCH2CH2CH2Ar J = 7.3 Hz), 3.82 (s, 3H,
OCH3), 6.00 (s, 2H, 2-NH2, exch), 6.38 (s, 1H, C6-CH), 7.15-7.21 (t, 2H, Ar, J = 10.9 Hz), 7.777.81 (t, 1H, Ar, J = 7.8 Hz), 10.14 (s, 1H, 3-NH, exch), 10.66 (s, 1H, 7-NH, exch).
4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)-2-fluorobenzoic
acid 240
To a solution of 239 (300 mg, 0.87 mmol) in MeOH (15 mL) was added 1 N NaOH (10
mL) and the mixture was stirred under N2 at room temperature for overnight. TLC showed the
disappearance of the starting material and one major spot at the origin. The reaction mixture was
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4.
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed
with 20-40 mL cold water and dried in dried in vacuum using P 2O5 to afford 240 (230 mg) yield
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81 % as green powder. Mp 202.0 0C.

1

H NMR (400 MHz, DMSO-d6) δ 1.91-1.96 (m, 2H,

ArCH2CH2CH2), 2.54-2.57 (t, 2H, ArCH2CH2CH2Ar, J = 7.6 Hz), 2.62-2.65 (t, 2H,
ArCH2CH2CH2Ar J = 7.4 Hz), 6.00 (s, 2H, 2-NH2, exch), 6.46 (s, 1H, C6-CH), 7.12-7.17 (t, 2H,
Ar, J = 7.9 Hz), 7.75-7.79 (t, 1H, Ar, J = 8.0 Hz), 10.67 (s, 1H, 3-NH, exch), 10.95 (s, 1H, 7-NH,
exch), 12.48 (br, 1H, COOH, exch)
Dimethyl (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)-2fluorobenzoyl)-L-glutamate 241
To a solution of 240 (200 mg, 0.58 mmol) in anhydrous DMF (10 mL) was added Nmethylmorpholine (105 mg, 1.04 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (185 mg, 1.04
mmol). The resulting mixture was stirred at room temperature for 2 h. To this
mixture were added N-methylmorpholine (105 mg, 1.04 mmol) and L-glutamate diethyl ester
hydrochloride (209 mg, 0.87 mmol). The reaction mixture was stirred for overnight at room
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 ×
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were
pooled, and the solvent evaporated to dryness to afford 241 (131 mg) yield 46 % as yellow powder.
TLC Rf = 0.5 (CHCl3/ MeOH, 6:1); Mp 192.8 0C.

1

H NMR (400 MHz, DMSO-d6) δ 1.91-1.98

(m, 2H, ArCH2), 2.07-2.14 (m, 2H, β-CH2), 2.44-2.51 (t, 2H, γ-CH2, J = 7.2 Hz), 2.56-2.59 (t, 2H,
ArCH2CH2CH2Ar, J = 7.6 Hz), 2.64-2.67 (t, 2H, ArCH2CH2CH2Ar J = 7.5 Hz), 3.59 (s, 3H,
COOCH3, exch), 3.66 (s, 3H, COOCH3, exch), 4.43-4.48 (m, 1H, α-CH), 5.99 (s, 2H, 2-NH2, exch),
6.38 (s, 1H, C6-CH), 7.12-7.17 (t, 2H, Ar, J = 10.1 Hz), 7.50-7.54 (t, 1H, Ar, J = 8.0 Hz), 8.608.62 (d, 1H, CONH, exch, J = 7.5 Hz,), 10.13 (s, 1H, 3-NH, exch), 10.66 (s, 1H, 7-NH, exch).
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(S)- (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)-2fluorobenzoyl)-L-glutamic acid 167
To a solution of 241 (85 mg, 0.17 mmol) in MeOH (20 mL) was added 1 N NaOH (10 mL).
The mixture was then stirred under N2 at room temperature overnight. TLC showed the
disappearance of the starting material and one major spot at the origin (CHCl 3/ MeOH, 6:1). The
reaction mixture was then evaporated to dryness under reduced pressure. The residue was
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was
adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5
0

C refrigerator and filtered. The residue was washed with 30-40 mL cold water and dried in

vacuum using P2O5 to afford 60 mg (77%) of 167 as a green powder. Mp 150.6 0C. 1 H NMR (400
MHz, DMSO-d6) δ 1.87-1.93 (m, 2H, ArCH2), 2.04-2.07 (m, 2H, β-CH2), 2.33-2.37 (t, 2H, γ-CH2,
J = 7.2 Hz), 2.56-2.59 (t, 2H, ArCH2CH2CH2Ar, J = 7.5 Hz), 2.64-2.67 (t, 2H, ArCH2CH2CH2Ar
J = 7.6 Hz), 4.37-4.41 (m, 1H, α-CH), 5.98 (s, 2H, 2-NH2, exch), 6.37 (s, 1H, C6-CH), 7.12-7.16
(t, 2H, Ar, J = 9.9 Hz), 7.51-7.54 (t, 1H, Ar, J = 7.5 Hz), 8.42-8.43 (d, 1H, CONH, exch, J = 6.8
Hz), 10.13(s, 1H, 3-NH, exch), 10.65 (s, 1H, 7-NH, exch), 12.48 (br, 2H, COOH, exch). Anal.
(C21H22FN5O6. 0.7908 CH3OH. 0.1795 HCl) C, H, N, F,Cl.
Methyl 4-(4-oxobutyl)thiophene-2-carboxylate 243
To a solution of methyl 4-bromothiophene-2-carboxylate 242 (4.42 g, 20 mmol) in 20mL
anhydrous DMF was added 3-buten-1-ol (1.75 g, 24 mmol), LiCl (840 mg, 20 mmol), LiOAc (3.4
g, 50 mmol), n-Bu4NCl (3.36g, 10 mmol), Pd(OAc)2 (240 mg, 1.2 mmol) and the mixture was
stirred at 85 0C for 3 hours. Then, silica gel (5 g) was added, and the solvent was evaporated to
afford a plug under reduced pressure. The resulting plug was loaded on to a silica gel column (3.5
× 12 cm) and eluted with hexane followed by 20% EtOAc in hexane. The desired fraction (TLC)
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were pooled and evaporated to afford 243 (2.35 g), yield 55% as yellow oil. TLC Rf = 0.6 (hexane/
EtOAc, 1:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.82-1.86 (m, 2H, ArCH2CH2CH2CHO), 2.422.45 (t, 2H, ArCH2CH2CHO, J = 3.0 Hz), 2.58-2.60 (t, 2H, ArCH2CH2CH2CHO, J = 3.3 Hz), 3.81
(s, 3H, OCH3), 7.61 (s, 1H, Ar), 7.70 (s, 1H, Ar), 9.64-9.66 (t, 1H, CHO, J = 1.5 Hz).
Methyl 4-(5-oxopentyl)thiophene-2-carboxylate 244
To a solution of methyl 4-bromothiophene-2-carboxylate 242 (4.42 g, 20 mmol) in 20mL
anhydrous DMF was added 4-penten-1-ol (2.06 g, 24 mmol), LiCl (840 mg, 20 mmol), LiOAc
(3.4 g, 50 mmol), n-Bu4NCl (3.36g, 10 mmol), Pd(OAc)2 (240 mg, 1.2 mmol) and the mixture was
stirred at 85 0C for 3 hours. Then, silica gel (5 g) was added, and the solvent was evaporated to
afford a plug under reduced pressure. The resulting plug was loaded on to a silica gel column (3.5
× 12 cm) and eluted with hexane followed by 20% EtOAc in hexane. The desired fraction (TLC)
were pooled and evaporated to afford 244 (1.60 g), yield 35 % as yellow oil. TLC Rf = 0.6 (hexane/
EtOAc, 1:1);

1

H NMR (400 MHz, DMSO-d6) δ 1.50-1.60 (m, 4H, ArCH2CH2CH2CH2CHO),

2.46-2.48 (t, 2H, ArCH2CH2CH2CH2CHO, J = 3.0 Hz), 2.58-2.60 (t, 2H, ArCH2CH2CH2CH2CHO,
J = 7.2 Hz), 3.80 (s, 3H, OCH3), 7.58 (s, 1H, Ar), 7.68 (s, 1H, Ar), 9.64-9.66 (t, 1H, CHO, J = 1.5
Hz).
Methyl 4-(6-oxohexyl)thiophene-2-carboxylate 245
To a solution of methyl 4-bromothiophene-2-carboxylate 242 (4.42 g, 20 mmol) in 20mL
anhydrous DMF was added 5-hexen-1-ol (2.4 g, 24 mmol), LiCl (840 mg, 20 mmol), LiOAc (3.4
g, 50 mmol), n-Bu4NCl (3.36g, 10 mmol), Pd(OAc)2 (240 mg, 1.2 mmol) and the mixture was
stirred at 85 0C for 3 hours. Then, silica gel (5 g) was added, and the solvent was evaporated to
afford a plug under reduced pressure. The resulting plug was loaded on to a silica gel column (3.5
× 12 cm) and eluted with hexane followed by 20% EtOAc in hexane. The desired fraction (TLC)
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were pooled and evaporated to afford 245 (2.16 g), yield 45 % as yellow oil. TLC Rf = 0.5 (hexane/
EtOAc, 1:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.25-1.28 (m, 2H, ArCH2CH2CH2 CH2CH2CHO),
1.50-1.61 (m, 4H, ArCH2CH2CH2CH2CH2CHO), 2.41-2.45 (t, 2H, ArCH2CH2CH2CH2CH2CHO,
J = 7.4 Hz), 2.57-2.60 (t, 2H, ArCH2CH2, J = 7.6 Hz), 3.80 (s, 3H, OCH3), 7.58 (s, 1H, Ar), 7.68
(s, 1H, Ar), 9.65-9.66 (t, 1H, CHO, J = 1.6 Hz).
Methyl 4-(3-bromo-4-oxobutyl)thiophene-2-carboxylate 246
To a solution of aldehyde 243 (1.0 g, 4.72 mmol) in 10 mL of anhydrous Et2O was added
5,5-dibromo-2,2-dimethyl-1,3-dioxane-4,6-dione (0.71 g, 2.36 mmol) and 2N HCl (245 µL, 0.23
mmol) in Et2O solution and the mixture was stirred at room temperature for 24 hours. TLC
(hexane/ EtOAc, 1:1) showed the disappearance of the starting material (R f = 0.60) and formation
of one major spot at Rf = 0.8 (hexane/ EtOAc, 1:1). The reaction solution was washed with 5%
NaHCO3 solution and extraction with H2O and dried over Na2SO4. After evaporation of solvent
the residue was dried in vacuo using P2O5 to afford 246 (1.26 g). Yield 91% as yellow oil. 246
wasn’t stable. Used directly for the next step without purification. 1 H NMR (400 MHz, DMSOd6) δ 2.72-2.74 (t, 2H, ArCH2CH2, J = 3.3 Hz), 2.79-2.81 (t, 2H, ArCH2CH2CHBr, J = 3.0 Hz),
3.81 (s, 3H, OCH3), 4.64-4.66 (m, 1H, CHBr), 7.67 (s, 1H, Ar), 7.74 (s, 1H, Ar), 9.42 (s, 1H,
CHO).
Methyl 4-(4-bromo-5-oxopentyl) thiophene-2-carboxylate 247
To a solution of aldehyde 244 (726 mg, 3.37 mmol) in 10 mL of anhydrous Et2O was added
5,5-dibromo-2,2-dimethyl-1,3-dioxane-4,6-dione (505 mg, 1.68 mmol) and 2N HCl (174 µL, 0.17
mmol) in Et2O solution and the mixture was stirred at room temperature for 24 hours. TLC
(hexane/ EtOAc, 1:1) showed the disappearance of the starting material (R f = 0.50) and formation
of one major spot at Rf = 0.5 (hexane/ EtOAc, 1:1). The reaction solution was washed with 5%
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NaHCO3 solution and extraction with H2O and dried over Na2SO4. After evaporation of solvent
the residue was dried in vacuo using P2O5 to afford 247 (700 mg). 247 wasn’t stable. Used directly
for the next step without purification.

1

H NMR (400 MHz, DMSO-d6) δ1.50-1.60 (m, 2H,

ArCH2CH2), 2.72-2.74 (t, 2H, ArCH2CH2, J = 3.3 Hz), 2.79-2.81 (t, 2H, ArCH2CH2CH2CHBr, J
= 3.0 Hz), 3.81 (s, 3H, OCH3), 4.73-4.76 (m, 1H, CHBr), 7.61 (d, 1H, Ar), 7.69 (s, 1H, Ar), 9.42
(s, 1H, CHO).
Methyl 4-(5-bromo-6-oxohexyl)thiophene-2-carboxylate 248
To a solution of aldehyde 245 (2.4 g, 1.0 mmol) in 10 mL of anhydrous Et2O was added
5,5-dibromo-2,2-dimethyl-1,3-dioxane-4,6-dione (600 mg, 2 mmol) and 2N HCl (210 µL, 0.2
mmol) in Et2O solution and the mixture was stirred at room temperature for 24 hours. TLC
(hexane/ EtOAc, 1:1) showed the disappearance of the starting material (R f = 0.50) and formation
of one major spot at Rf = 0.4 (hexane/ EtOAc, 1:1). The reaction solution was washed with 5%
NaHCO3 solution and extraction with H2O and dried over Na2SO4. After evaporation of solvent
the residue was dried in vacuo using P2O5 to afford 248 (700 mg) yield 25 % as yellow oil. 248
wasn’t stable. Used directly for the next step without purification.
Methyl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)thiophene2-carboxylate 249
To a solution of 2,6-diamino-3H-pyrimidin-4-one 214 (534 mg, 4.3 mmol) and sodium
acetate (740 mg, 9.0 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo aldehyde
246 (1.26, 4.3 mmol). The reaction mixture was stirred at 45 0C for 3 hours. TLC showed the
disappearance of starting materials and the formation of one major spot at R f = 0.5 (CHCl3/ MeOH,
6:1) After evaporation of solvent, CH3OH was added followed by silica gel (3 g). Evaporation of
the solvent afforded a plug, which was loaded onto a silica gel column (3.5 cm × 15 cm) and eluted

- 135 -

with CHCl3 followed by 10 % MeOH in CHCl3. The desired fraction (TLC) were pooled and
evaporated to afford 249 (861mg), yield 63% as red power. Mp: 124.1 0C. TLC Rf = 0.5 (CHCl3/
MeOH, 6:1);

1

H NMR (400 MHz, DMSO-d6) δ 2.84-2.87 (t, 2H, ArCH2CH2Ar, J = 8.2 Hz),

2.92-2.95 (t, 2H, ArCH2CH2Ar, J = 8.2 Hz), 3.80 (s, 3H, OCH3), 6.00 (s, 2H, 2-NH2, exch), 6.33
(s, 1H, C6-CH), 7.54 (s, 1H, Ar), 7.65 (s, 1H, Ar), 10.15 (s, 1H, 3-NH, exch), 10.64 (s, 1H, 7-NH,
exch).
Methyl 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-l)propyl)thiophene2-carboxylate 250
To a solution of 2,6-diamino-3H-pyrimidin-4-one 214 (1.03 g, 8.2 mmol) and sodium
acetate (1.4 g, 17.0 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo aldehyde
247 (2.6 g, 8.5 mmol). The reaction mixture was stirred at 45 0C for 3 hours. TLC showed the
disappearance of starting materials and the formation of one major spot at R f = 0.53 (CHCl3/ MeOH,
6:1) After evaporation of solvent, CH3OH was added followed by silica gel (3 g). Evaporation of
the solvent afforded a plug, which was loaded onto a silica gel column (3.5 cm × 15 cm) and eluted
with CHCl3 followed by 10% MeOH in CHCl3. The desired fraction (TLC) were pooled and
evaporated to afford 250 (861mg), yield 63% as red power. Mp : 186.2 0C TLC Rf = 0.73 (CHCl3/
MeOH, 6:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.92-1.95(m, 2H, ArCH2 CH2CH2Ar), 2.56-2.63
(m, 4H, ArCH2), 3.80 (s, 3H, OCH3), 6.00 (s, 2H, 2-NH2, exch), 6.37 (s, 1H, C6-CH), 7.60 (s, 1H,
Ar), 7.67 (s, 1H, Ar), 10.11 (s, 1H, 3-NH, exch), 10.64 (s, 1H, 7-NH, exch).
Methyl 4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)thiophene2-carboxylate 251
To a solution of 2,6-diamino-3H-pyrimidin-4-one 214 (1.15 g, 8.8 mmol) and sodium
acetate (1.56 g, 18.3 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo aldehyde
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248 (2.9 g, 9.14 mmol). The reaction mixture was stirred at 45 0C for 3 hours. TLC showed the
disappearance of starting materials and the formation of one major spot at R f = 0.53 (CHCl3/ MeOH,
6:1) After evaporation of solvent, CH3OH was added followed by silica gel (3 g). Evaporation of
the solvent afforded a plug, which was loaded onto a silica gel column (3.5 cm × 15 cm) and eluted
with CHCl3 followed by 10 % MeOH in CHCl3. The desired fraction (TLC) were pooled and
evaporated to afford 251 (2.12 g), yield 67% as red power. Mp 164.4 0C. TLC Rf = 0.5 (CHCl3/
MeOH, 6:1); 1 H NMR (400 MHz, DMSO-d6) δ 1.58-1.59(m, 4H, ArCH2CH2 CH2CH2Ar), 2.512.61 (m, 4H, ArCH2), 3.80 (s, 3H, OCH3), 5.98 (s, 2H, 2-NH2, exch), 6.33 (s, 1H, C6-CH), 7.56 (s,
1H, Ar), 7.65 (s, 1H, Ar), 10.12 (s, 1H, 3-NH, exch), 10.62 (s, 1H, 7-NH, exch).
4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)thiophene-2carboxylic acid 252
To a solution of 249 (318mg, 1.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL)
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the
disappearance of the starting material and one major spot at the origin. The reaction mixture was
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4.
The resulting suspension was stored in a 4-5 0C refrigerator, and flited. The residue was washed
with 20-40 mL cold water and dried in dried in vacuum using P 2O5 to afford 252 (256 mg) yield
84% as red power. Mp 183.9 0C.

1

H NMR (400 MHz, DMSO-d6) δ 2.73-2.91 (m, 4H,

ArCH2CH2Ar), 6.00 (s, 2H, 2-NH2, exch), 6.34 (s, 1H, C6-CH), 7.43 (s, 1H, Ar), 7.56 (s, 1H, Ar),
10.11(s, 1H, 3-NH, exch), 10.65 (s, 1H, 7-NH, exch), 12.88 (br, 1H, COOH, exch)
4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)thiophene-2carboxylic acid 253
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To a solution of 257 (332 mg, 1.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL)
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the
disappearance of the starting material and one major spot at the origin. The reaction mixture was
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4.
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed
with 20-40 mL cold water and dried in dried in vacuum using P 2O5 to afford 253 (287 mg) yield
92 % as blue powder. Mp 167.9 0C.

1

H NMR (400 MHz, DMSO-d6) δ 1.89-1.92 (m, 2H, ArCH2

CH2CH2Ar), 2.57-2.65 (m, 4H, ArCH2), 5.99 (s, 2H, 2-NH2, exch), 6.36 (s, 1H, C6-CH), 7.45 (s,
1H, Ar), 7.65 (s, 1H, Ar), 10.11(s, 1H, 3-NH, exch), 10.65 (s, 1H, 7-NH, exch), 12.88 (br, 1H,
COOH, exch).
4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)thiophene-2carboxylic acid 254
To a solution of 251 (692 mg, 2.0 mmol) in MeOH (15 mL) was added 1 N NaOH (10 mL)
and the mixture was stirred under N2 at room temperature for overnight. TLC showed the
disappearance of the starting material and one major spot at the origin. The reaction mixture was
evaporated to dryness under reduced pressure. The residue was dissolved in water (10 mL). The
resulting solution was cooled in ice bath and 1 N HCl was added by dropwise to adjust pH to 3-4.
The resulting suspension was stored in a 4-5 0C refrigerator, and flitered. The residue was washed
with 20-40 mL cold water and dried in dried in vacuum using P 2O5 to afford 254 (577 mg) yield
87% as red powder. Mp 153.2 0C.

1

H NMR (400 MHz, DMSO-d6) δ 1.52-1.64 (m, 4H, ArCH2

CH2CH2Ar), 2.55-2.64 (m, 4H, ArCH2), 6.13 (s, 2H, 2-NH2, exch), 6.35 (s, 1H, C6-CH), 7.49 (s,
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1H, Ar), 7.56 (s, 1H, Ar), 10.23 (s, 1H, 3-NH, exch), 10.67 (s, 1H, 7-NH, exch), 12.88 (br, 1H,
COOH, exch).
Dimethyl (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)
thiophene-2-carbonyl)glutamate 255
To a solution of 252 (230 mg, 0.75 mmol) in anhydrous DMF (10 mL) was added Nmethylmorpholine (137 mg, 1.35 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (241mg, 1.35
mmol). The resulting mixture was stirred at room temperature for 2 h. To this
mixture were added N-methylmorpholine (137 mg, 1.35 mmol) and L-glutamate diethyl ester
hydrochloride (272 mg, 1.13 mmol). The reaction mixture was stirred for overnight at room
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 ×
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were
pooled, and the solvent evaporated to dryness to afford 255 (172 mg) yield 50% as red powder.
TLC Rf = 0.78 (CHCl3/ MeOH, 6:1); Mp 189.3 0C.

1

H NMR (400 MHz, DMSO-d6) δ 2.07-2.13

(m, 2H, β-CH2), 2.44-2.47 (t, 2H, γ-CH2, J = 7.2 Hz), 2.85-2.90 (m, 4H, ArCH2CH2Ar), 3.59 (s,
3H, COOCH3, exch), 3.65 (s, 3H, COOCH3, exch), 4.39-4.47 (m, 1H, α-CH), 6.06 (s, 2H, 2-NH2,
exch), 6.37 (s, 1H, C6-CH), 7.39 (s, 1H, Ar), 7.80 (s, 1H, Ar), 8.74-8.76 (d, 1H, CONH, exch, J =
7.5 Hz,), 10.21 (s, 1H, 3-NH, exch), 10.66 (s, 1H, 7-NH, exch).
4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)thiophene-2carboxylic acid 257
To a solution of 253 (318 mg, 1.0 mmol) in anhydrous DMF (10 mL) was added Nmethylmorpholine (182 mg, 1.8 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (320 mg, 1.8
mmol). The resulting mixture was stirred at room temperature for 2 h. To this
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mixture were added N-methylmorpholine (182 mg, 1.8 mmol) and L-glutamate diethyl ester
hydrochloride (361 mg, 1.5 mmol). The reaction mixture was stirred for overnight at room
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 ×
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were
pooled, and the solvent evaporated to dryness to afford 256 (320 mg) yield 64 % as red power. 256
is not very pure.
4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)thiophene-2carboxylic acid 257
To a solution of 254 (508 mg, 1.47 mmol) in anhydrous DMF (10 mL) was added Nmethylmorpholine (267 mg, 2.6 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (469 mg, 2.6
mmol). The resulting mixture was stirred at room temperature for 2 h. To this
mixture were added N-methylmorpholine (267 mg, 2.6 mmol) and L-glutamate diethyl ester
hydrochloride (530 mg, 2.2 mmol). The reaction mixture was stirred for overnight at room
temperature and then evaporated to dryness under reduced pressure. The residue was dissolved in
the minimum amount of CHCl3/MeOH (10:1) and chromatographed on a silica gel column (2 ×
15 cm) with 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were
pooled, and the solvent evaporated to dryness to afford 257 (320 mg) yield 63% as red powder.
(S)- (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)thiophene-2carbonyl)glutamic acid 172
To a solution of 255 (240 mg, 0.5 mmol) in MeOH (20 mL) was added 1 N NaOH (10 mL).
The mixture was then stirred under N2 at room temperature overnight. TLC showed the
disappearance of the starting material and one major spot at the origin (CHCl 3/ MeOH, 6:1). The
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reaction mixture was then evaporated to dryness under reduced pressure. The residue was
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was
adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5
0

C refrigerator and filtered. The residue was washed with 30-40 mL cold water and dried in

vacuum using P2O5 to afford 172 82 mg yield 84% as red powder. Mp 169.0 0C. 1 H NMR (400
MHz, DMSO-d6) δ 1.84-2.16 (m, 2H, β-CH2), 2.28-2.34 (t, 2H, γ-CH2, J = 8.2 Hz), 2.83-2.95 (m,
4H, ArCH2CH2Ar), 4.29-4.41 (m, 1H, α-CH), 6.00 (s, 2H, 2-NH2, exch), 6.37 (s, 1H, C6-CH), 7.37
(s, 1H, Ar), 7.81 (s, 1H, Ar), 8.62-8.59 (d, 1H, CONH, exch, J = 10.8 Hz), 10.14 (s, 1H, 3-NH,
exch), 10.65 (s, 1H, 7-NH, exch), 12.48 (br, 2H, COOH, exch). Anal. (C 18H19N5O6S. 0.596
CH3OH. 0.6232 HCl) C, H, N, S.
(S)- 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)thiophene2-carbonyl)-L-glutamic acid 173
To a solution of 256 (100 mg, 0.21 mmol) in MeOH (20 mL) was added 1 N NaOH (10
mL). The mixture was then stirred under N2 at room temperature overnight. TLC showed the
disappearance of the starting material and one major spot at the origin (CHCl 3/ MeOH, 6:1). The
reaction mixture was then evaporated to dryness under reduced pressure. The residue was
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was
adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5
0

C refrigerator and filtered. The residue was washed with 30-40 mL cold water and dried in

vacuum using P2O5 to afford 184 mg (83%) of 173 as a red powder. Mp 239.8 0C. 1 H NMR (400
MHz, DMSO-d6) δ 1.88 -1.94 (m, 2H, ArCH2CH2CH2), 2.04 -2.11 (m, 2H, β-CH2), 2.28-2.39 (t,
2H, γ-CH2, J = 8.2 Hz), 2.59-2.63 (m, 4H, ArCH2), 4.30-4.37 (m, 1H, α-CH), 5.99 (s, 2H, 2-NH2,
exch), 6.38 (s, 1H, C6-CH), 7.42 (s, 1H, Ar), 7.76 (s, 1H, Ar), 8.56-8.60 (d, 1H, CONH, exch, J =
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10.8 Hz), 10.12 (s, 1H, 3-NH, exch), 10.66 (s, 1H, 7-NH, exch), 12.62 (br, 2H, COOH, exch).
Anal. (C19H21N5O6S. 2.2443 H2O) C, H, N, S.
(S)- 4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)thiophene-2carbonyl)-L-glutamic acid 174
To a solution of 257 (250 mg, 0.5 mmol) in MeOH (20 mL) was added 1 N NaOH (10 mL).
The mixture was then stirred under N2 at room temperature overnight. TLC showed the
disappearance of the starting material and one major spot at the origin (CHCl 3/ MeOH, 6:1). The
reaction mixture was then evaporated to dryness under reduced pressure. The residue was
dissolved in water (15 mL), the resulting solution was cooled in an ice bath, and the pH was
adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was stored in a 4-5
0

C refrigerator and filtered. The residue was washed with 30-40 mL cold water and dried in

vacuum using P2O5 to afford 190 mg (80%) of 174 as a green powder. Mp 146.1 0C. 1 H NMR
(400 MHz, DMSO-d6) δ 1.53 -1.59 (m, 2H, ArCH2CH2CH2), 1.88 -1.93 (m, 2H, ArCH2CH2CH2),
2.02 -2.07 (m, 2H, β-CH2), 2.30-2.35 (t, 2H, γ-CH2, J = 8.2 Hz), 2.56-2.65 (m, 4H, ArCH2), 4.304.35 (m, 1H, α-CH), 5.98 (s, 2H, 2-NH2, exch), 6.38 (s, 1H, C6-CH), 7.39 (s, 1H, Ar), 7.75 (s, 1H,
Ar), 8.55-8.56 (d, 1H, CONH, exch, J = 10.8 Hz), 10.12 (s, 1H, 3-NH, exch), 10.62 (s, 1H, 7-NH,
exch), 12.62 (br, 2H, COOH, exch). Anal. (C 20H23N5O6S. 0.333 CHCl3) C, H, N, S.
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APPENDIX 1
The biological evaluations of the analogs listed in the following tables were performed by
Dr. Larry H. Matherly (Developmental Therapeutics Program, Barbara Ann Karmanos Cancer
Institute and the Cancer Biology Program and Department of Pharmacology, Wayne State
University School of Medicine) against GARFTase, RFC-expressing PC43-10 cells, FRαexpressing RT16 cells, FRβ-expressing D4 cells and hPCFT-expressing R2/hPCFT4 cells.
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Cell Lines and Assays of Antitumor Drug Activities. RFC- and FRR-null
MTXRIIOuaR2-4 (R2) CHO cells were gifts from Dr. Wayne Flintoff (University of Western
Ontario) and were cultured in R-minimal essential medium (MEM) supplemented with 10%
bovine calf serum (Invitrogen, Carlsbad, CA), penicillin- streptomycin solution and L-glutamine
at 37 °C with 5% CO2. PC43-10 cells are R2 cells transfected with hRFC. RT16 cells are R2 cells
transfected with human FRα, and D4 cells are R2 cells transfected with human FRβ. R2/hPCFT4
cells were prepared by transfection of R2 cells with a hPCFT cDNA, epitope tagged at the Cterminus with Myc-His6 (hPCFTMyc-His6) and cloned in pCDNA3.1. All the R2 transfected cells
(PC43- 10, RT16, D4, R2/hPCFT4) were routinely cultured in R-MEM plus 1.5 mg/mL G418.
Prior to the cytotoxicity assays (see below), RT16 and D4 cells were cultured in complete folatefree RPMI1640 (without added folate) for 3 days. KB human cervical cancer cells were purchased
from the American Type Culture Collection (Manassas, VA), whereas IGROV1 ovarian carcinoma
cells were a gift of Dr. Manohar Ratnam (Medical University of Ohio). Cells were routinely
cultured in folate-free RPMI1640 medium, supplemented with 10% fetal bovine serum, penicillinstreptomycin solution, and 2 mM L-glutamine at 37 °C with 5% CO2. For growth inhibition assays,
cells (CHO, KB, or IGROV1) were plated in 96 well dishes (∼2500-5000 cells/well, total volume
of 200 µL medium) with a broad range of antifolate concentrations. The medium was RPMI1640
(contains 2.3 µM folic acid) with 10% dialyzed serum and antibiotics for experiments with R2 and
PC43-10 cells. For RT16, D4, KB, and IGROV1 cells, the cells were cultured in folate-free RPMI
media with 10% dialyzed fetal bovine serum (Invitrogen) and antibiotics supplemented with 2 nM
LCV. The requirement for FR mediated drug uptake in these assays was established in a parallel
incubation including 200 nM folic acid. For R2/hPCFT4 cells, the medium was folate-free
RPMI1640 (pH 7.2) containing 25 nM LCV, supplemented with 10% dialyzed fetal bovine serum
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(Invitrogen) and antibiotics. Cells were routinely incubated for up to 96 h, and metabolically active
cells (a measure of cell viability) were assayed with Cell Titer-blue cell viability assay (Promega,
Madison, WI), with fluorescence measured (590 nm emission, 560 nm excitation) using a
fluorescence plate reader. Raw data were exported from Softmax Pro software to an Excel
spreadsheet for analysis and determinations of IC 50s, corresponding to the drug concentrations that
result in 50% loss of cell growth. For some of the in vitro growth inhibition studies, the inhibitory
effects of the antifolate inhibitors on de novo thymidylate biosynthesis (i.e., TS) and de novo purine
biosynthesis (GARFTase and AICARFTase) were tested by coincubations with thymidine (10 µM)
and adenosine (60 µM), respectively. For de novo purine biosynthesis, additional protection
experiments used AICA (320 µM) as a means of distinguishing inhibitory effects at GARFTase
from those at AICARFTase. For assays of colony formation in the presence of the antifolate drugs,
KB cells were harvested and diluted. 200 cells were plated into 60mmdishes in folate-free
RPMI1640 medium supplemented with 2 nM LCV, 10% dialyzed fetal bovine serum, penicillinstreptomycin, and 2 mM L-glutamine in the presence of antifolate drugs. The dishes were
incubated at 37 °C with 5% CO2 for 10-14 days. At the end of the incubations, the dishes were
rinsed with Dulbecco’s phosphate-buffered saline (DPBS), 5%trichloroacetic acid, and borate
buffer (10 mM, pH 8.8), followed by 30 min incubation in 1% methylene blue in the borate buffer.
The dishes were rinsed with the borate buffer, and colonies were counted for calculating percent
colony-forming efficiency normalized to control.
FR Binding Assay. [3H]Folic acid binding was used to assess levels of surface FRs. Briefly,
cells (e.g., RT16 or D4; ∼1.6 × 106) were rinsed twice with Dulbecco’s phosphate-buffered saline
(DPBS) followed by two washes in acidic buffer (10 mM sodium acetate, 150 mM NaCl, pH 3.5)
to remove FR-bound folates. Cells were washed twice with ice-cold HEPES-buffered saline (20
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mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 5 mM glucose, pH 7.4; HBS), then
incubated in HBS with [3H]folic acid (50 nM, specific activity 0.5 Ci/mmol) in the presence and
absence of a range of concentrations of unlabeled folic acid or antifolate for 15 min at 0 °C. The
dishes were rinsed three times with ice-cold HBS, after which the cells were solubilized with 0.5
N sodium hydroxide and aliquots measured for radioactivity and protein contents. Protein
concentrations were measured with Folin phenol reagent. Bound [ 3H]folic acid was calculated as
pmol/mg protein. Relative binding affinities for assorted folate/antifolate substrates were
calculated as the inverse molar ratios of unlabeled ligands required to inhibit [ 3H]folic acid binding
by 50%. By definition, the relative affinity of folic acid is 1.
Transport Assays. For transport assays, R2/hPCFT4, PC43- 10, and R2(VC) CHO cells
grown as monolayers were used to seed spinner flasks. For experiments to determine the
inhibitions of transport by antifolate substrates, cells were collected and washed with DPBS and
resuspended in 2 mL of physiologic Hank’s balanced salts solution (HBSS) for PC43-10 cells and
in HBS adjusted to pH 7.2 or 6.8 or 4-morpholinepropanesulfonic acid (MES)-buffered saline (20
mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM glucose) adjusted to pH 6.5, 6.0,
or 5.5 for R2/hPCFT4 cells. In either case, uptakes of [ 3H]MTX (0.5 µM) were measured over 2
min at 37 °C in the presence and absence of unlabeled antifolates (10 µM). Uptakes of [3H]MTX
were quenched with ice-cold DPBS. Cells were washed with icecold DPBS (3×) and solubilized
with 0.5 N NaOH. Levels of intracellular radioactivity were expressed as pmol/mg protein,
calculated from direct measurements of radioactivity and protein contents of cell homogenates.
Protein concentrations were measured with Folin phenol reagent. Percent MTX transport
inhibition was calculated by comparing level of [3H]MTX uptake in the presence and absence of
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the inhibitors. Kinetic constants (Kt, Vmax) and Kis were calculated from Lineweaver-Burke and
Dixon plots, respectively.
In Vitro GARFTase Enzyme Inhibition Assay. Purified recombinant mouse GARFTase
enzyme was a gift from Dr. Richard Moran (Virginia Commonwealth University, Richmond, VA).
Briefly, enzyme activity was assayed spectrophotometrically at 37 °C using GARFTase (0.75 nM),
α,β-GAR (11 µM), and coenzyme 10-formyl-5,8-dideazafolic acid (10 µM) in HEPES buffer (75
mM, pH 7.5) with or without antifolate inhibitor (10-30 000 nM). The absorbance of the reaction
product, 5,8-dideazafolic acid, was monitored at 295 nM over the first minute as a measure of the
initial rate of enzyme activity. IC50s were calculated as the concentrations of inhibitors that resulted
in a 50% decrease in the initial velocity of the GARFTase reaction.
In Situ GARFT Enzyme Inhibition Assay. Incorporation of [14C]glycine into [14C]FGAR,
as an in situ measure of endogenous GARFTase activity, was described by Beardsley et al. and
modified by Deng et al. For these experiments, KB cells were seeded in 4 mL of complete folatefree RPMI1640 plus 2 nM LCVin 60 mm dishes at a density of 2 × 106 cells per dish. On the next
day, the medium was replaced with 2 mL of fresh complete folate-free RPMI1640 plus 2 nM LCV
(without supplementing glutamine). Azaserine (4 µM final concentration) was added in the
presence and absence of the antifolate inhibitors (0.1, 1, 10, 100, or 1000 nM). After 30 min, Lglutamine (final concentration, 2 mM) and [ 14C]glycine (tracer amounts; final specific activity 0.1
mCi/L) were added. Incubations were at 37 °C for 15 h, at which time cells were washed (onetime) with ice-cold folate-free RPMI1640 plus serum. Cell pellets were dissolved in 2mL of 5%
trichloroacetic acid at 0 °C. Cell debris was removed by centrifugation (the cell protein contents
in the pellets were measured), and the supernatants were extracted twice with 2 mL of ice-cold
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ether. The aqueous layer was passed through a 1 cm column of AG1 × 8 (chloride form), 100-200
mesh (Bio-Rad), washed with 10 mL of 0.5 N formic acid and then 10 mL of 4 N formic acid, and
finally eluted with 8 mL of 1 N HCl. The elutants were collected and determined for radioactivity.
The accumulation of radioactive FGAR was calculated as pmol per mg protein over a range of
inhibitor concentrations. IC50s were calculated as the concentrations of inhibitors that resulted in
a 50% decrease in FGAR synthesis.
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RFC
Comp
7
8
163
164
165
166
MTX
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PMX
RTX

FRα

FRβ

PCFT

R2

RT16

273.5(49.1)

0.31(0.14)

>1000

0.17(0.03

>1000

3.34(0.26)

288(12)

>1000
>1000
>1000
>1000
>1000
216(8.7)

1.82(0.28)
0.68
2.16
2.99
9.81
114(31)

>1000
>1000
>1000
>1000
>1000
461(62)

0.57(0.09
0.19
0.95
2.98
3.81
106(11)

>1000
>1000
>1000
>1000
>1000
211(43)

43.4(4.1)
2.07
35.7
132
140
120.5(16.8)

>1000
>1000
>1000
>1000
>1000
>1000

0.26
(0.03)
0.55(0.10)
0.3
1.38
0.98
5.32
6.0(0.6)

138(13)

894(93)

42(9)

388(68)

60(8)

254(78)

13.2(2.4)

974.0(18.1)

68(12)

6.3(1.3)

>1000

15(5)

>1000

22(10)

746(138)

99.5(11.4)

>1000

5.9(2.2)

PC43-10
101.0(16.6)
>1000
88.2
101.7
>1000
>1000
12(1.1)

D4

D4
(+FA)

R2/PCFT4

R2(VC)

RFC/FRα/PCFT
KB
KB
(+FA)

RT16
(+FA)

>1000
>1000
>1000
>1000
>1000
>1000
20(2.4)
327(103
)
22(5)

Table 1. IC50s (in nM) for 6-substituted pyrrolo[2,3-d]pyrimidine antifolates and classical antifolates in RFC-, PCFT-, and FRexpressing cell lines. Growth inhibition assays were performed for CHO sublines engineered to express human RFC (PC43-10), FRα
(RT16), FRβ (D4), or PCFT (R2/PCFT4), for comparison with transporter-null [R2, R2(VC)] CHO cells and for the KB human tumor
subline (expresses RFC, FRα, and PCFT), as described in the Experimental Section. For the FR experiments, growth inhibition assays
were performed in the presence and the absence of 200 nM folic acid (FA). The data shown are mean values from 3-10 experiments
(plus/minus SEM in parentheses). Results are presented as IC50 values, corresponding to the concentrations that inhibit growth by 50%
relative to cells incubated without drug.

RFC

FRα

FRβ

PCFT

RFC/FRα/PCFT

Com

4
160
161
162
173
MTX
PMX
RTX
LMTX
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PC43-10

R2

RT16

D4

R2/PCFT4

R2(VC)

KB

KB (+FA)

>1000
62(12)
510(90)
>1000
808 (81)
12(1.1)
138(13)
6.3(1.3)
12(2.3)

>1000
140(27)
>1000
>1000
>1000
114(31)
42(9)
15(5)
12(8)

6.3 (1.6)
1.12 (0.37)
3.04 (0.71)
1.3 (0.8)
4.1(1.4)
114 (31)
42 (9)
15 (5)
12 (8)

>1000
3.87 (0.14)
0.62 (0.20)
0.1 (0.02)
0.62 (0.04)
106 (11)
60 (8)
22 (10)
2.6 (1.0)

213 (28)
3.82 (0.27)
87.4(9.9)
245 (102)
125 (15)
121(17)
13.2(2.4)
99.5(11.4)
38.0(5.3)

>1000
ND
>1000
>1000
>1000
>1000
974 (18)
>1000
>1000

1.9 (0.7)
ND
0.32(0.05)
0.21(0.04)
3.81(0.92)
6.00(0.60)
68(12)
5.90(2.20)
1.20(0.60)

>1000
ND
666(46)
ND
ND
20(2.4)
327(103)
22(5)
31(7)

KB +
Ade/Thd/AIC
A
Ade/AICA
ND
Ade/AICA
ND
ND
Thd/Ade
Thd/Ade
Thd
Ade/ AICA

Table 2. IC50s (in nM) for 6-substituted pyrrrolo[2,3-d]pyrimidine benzoyl antifolates with heteroatom replacements, and
classical antifolates in RFC-, PCFT- and FR-expressing cell lines. Proliferation assays were performed for CHO sublines engineered
to express human RFC (PC43-10), FRα (RT16), FRβ (D4) or PCFT (R2/PCFT4), transporter-null [R2, R2(VC)] CHO cells,29, 46-48 and
KB human tumor cells (express RFC, FRα, and PCFT). For the experiments measuring FR-mediated effects, assays were performed in
the presence or absence of 200 nM folic acid (FA) (results are shown only for KB cells). Results are presented as IC50 values,
corresponding to the concentrations that inhibit growth by 50% relative to cells incubated without drug. The data are mean values from
5-16 experiments (+/- standard errors in parentheses). Results are also summarized for KB cells for the protective effects of adenosine
(60 µM), thymidine (10 µM), or 5-aminoimidazole-4-carboxamide (320 µM). Methods are summarized in the Experimental Section.
Undefined abbreviations: Ade, adenosine; AICA, 5-aminoimidazole-4-carboxamide; FA, folic acid; ND, not determined;

RFC

FRα

Com

164
165
166
167
MTX
PMX
RTX
LMTX
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PCFT

PC43-10

R2

RT16

RT16
(+FA)

56.6(5.8)
>1000
68.8 (21.2)
151
12(1.1)
138(13)
6.3(1.3)
12(2.3)

>1000
>1000
>1000
>1000
114(31)
42(9)
15(5)
12(8)

8.6 (2.1)
0.58
72.0 (27.1)
228
114 (31)
42 (9)
15 (5)
12 (8)

>1000
>1000
>1000
>1000
106 (11)
60 (8)
22 (10)
2.6 (1.0)

RFC/FRα/PCFT

R2/PCFT4

R2(VC)

KB

KB (+FA)

840(90)
75.4
329 (61)
59
121 (17)
13.2(2.4)
99.5(11.4)
38.0(5.3)

>1000
ND
>1000
>1000
>1000
974(18)
>1000
>1000

12.7 (5.4)
0.59
49.5 (13.2)
32.5
6.00(0.60)
68(12)
5.90(2.20)
1.20(0.60)

ND
ND
533(233)
ND
20(2.4)
327(103)
22(5)
31(7)

KB +
Ade/Thd/AI
CA
Ade
ND
Ade
ND
Thd/Ade
Thd/Ade
Thd
Ade/ AICA

Table 3. IC50s (in nM) for 5-substituted pyrrrolo[2,3-d]pyrimidine, and classical antifolates in RFC-, PCFT- and FR-expressing
cell lines. Proliferation assays were performed for CHO sublines engineered to express human RFC (PC43-10), FRα (RT16), FRβ (D4)
or PCFT (R2/PCFT4), transporter-null [R2, R2(VC)] CHO cells,29, 46-48 and KB human tumor cells (express RFC, FRα, and PCFT). For
the experiments measuring FR-mediated effects, assays were performed in the presence or absence of 200 nM folic acid (FA) (results
are shown only for KB cells). Results are presented as IC50 values, corresponding to the concentrations that inhibit growth by 50%
relative to cells incubated without drug. The data are mean values from 5-16 experiments (+/- standard errors in parentheses). Results
are also summarized for KB cells for the protective effects of adenosine (60 µM), thymidine (10 µM), or 5-aminoimidazole-4carboxamide (320 µM). Methods are summarized in the Experimental Section. Undefined abbreviations: Ade, adenosine; AICA, 5aminoimidazole-4-carboxamide; FA, folic acid; ND, not determined;

RFC
Comp
8
168
169
170
171
172
173
174
MTX
- 186 -

PMX
RTX

FRα

PC43-10
>1000
>1000
59.8(11.1)
116.0(22.5
)
38.3(6.6)
ND
>1000
>1000

R2
>1000
>1000
>1000

RT16
1.82(0.28)
2.54(0.52)
550 (50)

>1000
>1000
ND
>1000
>1000

109 (44)
49.3(11.5)
ND
>1000
>1000

12(1.1)

216(8.7)

114(31)

138(13)

894(93)

42(9)

6.3(1.3)

>1000

15(5)

FRβ
RT16
(+FA)
>1000
>1000
ND
ND
ND
ND
ND
ND
461(62
)
388(68
)
>1000

PCFT

RFC/FRα/PCFT
KB
KB
(+FA)
0.55(0.10) >1000
0.17(0.02) >1000
875 (125)
ND
>1000
211 (58)
66.0(14.4) >1000
ND
ND
320
ND
260
ND

D4
(+FA)
>1000
ND
ND

R2/PCFT4
43.4(4.1)
41.6 (13.1)
80.2(5.5)

R2(VC)
>1000
>1000
>1000

ND
ND
ND
ND

ND
ND
ND
ND
ND

312 (90)
141(40)
ND
>1000
125

>1000
>1000
ND
>1000
>1000

106(11)

211(43)

120.5(16.8)

>1000

6.0(0.6)

60(8)

254(78)

13.2(2.4)

974.0(18.1)

68(12)

22(10)

746(138)

99.5(11.4)

>1000

5.9(2.2)

D4
0.57(0.09
ND
ND
ND

20(2.4)
327(103
)
22(5)

Table 4. IC50s (in nM) for 5-substituted pyrrrolo[2,3-d]pyrimidine, and classical antifolates in RFC-, PCFT- and FR-expressing
cell lines. Proliferation assays were performed for CHO sublines engineered to express human RFC (PC43-10), FRα (RT16), FRβ (D4)
or PCFT (R2/PCFT4), transporter-null [R2, R2(VC)] CHO cells,29, 46-48 and KB human tumor cells (express RFC, FRα, and PCFT). For
the experiments measuring FR-mediated effects, assays were performed in the presence or absence of 200 nM folic acid (FA) (results
are shown only for KB cells). Results are presented as IC50 values, corresponding to the concentrations that inhibit growth by 50%
relative to cells incubated without drug. The data are mean values from 5-16 experiments (+/- standard errors in parentheses). Results
are also summarized for KB cells for the protective effects of adenosine (60 µM), thymidine (10 µM), or 5-aminoimidazole-4carboxamide (320 µM). Methods are summarized in the Experimental Section. Undefined abbreviations: Ade, adenosine; AICA, 5aminoimidazole-4-carboxamide; FA, folic acid; ND, not determined;

